#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Resting-State Connectivity Biomarkers of Cognitive Performance and Social Function in Schizophrenia Spectrum Disorders and Healthy Controls
#Text=Background
#Text=Deficits in neurocognition and social cognition are drivers of reduced functioning in schizophrenia spectrum disorders (SSDs), with potentially shared neurobiological underpinnings.
1-1	0-13	Resting-State	_	
1-2	14-26	Connectivity	_	
1-3	27-37	Biomarkers	_	
1-4	38-40	of	_	
1-5	41-50	Cognitive	_	
1-6	51-62	Performance	_	
1-7	63-66	and	_	
1-8	67-73	Social	_	
1-9	74-82	Function	_	
1-10	83-85	in	_	
1-11	86-99	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-12	100-108	Spectrum	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-13	109-118	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-14	119-122	and	_	
1-15	123-130	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
1-16	131-139	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
1-17	140-150	Background	_	
1-18	151-159	Deficits	_	
1-19	160-162	in	_	
1-20	163-177	neurocognition	_	
1-21	178-181	and	_	
1-22	182-188	social	_	
1-23	189-198	cognition	_	
1-24	199-202	are	_	
1-25	203-210	drivers	_	
1-26	211-213	of	_	
1-27	214-221	reduced	_	
1-28	222-233	functioning	_	
1-29	234-236	in	_	
1-30	237-250	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-31	251-259	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-32	260-269	disorders	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-33	270-271	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-34	271-275	SSDs	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-35	275-276	)	_	
1-36	276-277	,	_	
1-37	278-282	with	_	
1-38	283-294	potentially	_	
1-39	295-301	shared	_	
1-40	302-317	neurobiological	_	
1-41	318-331	underpinnings	_	
1-42	331-332	.	_	

#Text=Many studies have sought to identify brain-based biomarkers of these clinical variables using a priori dichotomies (i.e., good vs. poor cognition, deficit vs. nondeficit syndrome).
2-1	333-337	Many	_	
2-2	338-345	studies	_	
2-3	346-350	have	_	
2-4	351-357	sought	_	
2-5	358-360	to	_	
2-6	361-369	identify	_	
2-7	370-381	brain-based	_	
2-8	382-392	biomarkers	_	
2-9	393-395	of	_	
2-10	396-401	these	_	
2-11	402-410	clinical	_	
2-12	411-420	variables	_	
2-13	421-426	using	_	
2-14	427-428	a	_	
2-15	429-435	priori	_	
2-16	436-447	dichotomies	_	
2-17	448-449	(	_	
2-18	449-452	i.e	_	
2-19	452-453	.	_	
2-20	453-454	,	_	
2-21	455-459	good	_	
2-22	460-462	vs	_	
2-23	462-463	.	_	
2-24	464-468	poor	_	
2-25	469-478	cognition	_	
2-26	478-479	,	_	
2-27	480-487	deficit	_	
2-28	488-490	vs	_	
2-29	490-491	.	_	
2-30	492-502	nondeficit	_	
2-31	503-511	syndrome	_	
2-32	511-512	)	_	
2-33	512-513	.	_	

#Text=Methods
#Text=We evaluated a fully data-driven approach to do the same by building and validating a brain-connectivity-based biomarker of social cognitive and neurocognitive performance in a sample using resting state and task-based fMRI (n=75/133 healthy controls/SSDs, 188 total).
3-1	514-521	Methods	_	
3-2	522-524	We	_	
3-3	525-534	evaluated	_	
3-4	535-536	a	_	
3-5	537-542	fully	_	
3-6	543-554	data-driven	_	
3-7	555-563	approach	_	
3-8	564-566	to	_	
3-9	567-569	do	_	
3-10	570-573	the	_	
3-11	574-578	same	_	
3-12	579-581	by	_	
3-13	582-590	building	_	
3-14	591-594	and	_	
3-15	595-605	validating	_	
3-16	606-607	a	_	
3-17	608-632	brain-connectivity-based	_	
3-18	633-642	biomarker	_	
3-19	643-645	of	_	
3-20	646-652	social	_	
3-21	653-662	cognitive	_	
3-22	663-666	and	_	
3-23	667-681	neurocognitive	_	
3-24	682-693	performance	_	
3-25	694-696	in	_	
3-26	697-698	a	_	
3-27	699-705	sample	_	
3-28	706-711	using	_	
3-29	712-719	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
3-30	720-725	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
3-31	726-729	and	_	
3-32	730-740	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
3-33	741-745	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
3-34	746-747	(	_	
3-35	747-748	n	_	
3-36	748-749	=	_	
3-37	749-751	75	_	
3-38	751-752	/	_	
3-39	752-755	133	_	
3-40	756-763	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
3-41	764-772	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
3-42	772-773	/	_	
3-43	773-777	SSDs	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-44	777-778	,	_	
3-45	779-782	188	_	
3-46	783-788	total	_	
3-47	788-789	)	_	
3-48	789-790	.	_	

#Text=We used canonical correlation analysis followed by clustering to identify a functional connectivity signature of normal and poorly-performing social cognitive and neurocognitive performance.
4-1	791-793	We	_	
4-2	794-798	used	_	
4-3	799-808	canonical	_	
4-4	809-820	correlation	_	
4-5	821-829	analysis	_	
4-6	830-838	followed	_	
4-7	839-841	by	_	
4-8	842-852	clustering	_	
4-9	853-855	to	_	
4-10	856-864	identify	_	
4-11	865-866	a	_	
4-12	867-877	functional	_	
4-13	878-890	connectivity	_	
4-14	891-900	signature	_	
4-15	901-903	of	_	
4-16	904-910	normal	_	
4-17	911-914	and	_	
4-18	915-932	poorly-performing	_	
4-19	933-939	social	_	
4-20	940-949	cognitive	_	
4-21	950-953	and	_	
4-22	954-968	neurocognitive	_	
4-23	969-980	performance	_	
4-24	980-981	.	_	

#Text=Results
#Text=Those with poor social cognitive and neurocognitive performance were differentiated from those with normal performance by greater resting-state connectivity in the mirror neuron and mentalizing systems.
5-1	982-989	Results	_	
5-2	990-995	Those	_	
5-3	996-1000	with	_	
5-4	1001-1005	poor	_	
5-5	1006-1012	social	_	
5-6	1013-1022	cognitive	_	
5-7	1023-1026	and	_	
5-8	1027-1041	neurocognitive	_	
5-9	1042-1053	performance	_	
5-10	1054-1058	were	_	
5-11	1059-1073	differentiated	_	
5-12	1074-1078	from	_	
5-13	1079-1084	those	_	
5-14	1085-1089	with	_	
5-15	1090-1096	normal	_	
5-16	1097-1108	performance	_	
5-17	1109-1111	by	_	
5-18	1112-1119	greater	_	
5-19	1120-1133	resting-state	_	
5-20	1134-1146	connectivity	_	
5-21	1147-1149	in	_	
5-22	1150-1153	the	_	
5-23	1154-1160	mirror	_	
5-24	1161-1167	neuron	_	
5-25	1168-1171	and	_	
5-26	1172-1183	mentalizing	_	
5-27	1184-1191	systems	_	
5-28	1191-1192	.	_	

#Text=We validated our findings by showing that poor-performers also scored lower on functional outcome measures not included in the original analysis, and demonstrating neuroanatomical differences between the normal and poorly-performing groups.
6-1	1193-1195	We	_	
6-2	1196-1205	validated	_	
6-3	1206-1209	our	_	
6-4	1210-1218	findings	_	
6-5	1219-1221	by	_	
6-6	1222-1229	showing	_	
6-7	1230-1234	that	_	
6-8	1235-1250	poor-performers	_	
6-9	1251-1255	also	_	
6-10	1256-1262	scored	_	
6-11	1263-1268	lower	_	
6-12	1269-1271	on	_	
6-13	1272-1282	functional	_	
6-14	1283-1290	outcome	_	
6-15	1291-1299	measures	_	
6-16	1300-1303	not	_	
6-17	1304-1312	included	_	
6-18	1313-1315	in	_	
6-19	1316-1319	the	_	
6-20	1320-1328	original	_	
6-21	1329-1337	analysis	_	
6-22	1337-1338	,	_	
6-23	1339-1342	and	_	
6-24	1343-1356	demonstrating	_	
6-25	1357-1372	neuroanatomical	_	
6-26	1373-1384	differences	_	
6-27	1385-1392	between	_	
6-28	1393-1396	the	_	
6-29	1397-1403	normal	_	
6-30	1404-1407	and	_	
6-31	1408-1425	poorly-performing	_	
6-32	1426-1432	groups	_	
6-33	1432-1433	.	_	

#Text=We used a support vector machine classifier to demonstrate that functional connectivity alone is enough to distinguish normal and poorly-performing subjects, and replicated our findings in an independent sample (n=75 total).
7-1	1434-1436	We	_	
7-2	1437-1441	used	_	
7-3	1442-1443	a	_	
7-4	1444-1451	support	_	
7-5	1452-1458	vector	_	
7-6	1459-1466	machine	_	
7-7	1467-1477	classifier	_	
7-8	1478-1480	to	_	
7-9	1481-1492	demonstrate	_	
7-10	1493-1497	that	_	
7-11	1498-1508	functional	_	
7-12	1509-1521	connectivity	_	
7-13	1522-1527	alone	_	
7-14	1528-1530	is	_	
7-15	1531-1537	enough	_	
7-16	1538-1540	to	_	
7-17	1541-1552	distinguish	_	
7-18	1553-1559	normal	_	
7-19	1560-1563	and	_	
7-20	1564-1581	poorly-performing	_	
7-21	1582-1590	subjects	_	
7-22	1590-1591	,	_	
7-23	1592-1595	and	_	
7-24	1596-1606	replicated	_	
7-25	1607-1610	our	_	
7-26	1611-1619	findings	_	
7-27	1620-1622	in	_	
7-28	1623-1625	an	_	
7-29	1626-1637	independent	_	
7-30	1638-1644	sample	_	
7-31	1645-1646	(	_	
7-32	1646-1647	n	_	
7-33	1647-1648	=	_	
7-34	1648-1650	75	_	
7-35	1651-1656	total	_	
7-36	1656-1657	)	_	
7-37	1657-1658	.	_	

#Text=Conclusions
#Text=A brief fMRI scan may ultimately be useful in future studies aimed at characterizing long term illness trajectories, and treatments that target specific brain circuitry in those with impaired cognition and function.
8-1	1659-1670	Conclusions	_	
8-2	1671-1672	A	_	
8-3	1673-1678	brief	_	
8-4	1679-1683	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
8-5	1684-1688	scan	_	
8-6	1689-1692	may	_	
8-7	1693-1703	ultimately	_	
8-8	1704-1706	be	_	
8-9	1707-1713	useful	_	
8-10	1714-1716	in	_	
8-11	1717-1723	future	_	
8-12	1724-1731	studies	_	
8-13	1732-1737	aimed	_	
8-14	1738-1740	at	_	
8-15	1741-1755	characterizing	_	
8-16	1756-1760	long	_	
8-17	1761-1765	term	_	
8-18	1766-1773	illness	_	
8-19	1774-1786	trajectories	_	
8-20	1786-1787	,	_	
8-21	1788-1791	and	_	
8-22	1792-1802	treatments	_	
8-23	1803-1807	that	_	
8-24	1808-1814	target	_	
8-25	1815-1823	specific	_	
8-26	1824-1829	brain	_	
8-27	1830-1839	circuitry	_	
8-28	1840-1842	in	_	
8-29	1843-1848	those	_	
8-30	1849-1853	with	_	
8-31	1854-1862	impaired	_	
8-32	1863-1872	cognition	_	
8-33	1873-1876	and	_	
8-34	1877-1885	function	_	
8-35	1885-1886	.	_	

#Text=Introduction
#Text=Social cognitive and neurocognitive (SC/NC) deficits are associated with real-world functioning impairment in patients with schizophrenia spectrum disorders (SSDs; i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder).
9-1	1887-1899	Introduction	_	
9-2	1900-1906	Social	_	
9-3	1907-1916	cognitive	_	
9-4	1917-1920	and	_	
9-5	1921-1935	neurocognitive	_	
9-6	1936-1937	(	_	
9-7	1937-1939	SC	_	
9-8	1939-1940	/	_	
9-9	1940-1942	NC	_	
9-10	1942-1943	)	_	
9-11	1944-1952	deficits	_	
9-12	1953-1956	are	_	
9-13	1957-1967	associated	_	
9-14	1968-1972	with	_	
9-15	1973-1983	real-world	_	
9-16	1984-1995	functioning	_	
9-17	1996-2006	impairment	_	
9-18	2007-2009	in	_	
9-19	2010-2018	patients	_	
9-20	2019-2023	with	_	
9-21	2024-2037	schizophrenia	_	
9-22	2038-2046	spectrum	_	
9-23	2047-2056	disorders	_	
9-24	2057-2058	(	_	
9-25	2058-2062	SSDs	_	
9-26	2062-2063	;	_	
9-27	2064-2067	i.e	_	
9-28	2067-2068	.	_	
9-29	2068-2069	,	_	
9-30	2070-2083	schizophrenia	_	
9-31	2083-2084	,	_	
9-32	2085-2100	schizoaffective	_	
9-33	2101-2109	disorder	_	
9-34	2109-2110	,	_	
9-35	2111-2127	schizophreniform	_	
9-36	2128-2136	disorder	_	
9-37	2136-2137	)	_	
9-38	2137-2138	.	_	

#Text=However, these deficits can range from mild to severe, and some SSD cases perform just as well or even better than matched controls.
10-1	2139-2146	However	_	
10-2	2146-2147	,	_	
10-3	2148-2153	these	_	
10-4	2154-2162	deficits	_	
10-5	2163-2166	can	_	
10-6	2167-2172	range	_	
10-7	2173-2177	from	_	
10-8	2178-2182	mild	_	
10-9	2183-2185	to	_	
10-10	2186-2192	severe	_	
10-11	2192-2193	,	_	
10-12	2194-2197	and	_	
10-13	2198-2202	some	_	
10-14	2203-2206	SSD	_	
10-15	2207-2212	cases	_	
10-16	2213-2220	perform	_	
10-17	2221-2225	just	_	
10-18	2226-2228	as	_	
10-19	2229-2233	well	_	
10-20	2234-2236	or	_	
10-21	2237-2241	even	_	
10-22	2242-2248	better	_	
10-23	2249-2253	than	_	
10-24	2254-2261	matched	_	
10-25	2262-2270	controls	_	
10-26	2270-2271	.	_	

#Text=Past attempts to understand SC/NC deficits through separation into subtypes (e.g.
11-1	2272-2276	Past	_	
11-2	2277-2285	attempts	_	
11-3	2286-2288	to	_	
11-4	2289-2299	understand	_	
11-5	2300-2302	SC	_	
11-6	2302-2303	/	_	
11-7	2303-2305	NC	_	
11-8	2306-2314	deficits	_	
11-9	2315-2322	through	_	
11-10	2323-2333	separation	_	
11-11	2334-2338	into	_	
11-12	2339-2347	subtypes	_	
11-13	2348-2349	(	_	
11-14	2349-2352	e.g	_	
11-15	2352-2353	.	_	

#Text=Type 1 vs.
12-1	2354-2358	Type	_	
12-2	2359-2360	1	_	
12-3	2361-2363	vs	_	
12-4	2363-2364	.	_	

#Text=Type 2, good vs. poor outcomes, or deficit vs. nondeficit) are based on clinical characterization, rather than data-driven approaches.
13-1	2365-2369	Type	_	
13-2	2370-2371	2	_	
13-3	2371-2372	,	_	
13-4	2373-2377	good	_	
13-5	2378-2380	vs	_	
13-6	2380-2381	.	_	
13-7	2382-2386	poor	_	
13-8	2387-2395	outcomes	_	
13-9	2395-2396	,	_	
13-10	2397-2399	or	_	
13-11	2400-2407	deficit	_	
13-12	2408-2410	vs	_	
13-13	2410-2411	.	_	
13-14	2412-2422	nondeficit	_	
13-15	2422-2423	)	_	
13-16	2424-2427	are	_	
13-17	2428-2433	based	_	
13-18	2434-2436	on	_	
13-19	2437-2445	clinical	_	
13-20	2446-2462	characterization	_	
13-21	2462-2463	,	_	
13-22	2464-2470	rather	_	
13-23	2471-2475	than	_	
13-24	2476-2487	data-driven	_	
13-25	2488-2498	approaches	_	
13-26	2498-2499	.	_	

#Text=Additionally, while DSM-IV subtypes have demonstrated separable domains of psychopathology in schizophrenia (negative symptomatology, psychosis, and disorganization), they failed to produce distinct groups of SC/NC performers, or help uncover biomarkers of reduced functioning.
14-1	2500-2512	Additionally	_	
14-2	2512-2513	,	_	
14-3	2514-2519	while	_	
14-4	2520-2526	DSM-IV	_	
14-5	2527-2535	subtypes	_	
14-6	2536-2540	have	_	
14-7	2541-2553	demonstrated	_	
14-8	2554-2563	separable	_	
14-9	2564-2571	domains	_	
14-10	2572-2574	of	_	
14-11	2575-2590	psychopathology	_	
14-12	2591-2593	in	_	
14-13	2594-2607	schizophrenia	_	
14-14	2608-2609	(	_	
14-15	2609-2617	negative	_	
14-16	2618-2632	symptomatology	_	
14-17	2632-2633	,	_	
14-18	2634-2643	psychosis	_	
14-19	2643-2644	,	_	
14-20	2645-2648	and	_	
14-21	2649-2664	disorganization	_	
14-22	2664-2665	)	_	
14-23	2665-2666	,	_	
14-24	2667-2671	they	_	
14-25	2672-2678	failed	_	
14-26	2679-2681	to	_	
14-27	2682-2689	produce	_	
14-28	2690-2698	distinct	_	
14-29	2699-2705	groups	_	
14-30	2706-2708	of	_	
14-31	2709-2711	SC	_	
14-32	2711-2712	/	_	
14-33	2712-2714	NC	_	
14-34	2715-2725	performers	_	
14-35	2725-2726	,	_	
14-36	2727-2729	or	_	
14-37	2730-2734	help	_	
14-38	2735-2742	uncover	_	
14-39	2743-2753	biomarkers	_	
14-40	2754-2756	of	_	
14-41	2757-2764	reduced	_	
14-42	2765-2776	functioning	_	
14-43	2776-2777	.	_	

#Text=The variability in SC/NC function, social impairment, and brain circuitry among people with SSDs may explain why standard univariate or case-control approaches have not translated well to biomarker identification.
15-1	2778-2781	The	_	
15-2	2782-2793	variability	_	
15-3	2794-2796	in	_	
15-4	2797-2799	SC	_	
15-5	2799-2800	/	_	
15-6	2800-2802	NC	_	
15-7	2803-2811	function	_	
15-8	2811-2812	,	_	
15-9	2813-2819	social	_	
15-10	2820-2830	impairment	_	
15-11	2830-2831	,	_	
15-12	2832-2835	and	_	
15-13	2836-2841	brain	_	
15-14	2842-2851	circuitry	_	
15-15	2852-2857	among	_	
15-16	2858-2864	people	_	
15-17	2865-2869	with	_	
15-18	2870-2874	SSDs	_	
15-19	2875-2878	may	_	
15-20	2879-2886	explain	_	
15-21	2887-2890	why	_	
15-22	2891-2899	standard	_	
15-23	2900-2910	univariate	_	
15-24	2911-2913	or	_	
15-25	2914-2926	case-control	_	
15-26	2927-2937	approaches	_	
15-27	2938-2942	have	_	
15-28	2943-2946	not	_	
15-29	2947-2957	translated	_	
15-30	2958-2962	well	_	
15-31	2963-2965	to	_	
15-32	2966-2975	biomarker	_	
15-33	2976-2990	identification	_	
15-34	2990-2991	.	_	

#Text=Data driven approaches that group subjects into neurophysiological subtypes, or ‘biotypes’, have been applied to participants with psychosis and depression, producing novel subgroups with distinct biomarkers.
16-1	2992-2996	Data	_	
16-2	2997-3003	driven	_	
16-3	3004-3014	approaches	_	
16-4	3015-3019	that	_	
16-5	3020-3025	group	_	
16-6	3026-3034	subjects	_	
16-7	3035-3039	into	_	
16-8	3040-3058	neurophysiological	_	
16-9	3059-3067	subtypes	_	
16-10	3067-3068	,	_	
16-11	3069-3071	or	_	
16-12	3072-3073	‘	_	
16-13	3073-3081	biotypes	_	
16-14	3081-3082	’	_	
16-15	3082-3083	,	_	
16-16	3084-3088	have	_	
16-17	3089-3093	been	_	
16-18	3094-3101	applied	_	
16-19	3102-3104	to	_	
16-20	3105-3117	participants	_	
16-21	3118-3122	with	_	
16-22	3123-3132	psychosis	_	
16-23	3133-3136	and	_	
16-24	3137-3147	depression	_	
16-25	3147-3148	,	_	
16-26	3149-3158	producing	_	
16-27	3159-3164	novel	_	
16-28	3165-3174	subgroups	_	
16-29	3175-3179	with	_	
16-30	3180-3188	distinct	_	
16-31	3189-3199	biomarkers	_	
16-32	3199-3200	.	_	

#Text=These approaches can uncover distinct biological factors that give rise to overlapping clinical presentations in disease.
17-1	3201-3206	These	_	
17-2	3207-3217	approaches	_	
17-3	3218-3221	can	_	
17-4	3222-3229	uncover	_	
17-5	3230-3238	distinct	_	
17-6	3239-3249	biological	_	
17-7	3250-3257	factors	_	
17-8	3258-3262	that	_	
17-9	3263-3267	give	_	
17-10	3268-3272	rise	_	
17-11	3273-3275	to	_	
17-12	3276-3287	overlapping	_	
17-13	3288-3296	clinical	_	
17-14	3297-3310	presentations	_	
17-15	3311-3313	in	_	
17-16	3314-3321	disease	_	
17-17	3321-3322	.	_	

#Text=In SSDs, intact SC/NC processes are important for real-world function, and deficits in these domains are predictive of one’s ability to form or sustain relationships, employment, and long-term outcomes.
18-1	3323-3325	In	_	
18-2	3326-3330	SSDs	_	
18-3	3330-3331	,	_	
18-4	3332-3338	intact	_	
18-5	3339-3341	SC	_	
18-6	3341-3342	/	_	
18-7	3342-3344	NC	_	
18-8	3345-3354	processes	_	
18-9	3355-3358	are	_	
18-10	3359-3368	important	_	
18-11	3369-3372	for	_	
18-12	3373-3383	real-world	_	
18-13	3384-3392	function	_	
18-14	3392-3393	,	_	
18-15	3394-3397	and	_	
18-16	3398-3406	deficits	_	
18-17	3407-3409	in	_	
18-18	3410-3415	these	_	
18-19	3416-3423	domains	_	
18-20	3424-3427	are	_	
18-21	3428-3438	predictive	_	
18-22	3439-3441	of	_	
18-23	3442-3445	one	_	
18-24	3445-3446	’	_	
18-25	3446-3447	s	_	
18-26	3448-3455	ability	_	
18-27	3456-3458	to	_	
18-28	3459-3463	form	_	
18-29	3464-3466	or	_	
18-30	3467-3474	sustain	_	
18-31	3475-3488	relationships	_	
18-32	3488-3489	,	_	
18-33	3490-3500	employment	_	
18-34	3500-3501	,	_	
18-35	3502-3505	and	_	
18-36	3506-3515	long-term	_	
18-37	3516-3524	outcomes	_	
18-38	3524-3525	.	_	

#Text=Social cognitive processes have recently emerged as particularly strong determinants of functional outcome, and studies have identified the fronto-parietal, cortico-midline, and temporo-parietal (or ‘mirror neuron’) circuitry as important for imitation, empathy, theory of mind, and perspective-taking.
19-1	3526-3532	Social	_	
19-2	3533-3542	cognitive	_	
19-3	3543-3552	processes	_	
19-4	3553-3557	have	_	
19-5	3558-3566	recently	_	
19-6	3567-3574	emerged	_	
19-7	3575-3577	as	_	
19-8	3578-3590	particularly	_	
19-9	3591-3597	strong	_	
19-10	3598-3610	determinants	_	
19-11	3611-3613	of	_	
19-12	3614-3624	functional	_	
19-13	3625-3632	outcome	_	
19-14	3632-3633	,	_	
19-15	3634-3637	and	_	
19-16	3638-3645	studies	_	
19-17	3646-3650	have	_	
19-18	3651-3661	identified	_	
19-19	3662-3665	the	_	
19-20	3666-3681	fronto-parietal	_	
19-21	3681-3682	,	_	
19-22	3683-3698	cortico-midline	_	
19-23	3698-3699	,	_	
19-24	3700-3703	and	_	
19-25	3704-3720	temporo-parietal	_	
19-26	3721-3722	(	_	
19-27	3722-3724	or	_	
19-28	3725-3726	‘	_	
19-29	3726-3732	mirror	_	
19-30	3733-3739	neuron	_	
19-31	3739-3740	’	_	
19-32	3740-3741	)	_	
19-33	3742-3751	circuitry	_	
19-34	3752-3754	as	_	
19-35	3755-3764	important	_	
19-36	3765-3768	for	_	
19-37	3769-3778	imitation	_	
19-38	3778-3779	,	_	
19-39	3780-3787	empathy	_	
19-40	3787-3788	,	_	
19-41	3789-3795	theory	_	
19-42	3796-3798	of	_	
19-43	3799-3803	mind	_	
19-44	3803-3804	,	_	
19-45	3805-3808	and	_	
19-46	3809-3827	perspective-taking	_	
19-47	3827-3828	.	_	

#Text=Smaller fMRI studies have focused on case-control differences in these regions, and such differences have not clearly translated to real-world function.
20-1	3829-3836	Smaller	_	
20-2	3837-3841	fMRI	_	
20-3	3842-3849	studies	_	
20-4	3850-3854	have	_	
20-5	3855-3862	focused	_	
20-6	3863-3865	on	_	
20-7	3866-3878	case-control	_	
20-8	3879-3890	differences	_	
20-9	3891-3893	in	_	
20-10	3894-3899	these	_	
20-11	3900-3907	regions	_	
20-12	3907-3908	,	_	
20-13	3909-3912	and	_	
20-14	3913-3917	such	_	
20-15	3918-3929	differences	_	
20-16	3930-3934	have	_	
20-17	3935-3938	not	_	
20-18	3939-3946	clearly	_	
20-19	3947-3957	translated	_	
20-20	3958-3960	to	_	
20-21	3961-3971	real-world	_	
20-22	3972-3980	function	_	
20-23	3980-3981	.	_	

#Text=We assessed the utility of resting and task-based functional connectivity, and task activations for two social fMRI tasks, for identifying biologically different groups with differences in SC/NC performance.
21-1	3982-3984	We	_	
21-2	3985-3993	assessed	_	
21-3	3994-3997	the	_	
21-4	3998-4005	utility	_	
21-5	4006-4008	of	_	
21-6	4009-4016	resting	_	
21-7	4017-4020	and	_	
21-8	4021-4031	task-based	_	
21-9	4032-4042	functional	_	
21-10	4043-4055	connectivity	_	
21-11	4055-4056	,	_	
21-12	4057-4060	and	_	
21-13	4061-4065	task	_	
21-14	4066-4077	activations	_	
21-15	4078-4081	for	_	
21-16	4082-4085	two	_	
21-17	4086-4092	social	_	
21-18	4093-4097	fMRI	_	
21-19	4098-4103	tasks	_	
21-20	4103-4104	,	_	
21-21	4105-4108	for	_	
21-22	4109-4120	identifying	_	
21-23	4121-4133	biologically	_	
21-24	4134-4143	different	_	
21-25	4144-4150	groups	_	
21-26	4151-4155	with	_	
21-27	4156-4167	differences	_	
21-28	4168-4170	in	_	
21-29	4171-4173	SC	_	
21-30	4173-4174	/	_	
21-31	4174-4176	NC	_	
21-32	4177-4188	performance	_	
21-33	4188-4189	.	_	

#Text=We first aimed to identify the fMRI data type (comparing task activations and/or connectivity from the tasks and resting state data) that produced biotype groupings with the largest differences in SC/NC performance between groups using canonical correlation analysis (CCA), followed by hierarchical clustering which grouped the participants into biotypes based on these brain features.
22-1	4190-4192	We	_	
22-2	4193-4198	first	_	
22-3	4199-4204	aimed	_	
22-4	4205-4207	to	_	
22-5	4208-4216	identify	_	
22-6	4217-4220	the	_	
22-7	4221-4225	fMRI	_	
22-8	4226-4230	data	_	
22-9	4231-4235	type	_	
22-10	4236-4237	(	_	
22-11	4237-4246	comparing	_	
22-12	4247-4251	task	_	
22-13	4252-4263	activations	_	
22-14	4264-4267	and	_	
22-15	4267-4268	/	_	
22-16	4268-4270	or	_	
22-17	4271-4283	connectivity	_	
22-18	4284-4288	from	_	
22-19	4289-4292	the	_	
22-20	4293-4298	tasks	_	
22-21	4299-4302	and	_	
22-22	4303-4310	resting	_	
22-23	4311-4316	state	_	
22-24	4317-4321	data	_	
22-25	4321-4322	)	_	
22-26	4323-4327	that	_	
22-27	4328-4336	produced	_	
22-28	4337-4344	biotype	_	
22-29	4345-4354	groupings	_	
22-30	4355-4359	with	_	
22-31	4360-4363	the	_	
22-32	4364-4371	largest	_	
22-33	4372-4383	differences	_	
22-34	4384-4386	in	_	
22-35	4387-4389	SC	_	
22-36	4389-4390	/	_	
22-37	4390-4392	NC	_	
22-38	4393-4404	performance	_	
22-39	4405-4412	between	_	
22-40	4413-4419	groups	_	
22-41	4420-4425	using	_	
22-42	4426-4435	canonical	_	
22-43	4436-4447	correlation	_	
22-44	4448-4456	analysis	_	
22-45	4457-4458	(	_	
22-46	4458-4461	CCA	_	
22-47	4461-4462	)	_	
22-48	4462-4463	,	_	
22-49	4464-4472	followed	_	
22-50	4473-4475	by	_	
22-51	4476-4488	hierarchical	_	
22-52	4489-4499	clustering	_	
22-53	4500-4505	which	_	
22-54	4506-4513	grouped	_	
22-55	4514-4517	the	_	
22-56	4518-4530	participants	_	
22-57	4531-4535	into	_	
22-58	4536-4544	biotypes	_	
22-59	4545-4550	based	_	
22-60	4551-4553	on	_	
22-61	4554-4559	these	_	
22-62	4560-4565	brain	_	
22-63	4566-4574	features	_	
22-64	4574-4575	.	_	

#Text=We validated our findings by comparing the identified groups on symptom, functional outcome, and structural neuroimaging measures (subcortical volumes, cortical thickness, and diffusion-based white matter metrics) not included in the original biotyping.
23-1	4576-4578	We	_	
23-2	4579-4588	validated	_	
23-3	4589-4592	our	_	
23-4	4593-4601	findings	_	
23-5	4602-4604	by	_	
23-6	4605-4614	comparing	_	
23-7	4615-4618	the	_	
23-8	4619-4629	identified	_	
23-9	4630-4636	groups	_	
23-10	4637-4639	on	_	
23-11	4640-4647	symptom	_	
23-12	4647-4648	,	_	
23-13	4649-4659	functional	_	
23-14	4660-4667	outcome	_	
23-15	4667-4668	,	_	
23-16	4669-4672	and	_	
23-17	4673-4683	structural	_	
23-18	4684-4696	neuroimaging	_	
23-19	4697-4705	measures	_	
23-20	4706-4707	(	_	
23-21	4707-4718	subcortical	_	
23-22	4719-4726	volumes	_	
23-23	4726-4727	,	_	
23-24	4728-4736	cortical	_	
23-25	4737-4746	thickness	_	
23-26	4746-4747	,	_	
23-27	4748-4751	and	_	
23-28	4752-4767	diffusion-based	_	
23-29	4768-4773	white	_	
23-30	4774-4780	matter	_	
23-31	4781-4788	metrics	_	
23-32	4788-4789	)	_	
23-33	4790-4793	not	_	
23-34	4794-4802	included	_	
23-35	4803-4805	in	_	
23-36	4806-4809	the	_	
23-37	4810-4818	original	_	
23-38	4819-4828	biotyping	_	
23-39	4828-4829	.	_	

#Text=We also tested whether the biotype of held-out participants could be correctly identified by a support vector machine classifier (SVC) trained using fMRI features, similar to a diagnostic test, and ranked the utility of each fMRI input by SVC classification accuracy.
24-1	4830-4832	We	_	
24-2	4833-4837	also	_	
24-3	4838-4844	tested	_	
24-4	4845-4852	whether	_	
24-5	4853-4856	the	_	
24-6	4857-4864	biotype	_	
24-7	4865-4867	of	_	
24-8	4868-4876	held-out	_	
24-9	4877-4889	participants	_	
24-10	4890-4895	could	_	
24-11	4896-4898	be	_	
24-12	4899-4908	correctly	_	
24-13	4909-4919	identified	_	
24-14	4920-4922	by	_	
24-15	4923-4924	a	_	
24-16	4925-4932	support	_	
24-17	4933-4939	vector	_	
24-18	4940-4947	machine	_	
24-19	4948-4958	classifier	_	
24-20	4959-4960	(	_	
24-21	4960-4963	SVC	_	
24-22	4963-4964	)	_	
24-23	4965-4972	trained	_	
24-24	4973-4978	using	_	
24-25	4979-4983	fMRI	_	
24-26	4984-4992	features	_	
24-27	4992-4993	,	_	
24-28	4994-5001	similar	_	
24-29	5002-5004	to	_	
24-30	5005-5006	a	_	
24-31	5007-5017	diagnostic	_	
24-32	5018-5022	test	_	
24-33	5022-5023	,	_	
24-34	5024-5027	and	_	
24-35	5028-5034	ranked	_	
24-36	5035-5038	the	_	
24-37	5039-5046	utility	_	
24-38	5047-5049	of	_	
24-39	5050-5054	each	_	
24-40	5055-5059	fMRI	_	
24-41	5060-5065	input	_	
24-42	5066-5068	by	_	
24-43	5069-5072	SVC	_	
24-44	5073-5087	classification	_	
24-45	5088-5096	accuracy	_	
24-46	5096-5097	.	_	

#Text=As control analyses, we compared these accuracies with those from SVCs trained to distinguish participants with ‘normal’ or ‘poor’ SC/NC scores, and diagnosis (SSD vs. controls) using the same input fMRI data.
25-1	5098-5100	As	_	
25-2	5101-5108	control	_	
25-3	5109-5117	analyses	_	
25-4	5117-5118	,	_	
25-5	5119-5121	we	_	
25-6	5122-5130	compared	_	
25-7	5131-5136	these	_	
25-8	5137-5147	accuracies	_	
25-9	5148-5152	with	_	
25-10	5153-5158	those	_	
25-11	5159-5163	from	_	
25-12	5164-5168	SVCs	_	
25-13	5169-5176	trained	_	
25-14	5177-5179	to	_	
25-15	5180-5191	distinguish	_	
25-16	5192-5204	participants	_	
25-17	5205-5209	with	_	
25-18	5210-5211	‘	_	
25-19	5211-5217	normal	_	
25-20	5217-5218	’	_	
25-21	5219-5221	or	_	
25-22	5222-5223	‘	_	
25-23	5223-5227	poor	_	
25-24	5227-5228	’	_	
25-25	5229-5231	SC	_	
25-26	5231-5232	/	_	
25-27	5232-5234	NC	_	
25-28	5235-5241	scores	_	
25-29	5241-5242	,	_	
25-30	5243-5246	and	_	
25-31	5247-5256	diagnosis	_	
25-32	5257-5258	(	_	
25-33	5258-5261	SSD	_	
25-34	5262-5264	vs	_	
25-35	5264-5265	.	_	
25-36	5266-5274	controls	_	
25-37	5274-5275	)	_	
25-38	5276-5281	using	_	
25-39	5282-5285	the	_	
25-40	5286-5290	same	_	
25-41	5291-5296	input	_	
25-42	5297-5301	fMRI	_	
25-43	5302-5306	data	_	
25-44	5306-5307	.	_	

#Text=We hypothesized that SVCs trained to distinguish biotypes (i.e., groups informed by neurobiology) would achieve higher scores on held-out participants than classifiers trained on cognitive score-based groups or diagnostic groups.
26-1	5308-5310	We	_	
26-2	5311-5323	hypothesized	_	
26-3	5324-5328	that	_	
26-4	5329-5333	SVCs	_	
26-5	5334-5341	trained	_	
26-6	5342-5344	to	_	
26-7	5345-5356	distinguish	_	
26-8	5357-5365	biotypes	_	
26-9	5366-5367	(	_	
26-10	5367-5370	i.e	_	
26-11	5370-5371	.	_	
26-12	5371-5372	,	_	
26-13	5373-5379	groups	_	
26-14	5380-5388	informed	_	
26-15	5389-5391	by	_	
26-16	5392-5404	neurobiology	_	
26-17	5404-5405	)	_	
26-18	5406-5411	would	_	
26-19	5412-5419	achieve	_	
26-20	5420-5426	higher	_	
26-21	5427-5433	scores	_	
26-22	5434-5436	on	_	
26-23	5437-5445	held-out	_	
26-24	5446-5458	participants	_	
26-25	5459-5463	than	_	
26-26	5464-5475	classifiers	_	
26-27	5476-5483	trained	_	
26-28	5484-5486	on	_	
26-29	5487-5496	cognitive	_	
26-30	5497-5508	score-based	_	
26-31	5509-5515	groups	_	
26-32	5516-5518	or	_	
26-33	5519-5529	diagnostic	_	
26-34	5530-5536	groups	_	
26-35	5536-5537	.	_	

#Text=We finally repeated our analyses in an independent sample.
27-1	5538-5540	We	_	
27-2	5541-5548	finally	_	
27-3	5549-5557	repeated	_	
27-4	5558-5561	our	_	
27-5	5562-5570	analyses	_	
27-6	5571-5573	in	_	
27-7	5574-5576	an	_	
27-8	5577-5588	independent	_	
27-9	5589-5595	sample	_	
27-10	5595-5596	.	_	

#Text=Methods
#Text=We analyzed participant data from the three site Social Processes Initiative in Neurobiology of the Schizophrenia(s) (SPINS) study (n=188, age=33.0±10.2 years; SSD=133, age=34.1±10.1; controls=75, age=31.3±10.1).
28-1	5597-5604	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
28-2	5605-5607	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-3	5608-5616	analyzed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-4	5617-5628	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-5	5629-5633	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-6	5634-5638	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-7	5639-5642	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-8	5643-5648	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-9	5649-5653	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-10	5654-5660	Social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-11	5661-5670	Processes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-12	5671-5681	Initiative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-13	5682-5684	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-14	5685-5697	Neurobiology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-15	5698-5700	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-16	5701-5704	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-17	5705-5718	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-18	5718-5719	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-19	5719-5720	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-20	5720-5721	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-21	5722-5723	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-22	5723-5728	SPINS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-23	5728-5729	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-24	5730-5735	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-25	5736-5737	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-26	5737-5738	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-27	5738-5739	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-28	5739-5742	188	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-29	5742-5743	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-30	5744-5747	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-31	5747-5748	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-32	5748-5752	33.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-33	5752-5753	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-34	5753-5757	10.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-35	5758-5763	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-36	5763-5764	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-37	5765-5768	SSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-38	5768-5769	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-39	5769-5772	133	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-40	5772-5773	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-41	5774-5777	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-42	5777-5778	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-43	5778-5782	34.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-44	5782-5783	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-45	5783-5787	10.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-46	5787-5788	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-47	5789-5797	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-48	5797-5798	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-49	5798-5800	75	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-50	5800-5801	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-51	5802-5805	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-52	5805-5806	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-53	5806-5810	31.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-54	5810-5811	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-55	5811-5815	10.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-56	5815-5816	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
28-57	5816-5817	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Demographics are summarized in table 1, see table s5 for demographics at each site split by diagnosis.
29-1	5818-5830	Demographics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-2	5831-5834	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-3	5835-5845	summarized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-4	5846-5848	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-5	5849-5854	table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-6	5855-5856	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-7	5856-5857	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-8	5858-5861	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-9	5862-5867	table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-10	5868-5870	s5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-11	5871-5874	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-12	5875-5887	demographics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-13	5888-5890	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-14	5891-5895	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-15	5896-5900	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-16	5901-5906	split	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-17	5907-5909	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-18	5910-5919	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
29-19	5919-5920	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=See supplement for inclusion/exclusion criteria.
30-1	5921-5924	See	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-2	5925-5935	supplement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-3	5936-5939	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-4	5940-5949	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-5	5949-5950	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-6	5950-5959	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-7	5960-5968	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
30-8	5968-5969	.	_	

#Text=All participants signed an informed consent agreement and the study was approved by institutional ethics boards at all participating institutions.
31-1	5970-5973	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-2	5974-5986	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-3	5987-5993	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-4	5994-5996	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-5	5997-6005	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-6	6006-6013	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-7	6014-6023	agreement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-8	6024-6027	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-9	6028-6031	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-10	6032-6037	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-11	6038-6041	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-12	6042-6050	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-13	6051-6053	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-14	6054-6067	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-15	6068-6074	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-16	6075-6081	boards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-17	6082-6084	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-18	6085-6088	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-19	6089-6102	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-20	6103-6115	institutions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
31-21	6115-6116	.	_	

#Text=All participants completed multiple assessments out of the MRI scanner.
32-1	6117-6120	All	_	
32-2	6121-6133	participants	_	
32-3	6134-6143	completed	_	
32-4	6144-6152	multiple	_	
32-5	6153-6164	assessments	_	
32-6	6165-6168	out	_	
32-7	6169-6171	of	_	
32-8	6172-6175	the	_	
32-9	6176-6179	MRI	_	
32-10	6180-6187	scanner	_	
32-11	6187-6188	.	_	

#Text=SC/NC functioning was assessed via the Penn Emotion Recognition Task (ER40), Reading the Mind in the Eyes Test (RMET), Relationships Across Domains (RAD), the three scales from the Awareness of Social Inference Test Revised (TASIT), and six neurocognitive domains of the MATRICS.
33-1	6189-6191	SC	_	
33-2	6191-6192	/	_	
33-3	6192-6194	NC	_	
33-4	6195-6206	functioning	_	
33-5	6207-6210	was	_	
33-6	6211-6219	assessed	_	
33-7	6220-6223	via	_	
33-8	6224-6227	the	_	
33-9	6228-6232	Penn	_	
33-10	6233-6240	Emotion	_	
33-11	6241-6252	Recognition	_	
33-12	6253-6257	Task	_	
33-13	6258-6259	(	_	
33-14	6259-6263	ER40	_	
33-15	6263-6264	)	_	
33-16	6264-6265	,	_	
33-17	6266-6273	Reading	_	
33-18	6274-6277	the	_	
33-19	6278-6282	Mind	_	
33-20	6283-6285	in	_	
33-21	6286-6289	the	_	
33-22	6290-6294	Eyes	_	
33-23	6295-6299	Test	_	
33-24	6300-6301	(	_	
33-25	6301-6305	RMET	_	
33-26	6305-6306	)	_	
33-27	6306-6307	,	_	
33-28	6308-6321	Relationships	_	
33-29	6322-6328	Across	_	
33-30	6329-6336	Domains	_	
33-31	6337-6338	(	_	
33-32	6338-6341	RAD	_	
33-33	6341-6342	)	_	
33-34	6342-6343	,	_	
33-35	6344-6347	the	_	
33-36	6348-6353	three	_	
33-37	6354-6360	scales	_	
33-38	6361-6365	from	_	
33-39	6366-6369	the	_	
33-40	6370-6379	Awareness	_	
33-41	6380-6382	of	_	
33-42	6383-6389	Social	_	
33-43	6390-6399	Inference	_	
33-44	6400-6404	Test	_	
33-45	6405-6412	Revised	_	
33-46	6413-6414	(	_	
33-47	6414-6419	TASIT	_	
33-48	6419-6420	)	_	
33-49	6420-6421	,	_	
33-50	6422-6425	and	_	
33-51	6426-6429	six	_	
33-52	6430-6444	neurocognitive	_	
33-53	6445-6452	domains	_	
33-54	6453-6455	of	_	
33-55	6456-6459	the	_	
33-56	6460-6467	MATRICS	_	
33-57	6467-6468	.	_	

#Text=Social functioning and quality of life was assessed via the Birchwood Social Functioning Scale (BSFS) and Quality of Life Scale (QLS).
34-1	6469-6475	Social	_	
34-2	6476-6487	functioning	_	
34-3	6488-6491	and	_	
34-4	6492-6499	quality	_	
34-5	6500-6502	of	_	
34-6	6503-6507	life	_	
34-7	6508-6511	was	_	
34-8	6512-6520	assessed	_	
34-9	6521-6524	via	_	
34-10	6525-6528	the	_	
34-11	6529-6538	Birchwood	_	
34-12	6539-6545	Social	_	
34-13	6546-6557	Functioning	_	
34-14	6558-6563	Scale	_	
34-15	6564-6565	(	_	
34-16	6565-6569	BSFS	_	
34-17	6569-6570	)	_	
34-18	6571-6574	and	_	
34-19	6575-6582	Quality	_	
34-20	6583-6585	of	_	
34-21	6586-6590	Life	_	
34-22	6591-6596	Scale	_	
34-23	6597-6598	(	_	
34-24	6598-6601	QLS	_	
34-25	6601-6602	)	_	
34-26	6602-6603	.	_	

#Text=Psychiatric symptom burden was assessed via the Brief Psychiatric Rating Scale (BPRS) and Scale for the Assessment of Negative Symptoms (SANS).
35-1	6604-6615	Psychiatric	_	
35-2	6616-6623	symptom	_	
35-3	6624-6630	burden	_	
35-4	6631-6634	was	_	
35-5	6635-6643	assessed	_	
35-6	6644-6647	via	_	
35-7	6648-6651	the	_	
35-8	6652-6657	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-9	6658-6669	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-10	6670-6676	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-11	6677-6682	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-12	6683-6684	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-13	6684-6688	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-14	6688-6689	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[9]	
35-15	6690-6693	and	_	
35-16	6694-6699	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-17	6700-6703	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-18	6704-6707	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-19	6708-6718	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-20	6719-6721	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-21	6722-6730	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-22	6731-6739	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-23	6740-6741	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-24	6741-6745	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-25	6745-6746	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	
35-26	6746-6747	.	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[10]	

#Text=Two additional SANS-based measures of diminished emotional expression and poor motivation were included as they relate to functional outcomes in SSD.
36-1	6748-6751	Two	_	
36-2	6752-6762	additional	_	
36-3	6763-6773	SANS-based	_	
36-4	6774-6782	measures	_	
36-5	6783-6785	of	_	
36-6	6786-6796	diminished	_	
36-7	6797-6806	emotional	_	
36-8	6807-6817	expression	_	
36-9	6818-6821	and	_	
36-10	6822-6826	poor	_	
36-11	6827-6837	motivation	_	
36-12	6838-6842	were	_	
36-13	6843-6851	included	_	
36-14	6852-6854	as	_	
36-15	6855-6859	they	_	
36-16	6860-6866	relate	_	
36-17	6867-6869	to	_	
36-18	6870-6880	functional	_	
36-19	6881-6889	outcomes	_	
36-20	6890-6892	in	_	
36-21	6893-6896	SSD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
36-22	6896-6897	.	_	

#Text=Extrapyramidal symptoms were assessed via The Simpson-Angus Scale (SAS), general medical burden via the Cumulative Illness Rating Scale – Geriatrics (CIRSG) and antipsychotic medication exposure via chlorpromazine equivalents.
37-1	6898-6912	Extrapyramidal	_	
37-2	6913-6921	symptoms	_	
37-3	6922-6926	were	_	
37-4	6927-6935	assessed	_	
37-5	6936-6939	via	_	
37-6	6940-6943	The	_	
37-7	6944-6957	Simpson-Angus	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale[11]	
37-8	6958-6963	Scale	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale[11]	
37-9	6964-6965	(	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale[11]	
37-10	6965-6968	SAS	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale[11]	
37-11	6968-6969	)	_	
37-12	6969-6970	,	_	
37-13	6971-6978	general	_	
37-14	6979-6986	medical	_	
37-15	6987-6993	burden	_	
37-16	6994-6997	via	_	
37-17	6998-7001	the	_	
37-18	7002-7012	Cumulative	_	
37-19	7013-7020	Illness	_	
37-20	7021-7027	Rating	_	
37-21	7028-7033	Scale	_	
37-22	7034-7035	–	_	
37-23	7036-7046	Geriatrics	_	
37-24	7047-7048	(	_	
37-25	7048-7053	CIRSG	_	
37-26	7053-7054	)	_	
37-27	7055-7058	and	_	
37-28	7059-7072	antipsychotic	_	
37-29	7073-7083	medication	_	
37-30	7084-7092	exposure	_	
37-31	7093-7096	via	_	
37-32	7097-7111	chlorpromazine	_	
37-33	7112-7123	equivalents	_	
37-34	7123-7124	.	_	

#Text=All sites used weekly phantom scans to ensure the stability of the T1-weighted, DTI, and EPI-based sequences over time.
38-1	7125-7128	All	_	
38-2	7129-7134	sites	_	
38-3	7135-7139	used	_	
38-4	7140-7146	weekly	_	
38-5	7147-7154	phantom	_	
38-6	7155-7160	scans	_	
38-7	7161-7163	to	_	
38-8	7164-7170	ensure	_	
38-9	7171-7174	the	_	
38-10	7175-7184	stability	_	
38-11	7185-7187	of	_	
38-12	7188-7191	the	_	
38-13	7192-7194	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[12]	
38-14	7194-7195	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[12]	
38-15	7195-7203	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[12]	
38-16	7203-7204	,	_	
38-17	7205-7208	DTI	_	
38-18	7208-7209	,	_	
38-19	7210-7213	and	_	
38-20	7214-7223	EPI-based	_	
38-21	7224-7233	sequences	_	
38-22	7234-7238	over	_	
38-23	7239-7243	time	_	
38-24	7243-7244	.	_	

#Text=At all sites, we implemented standardized operating protocols (SOPs) to minimize inter-site variance in how the data was collected and how the participants behaved.
39-1	7245-7247	At	_	
39-2	7248-7251	all	_	
39-3	7252-7257	sites	_	
39-4	7257-7258	,	_	
39-5	7259-7261	we	_	
39-6	7262-7273	implemented	_	
39-7	7274-7286	standardized	_	
39-8	7287-7296	operating	_	
39-9	7297-7306	protocols	_	
39-10	7307-7308	(	_	
39-11	7308-7312	SOPs	_	
39-12	7312-7313	)	_	
39-13	7314-7316	to	_	
39-14	7317-7325	minimize	_	
39-15	7326-7336	inter-site	_	
39-16	7337-7345	variance	_	
39-17	7346-7348	in	_	
39-18	7349-7352	how	_	
39-19	7353-7356	the	_	
39-20	7357-7361	data	_	
39-21	7362-7365	was	_	
39-22	7366-7375	collected	_	
39-23	7376-7379	and	_	
39-24	7380-7383	how	_	
39-25	7384-7387	the	_	
39-26	7388-7400	participants	_	
39-27	7401-7408	behaved	_	
39-28	7408-7409	.	_	

#Text=These SOPs standardized the administration of all in and out-of-scanner tasks.
40-1	7410-7415	These	_	
40-2	7416-7420	SOPs	_	
40-3	7421-7433	standardized	_	
40-4	7434-7437	the	_	
40-5	7438-7452	administration	_	
40-6	7453-7455	of	_	
40-7	7456-7459	all	_	
40-8	7460-7462	in	_	
40-9	7463-7466	and	_	
40-10	7467-7481	out-of-scanner	_	
40-11	7482-7487	tasks	_	
40-12	7487-7488	.	_	

#Text=In addition, participants were trained on how to participate in all in-scanner tasks (including the resting state scan) with minimal head motion.
41-1	7489-7491	In	_	
41-2	7492-7500	addition	_	
41-3	7500-7501	,	_	
41-4	7502-7514	participants	_	
41-5	7515-7519	were	_	
41-6	7520-7527	trained	_	
41-7	7528-7530	on	_	
41-8	7531-7534	how	_	
41-9	7535-7537	to	_	
41-10	7538-7549	participate	_	
41-11	7550-7552	in	_	
41-12	7553-7556	all	_	
41-13	7557-7567	in-scanner	_	
41-14	7568-7573	tasks	_	
41-15	7574-7575	(	_	
41-16	7575-7584	including	_	
41-17	7585-7588	the	_	
41-18	7589-7596	resting	_	
41-19	7597-7602	state	_	
41-20	7603-7607	scan	_	
41-21	7607-7608	)	_	
41-22	7609-7613	with	_	
41-23	7614-7621	minimal	_	
41-24	7622-7626	head	_	
41-25	7627-7633	motion	_	
41-26	7633-7634	.	_	

#Text=An in-scanner camera was also employed to monitor participant movement during all scans.
42-1	7635-7637	An	_	
42-2	7638-7648	in-scanner	_	
42-3	7649-7655	camera	_	
42-4	7656-7659	was	_	
42-5	7660-7664	also	_	
42-6	7665-7673	employed	_	
42-7	7674-7676	to	_	
42-8	7677-7684	monitor	_	
42-9	7685-7696	participant	_	
42-10	7697-7705	movement	_	
42-11	7706-7712	during	_	
42-12	7713-7716	all	_	
42-13	7717-7722	scans	_	
42-14	7722-7723	.	_	

#Text=Finally, prior to analysis, all scans were checked for sufficient quality by experienced research staff, making use of in-house developed quality control system and accompanying dashboard (https://github.com/TIGRLab/datman; https://github.com/TIGRLab/dashboard).
43-1	7724-7731	Finally	_	
43-2	7731-7732	,	_	
43-3	7733-7738	prior	_	
43-4	7739-7741	to	_	
43-5	7742-7750	analysis	_	
43-6	7750-7751	,	_	
43-7	7752-7755	all	_	
43-8	7756-7761	scans	_	
43-9	7762-7766	were	_	
43-10	7767-7774	checked	_	
43-11	7775-7778	for	_	
43-12	7779-7789	sufficient	_	
43-13	7790-7797	quality	_	
43-14	7798-7800	by	_	
43-15	7801-7812	experienced	_	
43-16	7813-7821	research	_	
43-17	7822-7827	staff	_	
43-18	7827-7828	,	_	
43-19	7829-7835	making	_	
43-20	7836-7839	use	_	
43-21	7840-7842	of	_	
43-22	7843-7851	in-house	_	
43-23	7852-7861	developed	_	
43-24	7862-7869	quality	_	
43-25	7870-7877	control	_	
43-26	7878-7884	system	_	
43-27	7885-7888	and	_	
43-28	7889-7901	accompanying	_	
43-29	7902-7911	dashboard	_	
43-30	7912-7913	(	_	
43-31	7913-7918	https	_	
43-32	7918-7919	:	_	
43-33	7919-7920	/	_	
43-34	7920-7921	/	_	
43-35	7921-7931	github.com	_	
43-36	7931-7932	/	_	
43-37	7932-7939	TIGRLab	_	
43-38	7939-7940	/	_	
43-39	7940-7946	datman	_	
43-40	7946-7947	;	_	
43-41	7948-7953	https	_	
43-42	7953-7954	:	_	
43-43	7954-7955	/	_	
43-44	7955-7956	/	_	
43-45	7956-7966	github.com	_	
43-46	7966-7967	/	_	
43-47	7967-7974	TIGRLab	_	
43-48	7974-7975	/	_	
43-49	7975-7984	dashboard	_	
43-50	7984-7985	)	_	
43-51	7985-7986	.	_	

#Text=Quality control involved both quantitative (e.g., framewise displacement, signal-to-noise measures) and qualitative monitoring (e.g., detecting ‘sufficiently bad’ ghosting or blurring by eye).
44-1	7987-7994	Quality	_	
44-2	7995-8002	control	_	
44-3	8003-8011	involved	_	
44-4	8012-8016	both	_	
44-5	8017-8029	quantitative	_	
44-6	8030-8031	(	_	
44-7	8031-8034	e.g	_	
44-8	8034-8035	.	_	
44-9	8035-8036	,	_	
44-10	8037-8046	framewise	_	
44-11	8047-8059	displacement	_	
44-12	8059-8060	,	_	
44-13	8061-8076	signal-to-noise	_	
44-14	8077-8085	measures	_	
44-15	8085-8086	)	_	
44-16	8087-8090	and	_	
44-17	8091-8102	qualitative	_	
44-18	8103-8113	monitoring	_	
44-19	8114-8115	(	_	
44-20	8115-8118	e.g	_	
44-21	8118-8119	.	_	
44-22	8119-8120	,	_	
44-23	8121-8130	detecting	_	
44-24	8131-8132	‘	_	
44-25	8132-8144	sufficiently	_	
44-26	8145-8148	bad	_	
44-27	8148-8149	’	_	
44-28	8150-8158	ghosting	_	
44-29	8159-8161	or	_	
44-30	8162-8170	blurring	_	
44-31	8171-8173	by	_	
44-32	8174-8177	eye	_	
44-33	8177-8178	)	_	
44-34	8178-8179	.	_	

#Text=Some of results demonstrating inter-site stability have been documented in two recently published papers.
45-1	8180-8184	Some	_	
45-2	8185-8187	of	_	
45-3	8188-8195	results	_	
45-4	8196-8209	demonstrating	_	
45-5	8210-8220	inter-site	_	
45-6	8221-8230	stability	_	
45-7	8231-8235	have	_	
45-8	8236-8240	been	_	
45-9	8241-8251	documented	_	
45-10	8252-8254	in	_	
45-11	8255-8258	two	_	
45-12	8259-8267	recently	_	
45-13	8268-8277	published	_	
45-14	8278-8284	papers	_	
45-15	8284-8285	.	_	

#Text=We report participants who pass quality control after completing a T1-weighted and resting state (n=164) fMRI scan, imitate/observe (n=93) task, and empathic accuracy (n=183) task.
46-1	8286-8288	We	_	
46-2	8289-8295	report	_	
46-3	8296-8308	participants	_	
46-4	8309-8312	who	_	
46-5	8313-8317	pass	_	
46-6	8318-8325	quality	_	
46-7	8326-8333	control	_	
46-8	8334-8339	after	_	
46-9	8340-8350	completing	_	
46-10	8351-8352	a	_	
46-11	8353-8355	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
46-12	8355-8356	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
46-13	8356-8364	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
46-14	8365-8368	and	_	
46-15	8369-8376	resting	_	
46-16	8377-8382	state	_	
46-17	8383-8384	(	_	
46-18	8384-8385	n	_	
46-19	8385-8386	=	_	
46-20	8386-8389	164	_	
46-21	8389-8390	)	_	
46-22	8391-8395	fMRI	_	
46-23	8396-8400	scan	_	
46-24	8400-8401	,	_	
46-25	8402-8409	imitate	_	
46-26	8409-8410	/	_	
46-27	8410-8417	observe	_	
46-28	8418-8419	(	_	
46-29	8419-8420	n	_	
46-30	8420-8421	=	_	
46-31	8421-8423	93	_	
46-32	8423-8424	)	_	
46-33	8425-8429	task	_	
46-34	8429-8430	,	_	
46-35	8431-8434	and	_	
46-36	8435-8443	empathic	_	
46-37	8444-8452	accuracy	_	
46-38	8453-8454	(	_	
46-39	8454-8455	n	_	
46-40	8455-8456	=	_	
46-41	8456-8459	183	_	
46-42	8459-8460	)	_	
46-43	8461-8465	task	_	
46-44	8465-8466	.	_	

#Text=All three data types were analyzed via connectivity analysis, and the two tasks were also analyzed using a general linear model (GLM) to detect task activations using the original paper’s methods.
47-1	8467-8470	All	_	
47-2	8471-8476	three	_	
47-3	8477-8481	data	_	
47-4	8482-8487	types	_	
47-5	8488-8492	were	_	
47-6	8493-8501	analyzed	_	
47-7	8502-8505	via	_	
47-8	8506-8518	connectivity	_	
47-9	8519-8527	analysis	_	
47-10	8527-8528	,	_	
47-11	8529-8532	and	_	
47-12	8533-8536	the	_	
47-13	8537-8540	two	_	
47-14	8541-8546	tasks	_	
47-15	8547-8551	were	_	
47-16	8552-8556	also	_	
47-17	8557-8565	analyzed	_	
47-18	8566-8571	using	_	
47-19	8572-8573	a	_	
47-20	8574-8581	general	_	
47-21	8582-8588	linear	_	
47-22	8589-8594	model	_	
47-23	8595-8596	(	_	
47-24	8596-8599	GLM	_	
47-25	8599-8600	)	_	
47-26	8601-8603	to	_	
47-27	8604-8610	detect	_	
47-28	8611-8615	task	_	
47-29	8616-8627	activations	_	
47-30	8628-8633	using	_	
47-31	8634-8637	the	_	
47-32	8638-8646	original	_	
47-33	8647-8652	paper	_	
47-34	8652-8653	’	_	
47-35	8653-8654	s	_	
47-36	8655-8662	methods	_	
47-37	8662-8663	.	_	

#Text=All connectivity data was preprocessed with FreeSurfer, AFNI, and FSL, including steps to minimize the impact of head motion artifact (i.e., nuisance parameter regression, removing high-motion timepoints, rejecting high motion subjects).
48-1	8664-8667	All	_	
48-2	8668-8680	connectivity	_	
48-3	8681-8685	data	_	
48-4	8686-8689	was	_	
48-5	8690-8702	preprocessed	_	
48-6	8703-8707	with	_	
48-7	8708-8718	FreeSurfer	_	
48-8	8718-8719	,	_	
48-9	8720-8724	AFNI	_	
48-10	8724-8725	,	_	
48-11	8726-8729	and	_	
48-12	8730-8733	FSL	_	
48-13	8733-8734	,	_	
48-14	8735-8744	including	_	
48-15	8745-8750	steps	_	
48-16	8751-8753	to	_	
48-17	8754-8762	minimize	_	
48-18	8763-8766	the	_	
48-19	8767-8773	impact	_	
48-20	8774-8776	of	_	
48-21	8777-8781	head	_	
48-22	8782-8788	motion	_	
48-23	8789-8797	artifact	_	
48-24	8798-8799	(	_	
48-25	8799-8802	i.e	_	
48-26	8802-8803	.	_	
48-27	8803-8804	,	_	
48-28	8805-8813	nuisance	_	
48-29	8814-8823	parameter	_	
48-30	8824-8834	regression	_	
48-31	8834-8835	,	_	
48-32	8836-8844	removing	_	
48-33	8845-8856	high-motion	_	
48-34	8857-8867	timepoints	_	
48-35	8867-8868	,	_	
48-36	8869-8878	rejecting	_	
48-37	8879-8883	high	_	
48-38	8884-8890	motion	_	
48-39	8891-8899	subjects	_	
48-40	8899-8900	)	_	
48-41	8900-8901	.	_	

#Text=Both tasks also separately underwent standard task-based fMRI pre-processing.
49-1	8902-8906	Both	_	
49-2	8907-8912	tasks	_	
49-3	8913-8917	also	_	
49-4	8918-8928	separately	_	
49-5	8929-8938	underwent	_	
49-6	8939-8947	standard	_	
49-7	8948-8958	task-based	_	
49-8	8959-8963	fMRI	_	
49-9	8964-8978	pre-processing	_	
49-10	8978-8979	.	_	

#Text=For connectivity analysis, the Pearson’s correlation between the mean timeseries from each region of interest (ROI) in a 268-region atlas was calculated for a total of 35,778 r-values per participant.
50-1	8980-8983	For	_	
50-2	8984-8996	connectivity	_	
50-3	8997-9005	analysis	_	
50-4	9005-9006	,	_	
50-5	9007-9010	the	_	
50-6	9011-9018	Pearson	_	
50-7	9018-9019	’	_	
50-8	9019-9020	s	_	
50-9	9021-9032	correlation	_	
50-10	9033-9040	between	_	
50-11	9041-9044	the	_	
50-12	9045-9049	mean	_	
50-13	9050-9060	timeseries	_	
50-14	9061-9065	from	_	
50-15	9066-9070	each	_	
50-16	9071-9077	region	_	
50-17	9078-9080	of	_	
50-18	9081-9089	interest	_	
50-19	9090-9091	(	_	
50-20	9091-9094	ROI	_	
50-21	9094-9095	)	_	
50-22	9096-9098	in	_	
50-23	9099-9100	a	_	
50-24	9101-9104	268	_	
50-25	9104-9105	-	_	
50-26	9105-9111	region	_	
50-27	9112-9117	atlas	_	
50-28	9118-9121	was	_	
50-29	9122-9132	calculated	_	
50-30	9133-9136	for	_	
50-31	9137-9138	a	_	
50-32	9139-9144	total	_	
50-33	9145-9147	of	_	
50-34	9148-9154	35,778	_	
50-35	9155-9163	r-values	_	
50-36	9164-9167	per	_	
50-37	9168-9179	participant	_	
50-38	9179-9180	.	_	

#Text=For task activations, the mean t-statistic from each ROI was calculated for a total of 268 t-values per participant.
51-1	9181-9184	For	_	
51-2	9185-9189	task	_	
51-3	9190-9201	activations	_	
51-4	9201-9202	,	_	
51-5	9203-9206	the	_	
51-6	9207-9211	mean	_	
51-7	9212-9223	t-statistic	_	
51-8	9224-9228	from	_	
51-9	9229-9233	each	_	
51-10	9234-9237	ROI	_	
51-11	9238-9241	was	_	
51-12	9242-9252	calculated	_	
51-13	9253-9256	for	_	
51-14	9257-9258	a	_	
51-15	9259-9264	total	_	
51-16	9265-9267	of	_	
51-17	9268-9271	268	_	
51-18	9272-9280	t-values	_	
51-19	9281-9284	per	_	
51-20	9285-9296	participant	_	
51-21	9296-9297	.	_	

#Text=See supplement for details.
52-1	9298-9301	See	_	
52-2	9302-9312	supplement	_	
52-3	9313-9316	for	_	
52-4	9317-9324	details	_	
52-5	9324-9325	.	_	

#Text=The biotype analysis groups participants with similar brain connectivity/function in regions associated with the SC/NC variables.
53-1	9326-9329	The	_	
53-2	9330-9337	biotype	_	
53-3	9338-9346	analysis	_	
53-4	9347-9353	groups	_	
53-5	9354-9366	participants	_	
53-6	9367-9371	with	_	
53-7	9372-9379	similar	_	
53-8	9380-9385	brain	_	
53-9	9386-9398	connectivity	_	
53-10	9398-9399	/	_	
53-11	9399-9407	function	_	
53-12	9408-9410	in	_	
53-13	9411-9418	regions	_	
53-14	9419-9429	associated	_	
53-15	9430-9434	with	_	
53-16	9435-9438	the	_	
53-17	9439-9441	SC	_	
53-18	9441-9442	/	_	
53-19	9442-9444	NC	_	
53-20	9445-9454	variables	_	
53-21	9454-9455	.	_	

#Text=First, we found a low-dimensional representation of cognitively-relevant brain connections/task-activations (defined here by the 12 SC/NC variables) using canonical correlation analysis (CCA), which is then clustered (hierarchical using Ward’s method) into groups of participants with similar brain connectivity/function in regions associated with the cognitive variable of interest.
54-1	9456-9461	First	_	
54-2	9461-9462	,	_	
54-3	9463-9465	we	_	
54-4	9466-9471	found	_	
54-5	9472-9473	a	_	
54-6	9474-9489	low-dimensional	_	
54-7	9490-9504	representation	_	
54-8	9505-9507	of	_	
54-9	9508-9528	cognitively-relevant	_	
54-10	9529-9534	brain	_	
54-11	9535-9546	connections	_	
54-12	9546-9547	/	_	
54-13	9547-9563	task-activations	_	
54-14	9564-9565	(	_	
54-15	9565-9572	defined	_	
54-16	9573-9577	here	_	
54-17	9578-9580	by	_	
54-18	9581-9584	the	_	
54-19	9585-9587	12	_	
54-20	9588-9590	SC	_	
54-21	9590-9591	/	_	
54-22	9591-9593	NC	_	
54-23	9594-9603	variables	_	
54-24	9603-9604	)	_	
54-25	9605-9610	using	_	
54-26	9611-9620	canonical	_	
54-27	9621-9632	correlation	_	
54-28	9633-9641	analysis	_	
54-29	9642-9643	(	_	
54-30	9643-9646	CCA	_	
54-31	9646-9647	)	_	
54-32	9647-9648	,	_	
54-33	9649-9654	which	_	
54-34	9655-9657	is	_	
54-35	9658-9662	then	_	
54-36	9663-9672	clustered	_	
54-37	9673-9674	(	_	
54-38	9674-9686	hierarchical	_	
54-39	9687-9692	using	_	
54-40	9693-9697	Ward	_	
54-41	9697-9698	’	_	
54-42	9698-9699	s	_	
54-43	9700-9706	method	_	
54-44	9706-9707	)	_	
54-45	9708-9712	into	_	
54-46	9713-9719	groups	_	
54-47	9720-9722	of	_	
54-48	9723-9735	participants	_	
54-49	9736-9740	with	_	
54-50	9741-9748	similar	_	
54-51	9749-9754	brain	_	
54-52	9755-9767	connectivity	_	
54-53	9767-9768	/	_	
54-54	9768-9776	function	_	
54-55	9777-9779	in	_	
54-56	9780-9787	regions	_	
54-57	9788-9798	associated	_	
54-58	9799-9803	with	_	
54-59	9804-9807	the	_	
54-60	9808-9817	cognitive	_	
54-61	9818-9826	variable	_	
54-62	9827-9829	of	_	
54-63	9830-9838	interest	_	
54-64	9838-9839	.	_	

#Text=Group differences in brain connectivity/function between biotypes were calculated (q[FDR]=0.05) to visualize these regions.
55-1	9840-9845	Group	_	
55-2	9846-9857	differences	_	
55-3	9858-9860	in	_	
55-4	9861-9866	brain	_	
55-5	9867-9879	connectivity	_	
55-6	9879-9880	/	_	
55-7	9880-9888	function	_	
55-8	9889-9896	between	_	
55-9	9897-9905	biotypes	_	
55-10	9906-9910	were	_	
55-11	9911-9921	calculated	_	
55-12	9922-9923	(	_	
55-13	9923-9924	q	_	
55-14	9924-9925	[	_	
55-15	9925-9928	FDR	_	
55-16	9928-9929	]	_	
55-17	9929-9930	=	_	
55-18	9930-9934	0.05	_	
55-19	9934-9935	)	_	
55-20	9936-9938	to	_	
55-21	9939-9948	visualize	_	
55-22	9949-9954	these	_	
55-23	9955-9962	regions	_	
55-24	9962-9963	.	_	

#Text=See supplement for details.
56-1	9964-9967	See	_	
56-2	9968-9978	supplement	_	
56-3	9979-9982	for	_	
56-4	9983-9990	details	_	
56-5	9990-9991	.	_	

#Text=We ranked the utility of each fMRI input (resting state, imitate/observe, and empathic accuracy) and analysis method (connectivity vs. task activations) by comparing SC/NC scores between biotypes.
57-1	9992-9994	We	_	
57-2	9995-10001	ranked	_	
57-3	10002-10005	the	_	
57-4	10006-10013	utility	_	
57-5	10014-10016	of	_	
57-6	10017-10021	each	_	
57-7	10022-10026	fMRI	_	
57-8	10027-10032	input	_	
57-9	10033-10034	(	_	
57-10	10034-10041	resting	_	
57-11	10042-10047	state	_	
57-12	10047-10048	,	_	
57-13	10049-10056	imitate	_	
57-14	10056-10057	/	_	
57-15	10057-10064	observe	_	
57-16	10064-10065	,	_	
57-17	10066-10069	and	_	
57-18	10070-10078	empathic	_	
57-19	10079-10087	accuracy	_	
57-20	10087-10088	)	_	
57-21	10089-10092	and	_	
57-22	10093-10101	analysis	_	
57-23	10102-10108	method	_	
57-24	10109-10110	(	_	
57-25	10110-10122	connectivity	_	
57-26	10123-10125	vs	_	
57-27	10125-10126	.	_	
57-28	10127-10131	task	_	
57-29	10132-10143	activations	_	
57-30	10143-10144	)	_	
57-31	10145-10147	by	_	
57-32	10148-10157	comparing	_	
57-33	10158-10160	SC	_	
57-34	10160-10161	/	_	
57-35	10161-10163	NC	_	
57-36	10164-10170	scores	_	
57-37	10171-10178	between	_	
57-38	10179-10187	biotypes	_	
57-39	10187-10188	.	_	

#Text=We validated our biotypes by comparing functional outcome and symptom burden scores, which were not included in the original analysis.
58-1	10189-10191	We	_	
58-2	10192-10201	validated	_	
58-3	10202-10205	our	_	
58-4	10206-10214	biotypes	_	
58-5	10215-10217	by	_	
58-6	10218-10227	comparing	_	
58-7	10228-10238	functional	_	
58-8	10239-10246	outcome	_	
58-9	10247-10250	and	_	
58-10	10251-10258	symptom	_	
58-11	10259-10265	burden	_	
58-12	10266-10272	scores	_	
58-13	10272-10273	,	_	
58-14	10274-10279	which	_	
58-15	10280-10284	were	_	
58-16	10285-10288	not	_	
58-17	10289-10297	included	_	
58-18	10298-10300	in	_	
58-19	10301-10304	the	_	
58-20	10305-10313	original	_	
58-21	10314-10322	analysis	_	
58-22	10322-10323	.	_	

#Text=For all SC/NC comparisons, we conducted a series of t-tests to contrast the mean score of each group after Z-scoring against the controls.
59-1	10324-10327	For	_	
59-2	10328-10331	all	_	
59-3	10332-10334	SC	_	
59-4	10334-10335	/	_	
59-5	10335-10337	NC	_	
59-6	10338-10349	comparisons	_	
59-7	10349-10350	,	_	
59-8	10351-10353	we	_	
59-9	10354-10363	conducted	_	
59-10	10364-10365	a	_	
59-11	10366-10372	series	_	
59-12	10373-10375	of	_	
59-13	10376-10383	t-tests	_	
59-14	10384-10386	to	_	
59-15	10387-10395	contrast	_	
59-16	10396-10399	the	_	
59-17	10400-10404	mean	_	
59-18	10405-10410	score	_	
59-19	10411-10413	of	_	
59-20	10414-10418	each	_	
59-21	10419-10424	group	_	
59-22	10425-10430	after	_	
59-23	10431-10440	Z-scoring	_	
59-24	10441-10448	against	_	
59-25	10449-10452	the	_	
59-26	10453-10461	controls	_	
59-27	10461-10462	.	_	

#Text=Functional outcome and symptom burden scores were Z-scored and analyzed using only SSDs.
60-1	10463-10473	Functional	_	
60-2	10474-10481	outcome	_	
60-3	10482-10485	and	_	
60-4	10486-10493	symptom	_	
60-5	10494-10500	burden	_	
60-6	10501-10507	scores	_	
60-7	10508-10512	were	_	
60-8	10513-10521	Z-scored	_	
60-9	10522-10525	and	_	
60-10	10526-10534	analyzed	_	
60-11	10535-10540	using	_	
60-12	10541-10545	only	_	
60-13	10546-10550	SSDs	_	
60-14	10550-10551	.	_	

#Text=All tests were corrected for multiple comparisons using false discovery rate (q[FDR]=0.05).
61-1	10552-10555	All	_	
61-2	10556-10561	tests	_	
61-3	10562-10566	were	_	
61-4	10567-10576	corrected	_	
61-5	10577-10580	for	_	
61-6	10581-10589	multiple	_	
61-7	10590-10601	comparisons	_	
61-8	10602-10607	using	_	
61-9	10608-10613	false	_	
61-10	10614-10623	discovery	_	
61-11	10624-10628	rate	_	
61-12	10629-10630	(	_	
61-13	10630-10631	q	_	
61-14	10631-10632	[	_	
61-15	10632-10635	FDR	_	
61-16	10635-10636	]	_	
61-17	10636-10637	=	_	
61-18	10637-10641	0.05	_	
61-19	10641-10642	)	_	
61-20	10642-10643	.	_	

#Text=We further validated our biotypes using both FreeSurfer-derived cortical thickness and subcortical volumes, as well as tract-based spatial statistics-derived fractional anisotropy (FA) and mean diffusivity (MD).
62-1	10644-10646	We	_	
62-2	10647-10654	further	_	
62-3	10655-10664	validated	_	
62-4	10665-10668	our	_	
62-5	10669-10677	biotypes	_	
62-6	10678-10683	using	_	
62-7	10684-10688	both	_	
62-8	10689-10707	FreeSurfer-derived	_	
62-9	10708-10716	cortical	_	
62-10	10717-10726	thickness	_	
62-11	10727-10730	and	_	
62-12	10731-10742	subcortical	_	
62-13	10743-10750	volumes	_	
62-14	10750-10751	,	_	
62-15	10752-10754	as	_	
62-16	10755-10759	well	_	
62-17	10760-10762	as	_	
62-18	10763-10774	tract-based	_	
62-19	10775-10782	spatial	_	
62-20	10783-10801	statistics-derived	_	
62-21	10802-10812	fractional	_	
62-22	10813-10823	anisotropy	_	
62-23	10824-10825	(	_	
62-24	10825-10827	FA	_	
62-25	10827-10828	)	_	
62-26	10829-10832	and	_	
62-27	10833-10837	mean	_	
62-28	10838-10849	diffusivity	_	
62-29	10850-10851	(	_	
62-30	10851-10853	MD	_	
62-31	10853-10854	)	_	
62-32	10854-10855	.	_	

#Text=See supplement for details.
63-1	10856-10859	See	_	
63-2	10860-10870	supplement	_	
63-3	10871-10874	for	_	
63-4	10875-10882	details	_	
63-5	10882-10883	.	_	

#Text=We assessed the relationship between the fMRI features and defined groups (biotypes, cognitive score-based, or diagnosis-based) by training a linear SVC (using 10-fold cross validation) to predict the group of held-out participants (test-set) using the fMRI features from a training set.
64-1	10884-10886	We	_	
64-2	10887-10895	assessed	_	
64-3	10896-10899	the	_	
64-4	10900-10912	relationship	_	
64-5	10913-10920	between	_	
64-6	10921-10924	the	_	
64-7	10925-10929	fMRI	_	
64-8	10930-10938	features	_	
64-9	10939-10942	and	_	
64-10	10943-10950	defined	_	
64-11	10951-10957	groups	_	
64-12	10958-10959	(	_	
64-13	10959-10967	biotypes	_	
64-14	10967-10968	,	_	
64-15	10969-10978	cognitive	_	
64-16	10979-10990	score-based	_	
64-17	10990-10991	,	_	
64-18	10992-10994	or	_	
64-19	10995-11010	diagnosis-based	_	
64-20	11010-11011	)	_	
64-21	11012-11014	by	_	
64-22	11015-11023	training	_	
64-23	11024-11025	a	_	
64-24	11026-11032	linear	_	
64-25	11033-11036	SVC	_	
64-26	11037-11038	(	_	
64-27	11038-11043	using	_	
64-28	11044-11046	10	_	
64-29	11046-11047	-	_	
64-30	11047-11051	fold	_	
64-31	11052-11057	cross	_	
64-32	11058-11068	validation	_	
64-33	11068-11069	)	_	
64-34	11070-11072	to	_	
64-35	11073-11080	predict	_	
64-36	11081-11084	the	_	
64-37	11085-11090	group	_	
64-38	11091-11093	of	_	
64-39	11094-11102	held-out	_	
64-40	11103-11115	participants	_	
64-41	11116-11117	(	_	
64-42	11117-11125	test-set	_	
64-43	11125-11126	)	_	
64-44	11127-11132	using	_	
64-45	11133-11136	the	_	
64-46	11137-11141	fMRI	_	
64-47	11142-11150	features	_	
64-48	11151-11155	from	_	
64-49	11156-11157	a	_	
64-50	11158-11166	training	_	
64-51	11167-11170	set	_	
64-52	11170-11171	.	_	

#Text=Each column of the fMRI input matrix was Z-scored before training.
65-1	11172-11176	Each	_	
65-2	11177-11183	column	_	
65-3	11184-11186	of	_	
65-4	11187-11190	the	_	
65-5	11191-11195	fMRI	_	
65-6	11196-11201	input	_	
65-7	11202-11208	matrix	_	
65-8	11209-11212	was	_	
65-9	11213-11221	Z-scored	_	
65-10	11222-11228	before	_	
65-11	11229-11237	training	_	
65-12	11237-11238	.	_	

#Text=For all classification analyses conducted with biotype-groups, CCA and clustering was performed on the training set alone for each fold, to prevent any information sharing between the training and test set.
66-1	11239-11242	For	_	
66-2	11243-11246	all	_	
66-3	11247-11261	classification	_	
66-4	11262-11270	analyses	_	
66-5	11271-11280	conducted	_	
66-6	11281-11285	with	_	
66-7	11286-11300	biotype-groups	_	
66-8	11300-11301	,	_	
66-9	11302-11305	CCA	_	
66-10	11306-11309	and	_	
66-11	11310-11320	clustering	_	
66-12	11321-11324	was	_	
66-13	11325-11334	performed	_	
66-14	11335-11337	on	_	
66-15	11338-11341	the	_	
66-16	11342-11350	training	_	
66-17	11351-11354	set	_	
66-18	11355-11360	alone	_	
66-19	11361-11364	for	_	
66-20	11365-11369	each	_	
66-21	11370-11374	fold	_	
66-22	11374-11375	,	_	
66-23	11376-11378	to	_	
66-24	11379-11386	prevent	_	
66-25	11387-11390	any	_	
66-26	11391-11402	information	_	
66-27	11403-11410	sharing	_	
66-28	11411-11418	between	_	
66-29	11419-11422	the	_	
66-30	11423-11431	training	_	
66-31	11432-11435	and	_	
66-32	11436-11440	test	_	
66-33	11441-11444	set	_	
66-34	11444-11445	.	_	

#Text=The mean accuracy, recall, precision, f1 score (harmonic mean of precision and recall), and area under the curve of the receiver operator characteristic (AUC) was calculated across all folds.
67-1	11446-11449	The	_	
67-2	11450-11454	mean	_	
67-3	11455-11463	accuracy	_	
67-4	11463-11464	,	_	
67-5	11465-11471	recall	_	
67-6	11471-11472	,	_	
67-7	11473-11482	precision	_	
67-8	11482-11483	,	_	
67-9	11484-11486	f1	_	
67-10	11487-11492	score	_	
67-11	11493-11494	(	_	
67-12	11494-11502	harmonic	_	
67-13	11503-11507	mean	_	
67-14	11508-11510	of	_	
67-15	11511-11520	precision	_	
67-16	11521-11524	and	_	
67-17	11525-11531	recall	_	
67-18	11531-11532	)	_	
67-19	11532-11533	,	_	
67-20	11534-11537	and	_	
67-21	11538-11542	area	_	
67-22	11543-11548	under	_	
67-23	11549-11552	the	_	
67-24	11553-11558	curve	_	
67-25	11559-11561	of	_	
67-26	11562-11565	the	_	
67-27	11566-11574	receiver	_	
67-28	11575-11583	operator	_	
67-29	11584-11598	characteristic	_	
67-30	11599-11600	(	_	
67-31	11600-11603	AUC	_	
67-32	11603-11604	)	_	
67-33	11605-11608	was	_	
67-34	11609-11619	calculated	_	
67-35	11620-11626	across	_	
67-36	11627-11630	all	_	
67-37	11631-11636	folds	_	
67-38	11636-11637	.	_	

#Text=For all cognitive-score based group analyses, we split participants into a normal and poorly-performing group based on a percentile split of the first principal component of the 12 SC/NC scores.
68-1	11638-11641	For	_	
68-2	11642-11645	all	_	
68-3	11646-11661	cognitive-score	_	
68-4	11662-11667	based	_	
68-5	11668-11673	group	_	
68-6	11674-11682	analyses	_	
68-7	11682-11683	,	_	
68-8	11684-11686	we	_	
68-9	11687-11692	split	_	
68-10	11693-11705	participants	_	
68-11	11706-11710	into	_	
68-12	11711-11712	a	_	
68-13	11713-11719	normal	_	
68-14	11720-11723	and	_	
68-15	11724-11741	poorly-performing	_	
68-16	11742-11747	group	_	
68-17	11748-11753	based	_	
68-18	11754-11756	on	_	
68-19	11757-11758	a	_	
68-20	11759-11769	percentile	_	
68-21	11770-11775	split	_	
68-22	11776-11778	of	_	
68-23	11779-11782	the	_	
68-24	11783-11788	first	_	
68-25	11789-11798	principal	_	
68-26	11799-11808	component	_	
68-27	11809-11811	of	_	
68-28	11812-11815	the	_	
68-29	11816-11818	12	_	
68-30	11819-11821	SC	_	
68-31	11821-11822	/	_	
68-32	11822-11824	NC	_	
68-33	11825-11831	scores	_	
68-34	11831-11832	.	_	

#Text=We took diagnosis-prediction performance as baseline.
69-1	11833-11835	We	_	
69-2	11836-11840	took	_	
69-3	11841-11861	diagnosis-prediction	_	
69-4	11862-11873	performance	_	
69-5	11874-11876	as	_	
69-6	11877-11885	baseline	_	
69-7	11885-11886	.	_	

#Text=See figure s1 for an overview, and supplement for details.
70-1	11887-11890	See	_	
70-2	11891-11897	figure	_	
70-3	11898-11900	s1	_	
70-4	11901-11904	for	_	
70-5	11905-11907	an	_	
70-6	11908-11916	overview	_	
70-7	11916-11917	,	_	
70-8	11918-11921	and	_	
70-9	11922-11932	supplement	_	
70-10	11933-11936	for	_	
70-11	11937-11944	details	_	
70-12	11944-11945	.	_	

#Text=To rank the utility of the fMRI features, we compared their ability to split the sample into groups with large SC/NC score differences via the t-scores computed comparing SC/NC scores between biotypes (we report the mean t statistic across the 12 SC/NC scores assessed between groups in each case), and their performance when used to train a SVC to predict the biotype of held-out participants via the mean test-set AUC computed during cross-validation.
71-1	11946-11948	To	_	
71-2	11949-11953	rank	_	
71-3	11954-11957	the	_	
71-4	11958-11965	utility	_	
71-5	11966-11968	of	_	
71-6	11969-11972	the	_	
71-7	11973-11977	fMRI	_	
71-8	11978-11986	features	_	
71-9	11986-11987	,	_	
71-10	11988-11990	we	_	
71-11	11991-11999	compared	_	
71-12	12000-12005	their	_	
71-13	12006-12013	ability	_	
71-14	12014-12016	to	_	
71-15	12017-12022	split	_	
71-16	12023-12026	the	_	
71-17	12027-12033	sample	_	
71-18	12034-12038	into	_	
71-19	12039-12045	groups	_	
71-20	12046-12050	with	_	
71-21	12051-12056	large	_	
71-22	12057-12059	SC	_	
71-23	12059-12060	/	_	
71-24	12060-12062	NC	_	
71-25	12063-12068	score	_	
71-26	12069-12080	differences	_	
71-27	12081-12084	via	_	
71-28	12085-12088	the	_	
71-29	12089-12097	t-scores	_	
71-30	12098-12106	computed	_	
71-31	12107-12116	comparing	_	
71-32	12117-12119	SC	_	
71-33	12119-12120	/	_	
71-34	12120-12122	NC	_	
71-35	12123-12129	scores	_	
71-36	12130-12137	between	_	
71-37	12138-12146	biotypes	_	
71-38	12147-12148	(	_	
71-39	12148-12150	we	_	
71-40	12151-12157	report	_	
71-41	12158-12161	the	_	
71-42	12162-12166	mean	_	
71-43	12167-12168	t	_	
71-44	12169-12178	statistic	_	
71-45	12179-12185	across	_	
71-46	12186-12189	the	_	
71-47	12190-12192	12	_	
71-48	12193-12195	SC	_	
71-49	12195-12196	/	_	
71-50	12196-12198	NC	_	
71-51	12199-12205	scores	_	
71-52	12206-12214	assessed	_	
71-53	12215-12222	between	_	
71-54	12223-12229	groups	_	
71-55	12230-12232	in	_	
71-56	12233-12237	each	_	
71-57	12238-12242	case	_	
71-58	12242-12243	)	_	
71-59	12243-12244	,	_	
71-60	12245-12248	and	_	
71-61	12249-12254	their	_	
71-62	12255-12266	performance	_	
71-63	12267-12271	when	_	
71-64	12272-12276	used	_	
71-65	12277-12279	to	_	
71-66	12280-12285	train	_	
71-67	12286-12287	a	_	
71-68	12288-12291	SVC	_	
71-69	12292-12294	to	_	
71-70	12295-12302	predict	_	
71-71	12303-12306	the	_	
71-72	12307-12314	biotype	_	
71-73	12315-12317	of	_	
71-74	12318-12326	held-out	_	
71-75	12327-12339	participants	_	
71-76	12340-12343	via	_	
71-77	12344-12347	the	_	
71-78	12348-12352	mean	_	
71-79	12353-12361	test-set	_	
71-80	12362-12365	AUC	_	
71-81	12366-12374	computed	_	
71-82	12375-12381	during	_	
71-83	12382-12398	cross-validation	_	
71-84	12398-12399	.	_	

#Text=Each biotype model must surpass baseline SC/NC score differences between diagnostic groups to be considered useful.
72-1	12400-12404	Each	_	
72-2	12405-12412	biotype	_	
72-3	12413-12418	model	_	
72-4	12419-12423	must	_	
72-5	12424-12431	surpass	_	
72-6	12432-12440	baseline	_	
72-7	12441-12443	SC	_	
72-8	12443-12444	/	_	
72-9	12444-12446	NC	_	
72-10	12447-12452	score	_	
72-11	12453-12464	differences	_	
72-12	12465-12472	between	_	
72-13	12473-12483	diagnostic	_	
72-14	12484-12490	groups	_	
72-15	12491-12493	to	_	
72-16	12494-12496	be	_	
72-17	12497-12507	considered	_	
72-18	12508-12514	useful	_	
72-19	12514-12515	.	_	

#Text=While SC/NC score differences between biotypes are expected given that CCA selected fMRI features with a strong relationship to the SC/NC, the magnitude of the between-group differences should modulate depending on the strength of that relationship.
73-1	12516-12521	While	_	
73-2	12522-12524	SC	_	
73-3	12524-12525	/	_	
73-4	12525-12527	NC	_	
73-5	12528-12533	score	_	
73-6	12534-12545	differences	_	
73-7	12546-12553	between	_	
73-8	12554-12562	biotypes	_	
73-9	12563-12566	are	_	
73-10	12567-12575	expected	_	
73-11	12576-12581	given	_	
73-12	12582-12586	that	_	
73-13	12587-12590	CCA	_	
73-14	12591-12599	selected	_	
73-15	12600-12604	fMRI	_	
73-16	12605-12613	features	_	
73-17	12614-12618	with	_	
73-18	12619-12620	a	_	
73-19	12621-12627	strong	_	
73-20	12628-12640	relationship	_	
73-21	12641-12643	to	_	
73-22	12644-12647	the	_	
73-23	12648-12650	SC	_	
73-24	12650-12651	/	_	
73-25	12651-12653	NC	_	
73-26	12653-12654	,	_	
73-27	12655-12658	the	_	
73-28	12659-12668	magnitude	_	
73-29	12669-12671	of	_	
73-30	12672-12675	the	_	
73-31	12676-12689	between-group	_	
73-32	12690-12701	differences	_	
73-33	12702-12708	should	_	
73-34	12709-12717	modulate	_	
73-35	12718-12727	depending	_	
73-36	12728-12730	on	_	
73-37	12731-12734	the	_	
73-38	12735-12743	strength	_	
73-39	12744-12746	of	_	
73-40	12747-12751	that	_	
73-41	12752-12764	relationship	_	
73-42	12764-12765	.	_	

#Text=We then attempted to replicate our main fMRI findings an independent sample of 75 participants who completed the resting state and imitate/observe tasks; see supplement for details.
74-1	12766-12768	We	_	
74-2	12769-12773	then	_	
74-3	12774-12783	attempted	_	
74-4	12784-12786	to	_	
74-5	12787-12796	replicate	_	
74-6	12797-12800	our	_	
74-7	12801-12805	main	_	
74-8	12806-12810	fMRI	_	
74-9	12811-12819	findings	_	
74-10	12820-12822	an	_	
74-11	12823-12834	independent	_	
74-12	12835-12841	sample	_	
74-13	12842-12844	of	_	
74-14	12845-12847	75	_	
74-15	12848-12860	participants	_	
74-16	12861-12864	who	_	
74-17	12865-12874	completed	_	
74-18	12875-12878	the	_	
74-19	12879-12886	resting	_	
74-20	12887-12892	state	_	
74-21	12893-12896	and	_	
74-22	12897-12904	imitate	_	
74-23	12904-12905	/	_	
74-24	12905-12912	observe	_	
74-25	12913-12918	tasks	_	
74-26	12918-12919	;	_	
74-27	12920-12923	see	_	
74-28	12924-12934	supplement	_	
74-29	12935-12938	for	_	
74-30	12939-12946	details	_	
74-31	12946-12947	.	_	

#Text=The analysis code is packaged as a freely-available tool ‘xbrain’ (www.github.com/josephdviviano/xbrain), and the follow-up scripts used to analyze the outputs of xbrain can be found here (www.github.com/josephdviviano/biotype).
75-1	12948-12951	The	_	
75-2	12952-12960	analysis	_	
75-3	12961-12965	code	_	
75-4	12966-12968	is	_	
75-5	12969-12977	packaged	_	
75-6	12978-12980	as	_	
75-7	12981-12982	a	_	
75-8	12983-12999	freely-available	_	
75-9	13000-13004	tool	_	
75-10	13005-13006	‘	_	
75-11	13006-13012	xbrain	_	
75-12	13012-13013	’	_	
75-13	13014-13015	(	_	
75-14	13015-13029	www.github.com	_	
75-15	13029-13030	/	_	
75-16	13030-13044	josephdviviano	_	
75-17	13044-13045	/	_	
75-18	13045-13051	xbrain	_	
75-19	13051-13052	)	_	
75-20	13052-13053	,	_	
75-21	13054-13057	and	_	
75-22	13058-13061	the	_	
75-23	13062-13071	follow-up	_	
75-24	13072-13079	scripts	_	
75-25	13080-13084	used	_	
75-26	13085-13087	to	_	
75-27	13088-13095	analyze	_	
75-28	13096-13099	the	_	
75-29	13100-13107	outputs	_	
75-30	13108-13110	of	_	
75-31	13111-13117	xbrain	_	
75-32	13118-13121	can	_	
75-33	13122-13124	be	_	
75-34	13125-13130	found	_	
75-35	13131-13135	here	_	
75-36	13136-13137	(	_	
75-37	13137-13151	www.github.com	_	
75-38	13151-13152	/	_	
75-39	13152-13166	josephdviviano	_	
75-40	13166-13167	/	_	
75-41	13167-13174	biotype	_	
75-42	13174-13175	)	_	
75-43	13175-13176	.	_	

#Text=Results
#Text=All connectivity-based biotype analyses (resting state, imitate/observe, and empathic accuracy) consistently found two biotypes in our sample: a ‘normal’ and ‘poorly-performing’ biotype (in terms of SC/NC performance).
76-1	13177-13184	Results	_	
76-2	13185-13188	All	_	
76-3	13189-13207	connectivity-based	_	
76-4	13208-13215	biotype	_	
76-5	13216-13224	analyses	_	
76-6	13225-13226	(	_	
76-7	13226-13233	resting	_	
76-8	13234-13239	state	_	
76-9	13239-13240	,	_	
76-10	13241-13248	imitate	_	
76-11	13248-13249	/	_	
76-12	13249-13256	observe	_	
76-13	13256-13257	,	_	
76-14	13258-13261	and	_	
76-15	13262-13270	empathic	_	
76-16	13271-13279	accuracy	_	
76-17	13279-13280	)	_	
76-18	13281-13293	consistently	_	
76-19	13294-13299	found	_	
76-20	13300-13303	two	_	
76-21	13304-13312	biotypes	_	
76-22	13313-13315	in	_	
76-23	13316-13319	our	_	
76-24	13320-13326	sample	_	
76-25	13326-13327	:	_	
76-26	13328-13329	a	_	
76-27	13330-13331	‘	_	
76-28	13331-13337	normal	_	
76-29	13337-13338	’	_	
76-30	13339-13342	and	_	
76-31	13343-13344	‘	_	
76-32	13344-13361	poorly-performing	_	
76-33	13361-13362	’	_	
76-34	13363-13370	biotype	_	
76-35	13371-13372	(	_	
76-36	13372-13374	in	_	
76-37	13375-13380	terms	_	
76-38	13381-13383	of	_	
76-39	13384-13386	SC	_	
76-40	13386-13387	/	_	
76-41	13387-13389	NC	_	
76-42	13390-13401	performance	_	
76-43	13401-13402	)	_	
76-44	13402-13403	.	_	

#Text=CCA found different low-dimensional representations of each fMRI type considered, therefore biotype membership differed depending on the input fMRI data.
77-1	13404-13407	CCA	_	
77-2	13408-13413	found	_	
77-3	13414-13423	different	_	
77-4	13424-13439	low-dimensional	_	
77-5	13440-13455	representations	_	
77-6	13456-13458	of	_	
77-7	13459-13463	each	_	
77-8	13464-13468	fMRI	_	
77-9	13469-13473	type	_	
77-10	13474-13484	considered	_	
77-11	13484-13485	,	_	
77-12	13486-13495	therefore	_	
77-13	13496-13503	biotype	_	
77-14	13504-13514	membership	_	
77-15	13515-13523	differed	_	
77-16	13524-13533	depending	_	
77-17	13534-13536	on	_	
77-18	13537-13540	the	_	
77-19	13541-13546	input	_	
77-20	13547-13551	fMRI	_	
77-21	13552-13556	data	_	
77-22	13556-13557	.	_	

#Text=Defining biotype groups with resting state connectivity identified a poorly-performing biotype with significantly lower SC/NC scores than the normal biotype (mean t difference between biotypes=7.4, all significant q[FDR]=0.05).
78-1	13558-13566	Defining	_	
78-2	13567-13574	biotype	_	
78-3	13575-13581	groups	_	
78-4	13582-13586	with	_	
78-5	13587-13594	resting	_	
78-6	13595-13600	state	_	
78-7	13601-13613	connectivity	_	
78-8	13614-13624	identified	_	
78-9	13625-13626	a	_	
78-10	13627-13644	poorly-performing	_	
78-11	13645-13652	biotype	_	
78-12	13653-13657	with	_	
78-13	13658-13671	significantly	_	
78-14	13672-13677	lower	_	
78-15	13678-13680	SC	_	
78-16	13680-13681	/	_	
78-17	13681-13683	NC	_	
78-18	13684-13690	scores	_	
78-19	13691-13695	than	_	
78-20	13696-13699	the	_	
78-21	13700-13706	normal	_	
78-22	13707-13714	biotype	_	
78-23	13715-13716	(	_	
78-24	13716-13720	mean	_	
78-25	13721-13722	t	_	
78-26	13723-13733	difference	_	
78-27	13734-13741	between	_	
78-28	13742-13750	biotypes	_	
78-29	13750-13751	=	_	
78-30	13751-13754	7.4	_	
78-31	13754-13755	,	_	
78-32	13756-13759	all	_	
78-33	13760-13771	significant	_	
78-34	13772-13773	q	_	
78-35	13773-13774	[	_	
78-36	13774-13777	FDR	_	
78-37	13777-13778	]	_	
78-38	13778-13779	=	_	
78-39	13779-13783	0.05	_	
78-40	13783-13784	)	_	
78-41	13784-13785	.	_	

#Text=The differences in SC/NC scores between biotypes found using resting state data were greater than the SC/NC score differences found when comparing diagnostic groups in the same subjects, as well the SC/NC score differences found between the biotypes defined using all other functional MRI data (mean t=6.18, all significant q[FDR]=0.05; figure 1,s2; see supplement for replication and task details).
79-1	13786-13789	The	_	
79-2	13790-13801	differences	_	
79-3	13802-13804	in	_	
79-4	13805-13807	SC	_	
79-5	13807-13808	/	_	
79-6	13808-13810	NC	_	
79-7	13811-13817	scores	_	
79-8	13818-13825	between	_	
79-9	13826-13834	biotypes	_	
79-10	13835-13840	found	_	
79-11	13841-13846	using	_	
79-12	13847-13854	resting	_	
79-13	13855-13860	state	_	
79-14	13861-13865	data	_	
79-15	13866-13870	were	_	
79-16	13871-13878	greater	_	
79-17	13879-13883	than	_	
79-18	13884-13887	the	_	
79-19	13888-13890	SC	_	
79-20	13890-13891	/	_	
79-21	13891-13893	NC	_	
79-22	13894-13899	score	_	
79-23	13900-13911	differences	_	
79-24	13912-13917	found	_	
79-25	13918-13922	when	_	
79-26	13923-13932	comparing	_	
79-27	13933-13943	diagnostic	_	
79-28	13944-13950	groups	_	
79-29	13951-13953	in	_	
79-30	13954-13957	the	_	
79-31	13958-13962	same	_	
79-32	13963-13971	subjects	_	
79-33	13971-13972	,	_	
79-34	13973-13975	as	_	
79-35	13976-13980	well	_	
79-36	13981-13984	the	_	
79-37	13985-13987	SC	_	
79-38	13987-13988	/	_	
79-39	13988-13990	NC	_	
79-40	13991-13996	score	_	
79-41	13997-14008	differences	_	
79-42	14009-14014	found	_	
79-43	14015-14022	between	_	
79-44	14023-14026	the	_	
79-45	14027-14035	biotypes	_	
79-46	14036-14043	defined	_	
79-47	14044-14049	using	_	
79-48	14050-14053	all	_	
79-49	14054-14059	other	_	
79-50	14060-14070	functional	_	
79-51	14071-14074	MRI	_	
79-52	14075-14079	data	_	
79-53	14080-14081	(	_	
79-54	14081-14085	mean	_	
79-55	14086-14087	t	_	
79-56	14087-14088	=	_	
79-57	14088-14092	6.18	_	
79-58	14092-14093	,	_	
79-59	14094-14097	all	_	
79-60	14098-14109	significant	_	
79-61	14110-14111	q	_	
79-62	14111-14112	[	_	
79-63	14112-14115	FDR	_	
79-64	14115-14116	]	_	
79-65	14116-14117	=	_	
79-66	14117-14121	0.05	_	
79-67	14121-14122	;	_	
79-68	14123-14129	figure	_	
79-69	14130-14131	1	_	
79-70	14131-14132	,	_	
79-71	14132-14134	s2	_	
79-72	14134-14135	;	_	
79-73	14136-14139	see	_	
79-74	14140-14150	supplement	_	
79-75	14151-14154	for	_	
79-76	14155-14166	replication	_	
79-77	14167-14170	and	_	
79-78	14171-14175	task	_	
79-79	14176-14183	details	_	
79-80	14183-14184	)	_	
79-81	14184-14185	.	_	

#Text=While the poorly-performing biotype’s mean scores are lower, the distribution of their scores overlap with the normally- performing biotype around Z=0.
80-1	14186-14191	While	_	
80-2	14192-14195	the	_	
80-3	14196-14213	poorly-performing	_	
80-4	14214-14221	biotype	_	
80-5	14221-14222	’	_	
80-6	14222-14223	s	_	
80-7	14224-14228	mean	_	
80-8	14229-14235	scores	_	
80-9	14236-14239	are	_	
80-10	14240-14245	lower	_	
80-11	14245-14246	,	_	
80-12	14247-14250	the	_	
80-13	14251-14263	distribution	_	
80-14	14264-14266	of	_	
80-15	14267-14272	their	_	
80-16	14273-14279	scores	_	
80-17	14280-14287	overlap	_	
80-18	14288-14292	with	_	
80-19	14293-14296	the	_	
80-20	14297-14305	normally	_	
80-21	14305-14306	-	_	
80-22	14307-14317	performing	_	
80-23	14318-14325	biotype	_	
80-24	14326-14332	around	_	
80-25	14333-14334	Z	_	
80-26	14334-14335	=	_	
80-27	14335-14336	0	_	
80-28	14336-14337	.	_	

#Text=The poorly-performing biotype defined using resting state data was composed of 87% SSD (n=53/61), and the normal biotype consisted of 41% SSD (n=42/103; figure s3).
81-1	14338-14341	The	_	
81-2	14342-14359	poorly-performing	_	
81-3	14360-14367	biotype	_	
81-4	14368-14375	defined	_	
81-5	14376-14381	using	_	
81-6	14382-14389	resting	_	
81-7	14390-14395	state	_	
81-8	14396-14400	data	_	
81-9	14401-14404	was	_	
81-10	14405-14413	composed	_	
81-11	14414-14416	of	_	
81-12	14417-14420	87%	_	
81-13	14421-14424	SSD	_	
81-14	14425-14426	(	_	
81-15	14426-14427	n	_	
81-16	14427-14428	=	_	
81-17	14428-14430	53	_	
81-18	14430-14431	/	_	
81-19	14431-14433	61	_	
81-20	14433-14434	)	_	
81-21	14434-14435	,	_	
81-22	14436-14439	and	_	
81-23	14440-14443	the	_	
81-24	14444-14450	normal	_	
81-25	14451-14458	biotype	_	
81-26	14459-14468	consisted	_	
81-27	14469-14471	of	_	
81-28	14472-14475	41%	_	
81-29	14476-14479	SSD	_	
81-30	14480-14481	(	_	
81-31	14481-14482	n	_	
81-32	14482-14483	=	_	
81-33	14483-14485	42	_	
81-34	14485-14486	/	_	
81-35	14486-14489	103	_	
81-36	14489-14490	;	_	
81-37	14491-14497	figure	_	
81-38	14498-14500	s3	_	
81-39	14500-14501	)	_	
81-40	14501-14502	.	_	

#Text=There was no significant difference in the proportions of participants by site in each biotype (see table 2 for complete resting state connectivity-based biotype demographics).
82-1	14503-14508	There	_	
82-2	14509-14512	was	_	
82-3	14513-14515	no	_	
82-4	14516-14527	significant	_	
82-5	14528-14538	difference	_	
82-6	14539-14541	in	_	
82-7	14542-14545	the	_	
82-8	14546-14557	proportions	_	
82-9	14558-14560	of	_	
82-10	14561-14573	participants	_	
82-11	14574-14576	by	_	
82-12	14577-14581	site	_	
82-13	14582-14584	in	_	
82-14	14585-14589	each	_	
82-15	14590-14597	biotype	_	
82-16	14598-14599	(	_	
82-17	14599-14602	see	_	
82-18	14603-14608	table	_	
82-19	14609-14610	2	_	
82-20	14611-14614	for	_	
82-21	14615-14623	complete	_	
82-22	14624-14631	resting	_	
82-23	14632-14637	state	_	
82-24	14638-14656	connectivity-based	_	
82-25	14657-14664	biotype	_	
82-26	14665-14677	demographics	_	
82-27	14677-14678	)	_	
82-28	14678-14679	.	_	

#Text=The pattern observed for the 12 SC/NC scores included in the biotype procedure held for both the composite MATRICS score (t(164)=9.45, p=3.69×10−17) and the number of correct responses from the ER40 (t(164)=5.93, p=1.75×10−8).
83-1	14680-14683	The	_	
83-2	14684-14691	pattern	_	
83-3	14692-14700	observed	_	
83-4	14701-14704	for	_	
83-5	14705-14708	the	_	
83-6	14709-14711	12	_	
83-7	14712-14714	SC	_	
83-8	14714-14715	/	_	
83-9	14715-14717	NC	_	
83-10	14718-14724	scores	_	
83-11	14725-14733	included	_	
83-12	14734-14736	in	_	
83-13	14737-14740	the	_	
83-14	14741-14748	biotype	_	
83-15	14749-14758	procedure	_	
83-16	14759-14763	held	_	
83-17	14764-14767	for	_	
83-18	14768-14772	both	_	
83-19	14773-14776	the	_	
83-20	14777-14786	composite	_	
83-21	14787-14794	MATRICS	_	
83-22	14795-14800	score	_	
83-23	14801-14802	(	_	
83-24	14802-14803	t	_	
83-25	14803-14804	(	_	
83-26	14804-14807	164	_	
83-27	14807-14808	)	_	
83-28	14808-14809	=	_	
83-29	14809-14813	9.45	_	
83-30	14813-14814	,	_	
83-31	14815-14816	p	_	
83-32	14816-14817	=	_	
83-33	14817-14821	3.69	_	
83-34	14821-14822	×	_	
83-35	14822-14824	10	_	
83-36	14824-14825	−	_	
83-37	14825-14827	17	_	
83-38	14827-14828	)	_	
83-39	14829-14832	and	_	
83-40	14833-14836	the	_	
83-41	14837-14843	number	_	
83-42	14844-14846	of	_	
83-43	14847-14854	correct	_	
83-44	14855-14864	responses	_	
83-45	14865-14869	from	_	
83-46	14870-14873	the	_	
83-47	14874-14878	ER40	_	
83-48	14879-14880	(	_	
83-49	14880-14881	t	_	
83-50	14881-14882	(	_	
83-51	14882-14885	164	_	
83-52	14885-14886	)	_	
83-53	14886-14887	=	_	
83-54	14887-14891	5.93	_	
83-55	14891-14892	,	_	
83-56	14893-14894	p	_	
83-57	14894-14895	=	_	
83-58	14895-14899	1.75	_	
83-59	14899-14900	×	_	
83-60	14900-14902	10	_	
83-61	14902-14903	−	_	
83-62	14903-14904	8	_	
83-63	14904-14905	)	_	
83-64	14905-14906	.	_	

#Text=Since these 12 SC/NC scores were used to define the biotypes in question, the test statistics were only used on as an ordinal ranking measure to compare the utility of each input fMRI data type investigated.
84-1	14907-14912	Since	_	
84-2	14913-14918	these	_	
84-3	14919-14921	12	_	
84-4	14922-14924	SC	_	
84-5	14924-14925	/	_	
84-6	14925-14927	NC	_	
84-7	14928-14934	scores	_	
84-8	14935-14939	were	_	
84-9	14940-14944	used	_	
84-10	14945-14947	to	_	
84-11	14948-14954	define	_	
84-12	14955-14958	the	_	
84-13	14959-14967	biotypes	_	
84-14	14968-14970	in	_	
84-15	14971-14979	question	_	
84-16	14979-14980	,	_	
84-17	14981-14984	the	_	
84-18	14985-14989	test	_	
84-19	14990-15000	statistics	_	
84-20	15001-15005	were	_	
84-21	15006-15010	only	_	
84-22	15011-15015	used	_	
84-23	15016-15018	on	_	
84-24	15019-15021	as	_	
84-25	15022-15024	an	_	
84-26	15025-15032	ordinal	_	
84-27	15033-15040	ranking	_	
84-28	15041-15048	measure	_	
84-29	15049-15051	to	_	
84-30	15052-15059	compare	_	
84-31	15060-15063	the	_	
84-32	15064-15071	utility	_	
84-33	15072-15074	of	_	
84-34	15075-15079	each	_	
84-35	15080-15085	input	_	
84-36	15086-15090	fMRI	_	
84-37	15091-15095	data	_	
84-38	15096-15100	type	_	
84-39	15101-15113	investigated	_	
84-40	15113-15114	.	_	

#Text=Only the SSDs from each biotype of the resting state connectivity analyses were compared on functional outcome and burden scores (n=95).
85-1	15115-15119	Only	_	
85-2	15120-15123	the	_	
85-3	15124-15128	SSDs	_	
85-4	15129-15133	from	_	
85-5	15134-15138	each	_	
85-6	15139-15146	biotype	_	
85-7	15147-15149	of	_	
85-8	15150-15153	the	_	
85-9	15154-15161	resting	_	
85-10	15162-15167	state	_	
85-11	15168-15180	connectivity	_	
85-12	15181-15189	analyses	_	
85-13	15190-15194	were	_	
85-14	15195-15203	compared	_	
85-15	15204-15206	on	_	
85-16	15207-15217	functional	_	
85-17	15218-15225	outcome	_	
85-18	15226-15229	and	_	
85-19	15230-15236	burden	_	
85-20	15237-15243	scores	_	
85-21	15244-15245	(	_	
85-22	15245-15246	n	_	
85-23	15246-15247	=	_	
85-24	15247-15249	95	_	
85-25	15249-15250	)	_	
85-26	15250-15251	.	_	

#Text=SSD participants in the poorly-performing biotype had significantly lower outcome scores as well higher general health burden as measured by the CIRSG (figure 1, table s1) compared to the the normal biotype.
86-1	15252-15255	SSD	_	
86-2	15256-15268	participants	_	
86-3	15269-15271	in	_	
86-4	15272-15275	the	_	
86-5	15276-15293	poorly-performing	_	
86-6	15294-15301	biotype	_	
86-7	15302-15305	had	_	
86-8	15306-15319	significantly	_	
86-9	15320-15325	lower	_	
86-10	15326-15333	outcome	_	
86-11	15334-15340	scores	_	
86-12	15341-15343	as	_	
86-13	15344-15348	well	_	
86-14	15349-15355	higher	_	
86-15	15356-15363	general	_	
86-16	15364-15370	health	_	
86-17	15371-15377	burden	_	
86-18	15378-15380	as	_	
86-19	15381-15389	measured	_	
86-20	15390-15392	by	_	
86-21	15393-15396	the	_	
86-22	15397-15402	CIRSG	_	
86-23	15403-15404	(	_	
86-24	15404-15410	figure	_	
86-25	15411-15412	1	_	
86-26	15412-15413	,	_	
86-27	15414-15419	table	_	
86-28	15420-15422	s1	_	
86-29	15422-15423	)	_	
86-30	15424-15432	compared	_	
86-31	15433-15435	to	_	
86-32	15436-15439	the	_	
86-33	15440-15443	the	_	
86-34	15444-15450	normal	_	
86-35	15451-15458	biotype	_	
86-36	15458-15459	.	_	

#Text=CPZE comparisons revealed no significant difference in medication load between biotypes.
87-1	15460-15464	CPZE	_	
87-2	15465-15476	comparisons	_	
87-3	15477-15485	revealed	_	
87-4	15486-15488	no	_	
87-5	15489-15500	significant	_	
87-6	15501-15511	difference	_	
87-7	15512-15514	in	_	
87-8	15515-15525	medication	_	
87-9	15526-15530	load	_	
87-10	15531-15538	between	_	
87-11	15539-15547	biotypes	_	
87-12	15547-15548	.	_	

#Text=Compared to the normal biotype, the poorly-performing biotype had smaller hippocampal, smaller nucleus accumbens, larger ventricles, and larger left globus pallidus volumes (p<=0.017); cortical thinning in the bilateral frontal and temporal cortex (p<=8.04×10−3), and greater MD in the bilateral external capsule, internal capsule, and fornix (p<=4.95×10−3).
88-1	15549-15557	Compared	_	
88-2	15558-15560	to	_	
88-3	15561-15564	the	_	
88-4	15565-15571	normal	_	
88-5	15572-15579	biotype	_	
88-6	15579-15580	,	_	
88-7	15581-15584	the	_	
88-8	15585-15602	poorly-performing	_	
88-9	15603-15610	biotype	_	
88-10	15611-15614	had	_	
88-11	15615-15622	smaller	_	
88-12	15623-15634	hippocampal	_	
88-13	15634-15635	,	_	
88-14	15636-15643	smaller	_	
88-15	15644-15651	nucleus	_	
88-16	15652-15661	accumbens	_	
88-17	15661-15662	,	_	
88-18	15663-15669	larger	_	
88-19	15670-15680	ventricles	_	
88-20	15680-15681	,	_	
88-21	15682-15685	and	_	
88-22	15686-15692	larger	_	
88-23	15693-15697	left	_	
88-24	15698-15704	globus	_	
88-25	15705-15713	pallidus	_	
88-26	15714-15721	volumes	_	
88-27	15722-15723	(	_	
88-28	15723-15724	p	_	
88-29	15724-15725	<	_	
88-30	15725-15726	=	_	
88-31	15726-15731	0.017	_	
88-32	15731-15732	)	_	
88-33	15732-15733	;	_	
88-34	15734-15742	cortical	_	
88-35	15743-15751	thinning	_	
88-36	15752-15754	in	_	
88-37	15755-15758	the	_	
88-38	15759-15768	bilateral	_	
88-39	15769-15776	frontal	_	
88-40	15777-15780	and	_	
88-41	15781-15789	temporal	_	
88-42	15790-15796	cortex	_	
88-43	15797-15798	(	_	
88-44	15798-15799	p	_	
88-45	15799-15800	<	_	
88-46	15800-15801	=	_	
88-47	15801-15805	8.04	_	
88-48	15805-15806	×	_	
88-49	15806-15808	10	_	
88-50	15808-15809	−	_	
88-51	15809-15810	3	_	
88-52	15810-15811	)	_	
88-53	15811-15812	,	_	
88-54	15813-15816	and	_	
88-55	15817-15824	greater	_	
88-56	15825-15827	MD	_	
88-57	15828-15830	in	_	
88-58	15831-15834	the	_	
88-59	15835-15844	bilateral	_	
88-60	15845-15853	external	_	
88-61	15854-15861	capsule	_	
88-62	15861-15862	,	_	
88-63	15863-15871	internal	_	
88-64	15872-15879	capsule	_	
88-65	15879-15880	,	_	
88-66	15881-15884	and	_	
88-67	15885-15891	fornix	_	
88-68	15892-15893	(	_	
88-69	15893-15894	p	_	
88-70	15894-15895	<	_	
88-71	15895-15896	=	_	
88-72	15896-15900	4.95	_	
88-73	15900-15901	×	_	
88-74	15901-15903	10	_	
88-75	15903-15904	−	_	
88-76	15904-15905	3	_	
88-77	15905-15906	)	_	
88-78	15906-15907	.	_	

#Text=See supplement for details.
89-1	15908-15911	See	_	
89-2	15912-15922	supplement	_	
89-3	15923-15926	for	_	
89-4	15927-15934	details	_	
89-5	15934-15935	.	_	

#Text=In contrast to the biotypes found using resting state, those found using imitate/observe and empathic accuracy showed no significant differences when comparing functional outcome and symptom burden measures (data not shown).
90-1	15936-15938	In	_	
90-2	15939-15947	contrast	_	
90-3	15948-15950	to	_	
90-4	15951-15954	the	_	
90-5	15955-15963	biotypes	_	
90-6	15964-15969	found	_	
90-7	15970-15975	using	_	
90-8	15976-15983	resting	_	
90-9	15984-15989	state	_	
90-10	15989-15990	,	_	
90-11	15991-15996	those	_	
90-12	15997-16002	found	_	
90-13	16003-16008	using	_	
90-14	16009-16016	imitate	_	
90-15	16016-16017	/	_	
90-16	16017-16024	observe	_	
90-17	16025-16028	and	_	
90-18	16029-16037	empathic	_	
90-19	16038-16046	accuracy	_	
90-20	16047-16053	showed	_	
90-21	16054-16056	no	_	
90-22	16057-16068	significant	_	
90-23	16069-16080	differences	_	
90-24	16081-16085	when	_	
90-25	16086-16095	comparing	_	
90-26	16096-16106	functional	_	
90-27	16107-16114	outcome	_	
90-28	16115-16118	and	_	
90-29	16119-16126	symptom	_	
90-30	16127-16133	burden	_	
90-31	16134-16142	measures	_	
90-32	16143-16144	(	_	
90-33	16144-16148	data	_	
90-34	16149-16152	not	_	
90-35	16153-16158	shown	_	
90-36	16158-16159	)	_	
90-37	16159-16160	.	_	

#Text=Structural validation analysis of the imitate/observe biotypes found cortical thickness differences in the left superior temporal sulcus (p=5.78×10−4) and no other significant differences among subcortical volumes and FA/MD comparisons.
91-1	16161-16171	Structural	_	
91-2	16172-16182	validation	_	
91-3	16183-16191	analysis	_	
91-4	16192-16194	of	_	
91-5	16195-16198	the	_	
91-6	16199-16206	imitate	_	
91-7	16206-16207	/	_	
91-8	16207-16214	observe	_	
91-9	16215-16223	biotypes	_	
91-10	16224-16229	found	_	
91-11	16230-16238	cortical	_	
91-12	16239-16248	thickness	_	
91-13	16249-16260	differences	_	
91-14	16261-16263	in	_	
91-15	16264-16267	the	_	
91-16	16268-16272	left	_	
91-17	16273-16281	superior	_	
91-18	16282-16290	temporal	_	
91-19	16291-16297	sulcus	_	
91-20	16298-16299	(	_	
91-21	16299-16300	p	_	
91-22	16300-16301	=	_	
91-23	16301-16305	5.78	_	
91-24	16305-16306	×	_	
91-25	16306-16308	10	_	
91-26	16308-16309	−	_	
91-27	16309-16310	4	_	
91-28	16310-16311	)	_	
91-29	16312-16315	and	_	
91-30	16316-16318	no	_	
91-31	16319-16324	other	_	
91-32	16325-16336	significant	_	
91-33	16337-16348	differences	_	
91-34	16349-16354	among	_	
91-35	16355-16366	subcortical	_	
91-36	16367-16374	volumes	_	
91-37	16375-16378	and	_	
91-38	16379-16381	FA	_	
91-39	16381-16382	/	_	
91-40	16382-16384	MD	_	
91-41	16385-16396	comparisons	_	
91-42	16396-16397	.	_	

#Text=Structural validation analysis of empathic accuracy biotypes found no significant differences among any of the structural measures considered.
92-1	16398-16408	Structural	_	
92-2	16409-16419	validation	_	
92-3	16420-16428	analysis	_	
92-4	16429-16431	of	_	
92-5	16432-16440	empathic	_	
92-6	16441-16449	accuracy	_	
92-7	16450-16458	biotypes	_	
92-8	16459-16464	found	_	
92-9	16465-16467	no	_	
92-10	16468-16479	significant	_	
92-11	16480-16491	differences	_	
92-12	16492-16497	among	_	
92-13	16498-16501	any	_	
92-14	16502-16504	of	_	
92-15	16505-16508	the	_	
92-16	16509-16519	structural	_	
92-17	16520-16528	measures	_	
92-18	16529-16539	considered	_	
92-19	16539-16540	.	_	

#Text=The classification analyses where the goal was to predict biotype outperformed both cognitive score- based group prediction analyses and diagnosis prediction analyses, as measured by mean AUC in the held-out participants (test set) across all 10 folds during cross validation.
93-1	16541-16544	The	_	
93-2	16545-16559	classification	_	
93-3	16560-16568	analyses	_	
93-4	16569-16574	where	_	
93-5	16575-16578	the	_	
93-6	16579-16583	goal	_	
93-7	16584-16587	was	_	
93-8	16588-16590	to	_	
93-9	16591-16598	predict	_	
93-10	16599-16606	biotype	_	
93-11	16607-16619	outperformed	_	
93-12	16620-16624	both	_	
93-13	16625-16634	cognitive	_	
93-14	16635-16640	score	_	
93-15	16640-16641	-	_	
93-16	16642-16647	based	_	
93-17	16648-16653	group	_	
93-18	16654-16664	prediction	_	
93-19	16665-16673	analyses	_	
93-20	16674-16677	and	_	
93-21	16678-16687	diagnosis	_	
93-22	16688-16698	prediction	_	
93-23	16699-16707	analyses	_	
93-24	16707-16708	,	_	
93-25	16709-16711	as	_	
93-26	16712-16720	measured	_	
93-27	16721-16723	by	_	
93-28	16724-16728	mean	_	
93-29	16729-16732	AUC	_	
93-30	16733-16735	in	_	
93-31	16736-16739	the	_	
93-32	16740-16748	held-out	_	
93-33	16749-16761	participants	_	
93-34	16762-16763	(	_	
93-35	16763-16767	test	_	
93-36	16768-16771	set	_	
93-37	16771-16772	)	_	
93-38	16773-16779	across	_	
93-39	16780-16783	all	_	
93-40	16784-16786	10	_	
93-41	16787-16792	folds	_	
93-42	16793-16799	during	_	
93-43	16800-16805	cross	_	
93-44	16806-16816	validation	_	
93-45	16816-16817	.	_	

#Text=Resting state connectivity produced an accurate model for held-out participants (AUC=0.88), outperforming most connectivity and task activations from both tasks (AUC=0.39–0.86), with the exception of the imitate/observe task activations (AUC=0.89).
94-1	16818-16825	Resting	_	
94-2	16826-16831	state	_	
94-3	16832-16844	connectivity	_	
94-4	16845-16853	produced	_	
94-5	16854-16856	an	_	
94-6	16857-16865	accurate	_	
94-7	16866-16871	model	_	
94-8	16872-16875	for	_	
94-9	16876-16884	held-out	_	
94-10	16885-16897	participants	_	
94-11	16898-16899	(	_	
94-12	16899-16902	AUC	_	
94-13	16902-16903	=	_	
94-14	16903-16907	0.88	_	
94-15	16907-16908	)	_	
94-16	16908-16909	,	_	
94-17	16910-16923	outperforming	_	
94-18	16924-16928	most	_	
94-19	16929-16941	connectivity	_	
94-20	16942-16945	and	_	
94-21	16946-16950	task	_	
94-22	16951-16962	activations	_	
94-23	16963-16967	from	_	
94-24	16968-16972	both	_	
94-25	16973-16978	tasks	_	
94-26	16979-16980	(	_	
94-27	16980-16983	AUC	_	
94-28	16983-16984	=	_	
94-29	16984-16988	0.39	_	
94-30	16988-16989	–	_	
94-31	16989-16993	0.86	_	
94-32	16993-16994	)	_	
94-33	16994-16995	,	_	
94-34	16996-17000	with	_	
94-35	17001-17004	the	_	
94-36	17005-17014	exception	_	
94-37	17015-17017	of	_	
94-38	17018-17021	the	_	
94-39	17022-17029	imitate	_	
94-40	17029-17030	/	_	
94-41	17030-17037	observe	_	
94-42	17038-17042	task	_	
94-43	17043-17054	activations	_	
94-44	17055-17056	(	_	
94-45	17056-17059	AUC	_	
94-46	17059-17060	=	_	
94-47	17060-17064	0.89	_	
94-48	17064-17065	)	_	
94-49	17065-17066	.	_	

#Text=For prediction of cognitive-score based groups of either a 30th or 50th percentile cutoff, all analyses performed close to chance (AUC=0.53–0.60) with the exception of resting state connectivity (AUC=0.64,0.67).
95-1	17067-17070	For	_	
95-2	17071-17081	prediction	_	
95-3	17082-17084	of	_	
95-4	17085-17100	cognitive-score	_	
95-5	17101-17106	based	_	
95-6	17107-17113	groups	_	
95-7	17114-17116	of	_	
95-8	17117-17123	either	_	
95-9	17124-17125	a	_	
95-10	17126-17130	30th	_	
95-11	17131-17133	or	_	
95-12	17134-17138	50th	_	
95-13	17139-17149	percentile	_	
95-14	17150-17156	cutoff	_	
95-15	17156-17157	,	_	
95-16	17158-17161	all	_	
95-17	17162-17170	analyses	_	
95-18	17171-17180	performed	_	
95-19	17181-17186	close	_	
95-20	17187-17189	to	_	
95-21	17190-17196	chance	_	
95-22	17197-17198	(	_	
95-23	17198-17201	AUC	_	
95-24	17201-17202	=	_	
95-25	17202-17206	0.53	_	
95-26	17206-17207	–	_	
95-27	17207-17211	0.60	_	
95-28	17211-17212	)	_	
95-29	17213-17217	with	_	
95-30	17218-17221	the	_	
95-31	17222-17231	exception	_	
95-32	17232-17234	of	_	
95-33	17235-17242	resting	_	
95-34	17243-17248	state	_	
95-35	17249-17261	connectivity	_	
95-36	17262-17263	(	_	
95-37	17263-17266	AUC	_	
95-38	17266-17267	=	_	
95-39	17267-17276	0.64,0.67	_	
95-40	17276-17277	)	_	
95-41	17277-17278	.	_	

#Text=Classification performance did not rely on the cutoff chosen as all score distributions overlapped between biotypes (figure 1,s3).
96-1	17279-17293	Classification	_	
96-2	17294-17305	performance	_	
96-3	17306-17309	did	_	
96-4	17310-17313	not	_	
96-5	17314-17318	rely	_	
96-6	17319-17321	on	_	
96-7	17322-17325	the	_	
96-8	17326-17332	cutoff	_	
96-9	17333-17339	chosen	_	
96-10	17340-17342	as	_	
96-11	17343-17346	all	_	
96-12	17347-17352	score	_	
96-13	17353-17366	distributions	_	
96-14	17367-17377	overlapped	_	
96-15	17378-17385	between	_	
96-16	17386-17394	biotypes	_	
96-17	17395-17396	(	_	
96-18	17396-17402	figure	_	
96-19	17403-17404	1	_	
96-20	17404-17405	,	_	
96-21	17405-17407	s3	_	
96-22	17407-17408	)	_	
96-23	17408-17409	.	_	

#Text=SVCs trained to distinguish biotypes outperformed SVCs trained to distinguish diagnosis in all cases.
97-1	17410-17414	SVCs	_	
97-2	17415-17422	trained	_	
97-3	17423-17425	to	_	
97-4	17426-17437	distinguish	_	
97-5	17438-17446	biotypes	_	
97-6	17447-17459	outperformed	_	
97-7	17460-17464	SVCs	_	
97-8	17465-17472	trained	_	
97-9	17473-17475	to	_	
97-10	17476-17487	distinguish	_	
97-11	17488-17497	diagnosis	_	
97-12	17498-17500	in	_	
97-13	17501-17504	all	_	
97-14	17505-17510	cases	_	
97-15	17510-17511	.	_	

#Text=Only the resting state connectivity-trained SVC predicted diagnosis well above chance (AUC=0.74).
98-1	17512-17516	Only	_	
98-2	17517-17520	the	_	
98-3	17521-17528	resting	_	
98-4	17529-17534	state	_	
98-5	17535-17555	connectivity-trained	_	
98-6	17556-17559	SVC	_	
98-7	17560-17569	predicted	_	
98-8	17570-17579	diagnosis	_	
98-9	17580-17584	well	_	
98-10	17585-17590	above	_	
98-11	17591-17597	chance	_	
98-12	17598-17599	(	_	
98-13	17599-17602	AUC	_	
98-14	17602-17603	=	_	
98-15	17603-17607	0.74	_	
98-16	17607-17608	)	_	
98-17	17608-17609	.	_	

#Text=The results from all classification experiments can be found in table 3; see supplement for replication details and follow up null experiments where either the class labels were randomized or the data was permuted before the CCA step (table s4).
99-1	17610-17613	The	_	
99-2	17614-17621	results	_	
99-3	17622-17626	from	_	
99-4	17627-17630	all	_	
99-5	17631-17645	classification	_	
99-6	17646-17657	experiments	_	
99-7	17658-17661	can	_	
99-8	17662-17664	be	_	
99-9	17665-17670	found	_	
99-10	17671-17673	in	_	
99-11	17674-17679	table	_	
99-12	17680-17681	3	_	
99-13	17681-17682	;	_	
99-14	17683-17686	see	_	
99-15	17687-17697	supplement	_	
99-16	17698-17701	for	_	
99-17	17702-17713	replication	_	
99-18	17714-17721	details	_	
99-19	17722-17725	and	_	
99-20	17726-17732	follow	_	
99-21	17733-17735	up	_	
99-22	17736-17740	null	_	
99-23	17741-17752	experiments	_	
99-24	17753-17758	where	_	
99-25	17759-17765	either	_	
99-26	17766-17769	the	_	
99-27	17770-17775	class	_	
99-28	17776-17782	labels	_	
99-29	17783-17787	were	_	
99-30	17788-17798	randomized	_	
99-31	17799-17801	or	_	
99-32	17802-17805	the	_	
99-33	17806-17810	data	_	
99-34	17811-17814	was	_	
99-35	17815-17823	permuted	_	
99-36	17824-17830	before	_	
99-37	17831-17834	the	_	
99-38	17835-17838	CCA	_	
99-39	17839-17843	step	_	
99-40	17844-17845	(	_	
99-41	17845-17850	table	_	
99-42	17851-17853	s4	_	
99-43	17853-17854	)	_	
99-44	17854-17855	.	_	

#Text=Connectivity differences between resting state biotypes show widespread differences in the brain’s posterior regions (figure 2).
100-1	17856-17868	Connectivity	_	
100-2	17869-17880	differences	_	
100-3	17881-17888	between	_	
100-4	17889-17896	resting	_	
100-5	17897-17902	state	_	
100-6	17903-17911	biotypes	_	
100-7	17912-17916	show	_	
100-8	17917-17927	widespread	_	
100-9	17928-17939	differences	_	
100-10	17940-17942	in	_	
100-11	17943-17946	the	_	
100-12	17947-17952	brain	_	
100-13	17952-17953	’	_	
100-14	17953-17954	s	_	
100-15	17955-17964	posterior	_	
100-16	17965-17972	regions	_	
100-17	17973-17974	(	_	
100-18	17974-17980	figure	_	
100-19	17981-17982	2	_	
100-20	17982-17983	)	_	
100-21	17983-17984	.	_	

#Text=The normal biotype showed stronger whole-brain connectivity in ROIs associated with both the general cognition and reaction time networks (i.e., the thalamus and right superior temporal sulcus, which overlaps with the ventral attention network), while the poorly-performing biotype shows stronger whole- brain connectivity in the occipital regions and ROIs associated with the somatomotor, mirror, and mentalizing network, including the insula, inferior parietal lobule, postcentral gyrus, fusiform gyrus, and posterior cingulate.
101-1	17985-17988	The	_	
101-2	17989-17995	normal	_	
101-3	17996-18003	biotype	_	
101-4	18004-18010	showed	_	
101-5	18011-18019	stronger	_	
101-6	18020-18031	whole-brain	_	
101-7	18032-18044	connectivity	_	
101-8	18045-18047	in	_	
101-9	18048-18052	ROIs	_	
101-10	18053-18063	associated	_	
101-11	18064-18068	with	_	
101-12	18069-18073	both	_	
101-13	18074-18077	the	_	
101-14	18078-18085	general	_	
101-15	18086-18095	cognition	_	
101-16	18096-18099	and	_	
101-17	18100-18108	reaction	_	
101-18	18109-18113	time	_	
101-19	18114-18122	networks	_	
101-20	18123-18124	(	_	
101-21	18124-18127	i.e	_	
101-22	18127-18128	.	_	
101-23	18128-18129	,	_	
101-24	18130-18133	the	_	
101-25	18134-18142	thalamus	_	
101-26	18143-18146	and	_	
101-27	18147-18152	right	_	
101-28	18153-18161	superior	_	
101-29	18162-18170	temporal	_	
101-30	18171-18177	sulcus	_	
101-31	18177-18178	,	_	
101-32	18179-18184	which	_	
101-33	18185-18193	overlaps	_	
101-34	18194-18198	with	_	
101-35	18199-18202	the	_	
101-36	18203-18210	ventral	_	
101-37	18211-18220	attention	_	
101-38	18221-18228	network	_	
101-39	18228-18229	)	_	
101-40	18229-18230	,	_	
101-41	18231-18236	while	_	
101-42	18237-18240	the	_	
101-43	18241-18258	poorly-performing	_	
101-44	18259-18266	biotype	_	
101-45	18267-18272	shows	_	
101-46	18273-18281	stronger	_	
101-47	18282-18287	whole	_	
101-48	18287-18288	-	_	
101-49	18289-18294	brain	_	
101-50	18295-18307	connectivity	_	
101-51	18308-18310	in	_	
101-52	18311-18314	the	_	
101-53	18315-18324	occipital	_	
101-54	18325-18332	regions	_	
101-55	18333-18336	and	_	
101-56	18337-18341	ROIs	_	
101-57	18342-18352	associated	_	
101-58	18353-18357	with	_	
101-59	18358-18361	the	_	
101-60	18362-18373	somatomotor	_	
101-61	18373-18374	,	_	
101-62	18375-18381	mirror	_	
101-63	18381-18382	,	_	
101-64	18383-18386	and	_	
101-65	18387-18398	mentalizing	_	
101-66	18399-18406	network	_	
101-67	18406-18407	,	_	
101-68	18408-18417	including	_	
101-69	18418-18421	the	_	
101-70	18422-18428	insula	_	
101-71	18428-18429	,	_	
101-72	18430-18438	inferior	_	
101-73	18439-18447	parietal	_	
101-74	18448-18454	lobule	_	
101-75	18454-18455	,	_	
101-76	18456-18467	postcentral	_	
101-77	18468-18473	gyrus	_	
101-78	18473-18474	,	_	
101-79	18475-18483	fusiform	_	
101-80	18484-18489	gyrus	_	
101-81	18489-18490	,	_	
101-82	18491-18494	and	_	
101-83	18495-18504	posterior	_	
101-84	18505-18514	cingulate	_	
101-85	18514-18515	.	_	

#Text=The majority of the strongest group differences that replicated represented over-connectivity of the occipital and parietal regions with the rest of the brain, including the mirror network, in the poorly-performing biotype (see supplement).
102-1	18516-18519	The	_	
102-2	18520-18528	majority	_	
102-3	18529-18531	of	_	
102-4	18532-18535	the	_	
102-5	18536-18545	strongest	_	
102-6	18546-18551	group	_	
102-7	18552-18563	differences	_	
102-8	18564-18568	that	_	
102-9	18569-18579	replicated	_	
102-10	18580-18591	represented	_	
102-11	18592-18609	over-connectivity	_	
102-12	18610-18612	of	_	
102-13	18613-18616	the	_	
102-14	18617-18626	occipital	_	
102-15	18627-18630	and	_	
102-16	18631-18639	parietal	_	
102-17	18640-18647	regions	_	
102-18	18648-18652	with	_	
102-19	18653-18656	the	_	
102-20	18657-18661	rest	_	
102-21	18662-18664	of	_	
102-22	18665-18668	the	_	
102-23	18669-18674	brain	_	
102-24	18674-18675	,	_	
102-25	18676-18685	including	_	
102-26	18686-18689	the	_	
102-27	18690-18696	mirror	_	
102-28	18697-18704	network	_	
102-29	18704-18705	,	_	
102-30	18706-18708	in	_	
102-31	18709-18712	the	_	
102-32	18713-18730	poorly-performing	_	
102-33	18731-18738	biotype	_	
102-34	18739-18740	(	_	
102-35	18740-18743	see	_	
102-36	18744-18754	supplement	_	
102-37	18754-18755	)	_	
102-38	18755-18756	.	_	

#Text=Task connectivity group differences did not replicate (see supplement).
103-1	18757-18761	Task	_	
103-2	18762-18774	connectivity	_	
103-3	18775-18780	group	_	
103-4	18781-18792	differences	_	
103-5	18793-18796	did	_	
103-6	18797-18800	not	_	
103-7	18801-18810	replicate	_	
103-8	18811-18812	(	_	
103-9	18812-18815	see	_	
103-10	18816-18826	supplement	_	
103-11	18826-18827	)	_	
103-12	18827-18828	.	_	

#Text=Please see the supplement for a comparison of quality control metrics on the TI, DTI, and fMRI data.
104-1	18829-18835	Please	_	
104-2	18836-18839	see	_	
104-3	18840-18843	the	_	
104-4	18844-18854	supplement	_	
104-5	18855-18858	for	_	
104-6	18859-18860	a	_	
104-7	18861-18871	comparison	_	
104-8	18872-18874	of	_	
104-9	18875-18882	quality	_	
104-10	18883-18890	control	_	
104-11	18891-18898	metrics	_	
104-12	18899-18901	on	_	
104-13	18902-18905	the	_	
104-14	18906-18908	TI	_	
104-15	18908-18909	,	_	
104-16	18910-18913	DTI	_	
104-17	18913-18914	,	_	
104-18	18915-18918	and	_	
104-19	18919-18923	fMRI	_	
104-20	18924-18928	data	_	
104-21	18928-18929	.	_	

#Text=Discussion
#Text=Our data-driven approach found a poorly-performing biotype of people with SSDs and a normally-performing biotype, with respect to SC/NC performance.
105-1	18930-18940	Discussion	_	
105-2	18941-18944	Our	_	
105-3	18945-18956	data-driven	_	
105-4	18957-18965	approach	_	
105-5	18966-18971	found	_	
105-6	18972-18973	a	_	
105-7	18974-18991	poorly-performing	_	
105-8	18992-18999	biotype	_	
105-9	19000-19002	of	_	
105-10	19003-19009	people	_	
105-11	19010-19014	with	_	
105-12	19015-19019	SSDs	_	
105-13	19020-19023	and	_	
105-14	19024-19025	a	_	
105-15	19026-19045	normally-performing	_	
105-16	19046-19053	biotype	_	
105-17	19053-19054	,	_	
105-18	19055-19059	with	_	
105-19	19060-19067	respect	_	
105-20	19068-19070	to	_	
105-21	19071-19073	SC	_	
105-22	19073-19074	/	_	
105-23	19074-19076	NC	_	
105-24	19077-19088	performance	_	
105-25	19088-19089	.	_	

#Text=These fMRI features generalized to held-out participants: a linear SVC trained on brain connectivity data alone accurately predicted the biotype of held out scans.
106-1	19090-19095	These	_	
106-2	19096-19100	fMRI	_	
106-3	19101-19109	features	_	
106-4	19110-19121	generalized	_	
106-5	19122-19124	to	_	
106-6	19125-19133	held-out	_	
106-7	19134-19146	participants	_	
106-8	19146-19147	:	_	
106-9	19148-19149	a	_	
106-10	19150-19156	linear	_	
106-11	19157-19160	SVC	_	
106-12	19161-19168	trained	_	
106-13	19169-19171	on	_	
106-14	19172-19177	brain	_	
106-15	19178-19190	connectivity	_	
106-16	19191-19195	data	_	
106-17	19196-19201	alone	_	
106-18	19202-19212	accurately	_	
106-19	19213-19222	predicted	_	
106-20	19223-19226	the	_	
106-21	19227-19234	biotype	_	
106-22	19235-19237	of	_	
106-23	19238-19242	held	_	
106-24	19243-19246	out	_	
106-25	19247-19252	scans	_	
106-26	19252-19253	.	_	

#Text=Comparisons of brain connectivity between the two biotypes revealed that the mirror and mentalizing regions are over-connected with the rest of the brain in the poorly performing biotype, and this result was replicated in a second, independent sample from a single site in the resting state data.
107-1	19254-19265	Comparisons	_	
107-2	19266-19268	of	_	
107-3	19269-19274	brain	_	
107-4	19275-19287	connectivity	_	
107-5	19288-19295	between	_	
107-6	19296-19299	the	_	
107-7	19300-19303	two	_	
107-8	19304-19312	biotypes	_	
107-9	19313-19321	revealed	_	
107-10	19322-19326	that	_	
107-11	19327-19330	the	_	
107-12	19331-19337	mirror	_	
107-13	19338-19341	and	_	
107-14	19342-19353	mentalizing	_	
107-15	19354-19361	regions	_	
107-16	19362-19365	are	_	
107-17	19366-19380	over-connected	_	
107-18	19381-19385	with	_	
107-19	19386-19389	the	_	
107-20	19390-19394	rest	_	
107-21	19395-19397	of	_	
107-22	19398-19401	the	_	
107-23	19402-19407	brain	_	
107-24	19408-19410	in	_	
107-25	19411-19414	the	_	
107-26	19415-19421	poorly	_	
107-27	19422-19432	performing	_	
107-28	19433-19440	biotype	_	
107-29	19440-19441	,	_	
107-30	19442-19445	and	_	
107-31	19446-19450	this	_	
107-32	19451-19457	result	_	
107-33	19458-19461	was	_	
107-34	19462-19472	replicated	_	
107-35	19473-19475	in	_	
107-36	19476-19477	a	_	
107-37	19478-19484	second	_	
107-38	19484-19485	,	_	
107-39	19486-19497	independent	_	
107-40	19498-19504	sample	_	
107-41	19505-19509	from	_	
107-42	19510-19511	a	_	
107-43	19512-19518	single	_	
107-44	19519-19523	site	_	
107-45	19524-19526	in	_	
107-46	19527-19530	the	_	
107-47	19531-19538	resting	_	
107-48	19539-19544	state	_	
107-49	19545-19549	data	_	
107-50	19549-19550	.	_	

#Text=The normal biotype had an equal balance of healthy controls and people with an SSD, while the poorly-performing biotype was almost entirely comprised of people with an SSD.
108-1	19551-19554	The	_	
108-2	19555-19561	normal	_	
108-3	19562-19569	biotype	_	
108-4	19570-19573	had	_	
108-5	19574-19576	an	_	
108-6	19577-19582	equal	_	
108-7	19583-19590	balance	_	
108-8	19591-19593	of	_	
108-9	19594-19601	healthy	_	
108-10	19602-19610	controls	_	
108-11	19611-19614	and	_	
108-12	19615-19621	people	_	
108-13	19622-19626	with	_	
108-14	19627-19629	an	_	
108-15	19630-19633	SSD	_	
108-16	19633-19634	,	_	
108-17	19635-19640	while	_	
108-18	19641-19644	the	_	
108-19	19645-19662	poorly-performing	_	
108-20	19663-19670	biotype	_	
108-21	19671-19674	was	_	
108-22	19675-19681	almost	_	
108-23	19682-19690	entirely	_	
108-24	19691-19700	comprised	_	
108-25	19701-19703	of	_	
108-26	19704-19710	people	_	
108-27	19711-19715	with	_	
108-28	19716-19718	an	_	
108-29	19719-19722	SSD	_	
108-30	19722-19723	.	_	

#Text=Validation using neuroanatomical analyses showed that the poorly performing biotype had lower cortical thickness, subcortical volumes, and higher white matter FA.
109-1	19724-19734	Validation	_	
109-2	19735-19740	using	_	
109-3	19741-19756	neuroanatomical	_	
109-4	19757-19765	analyses	_	
109-5	19766-19772	showed	_	
109-6	19773-19777	that	_	
109-7	19778-19781	the	_	
109-8	19782-19788	poorly	_	
109-9	19789-19799	performing	_	
109-10	19800-19807	biotype	_	
109-11	19808-19811	had	_	
109-12	19812-19817	lower	_	
109-13	19818-19826	cortical	_	
109-14	19827-19836	thickness	_	
109-15	19836-19837	,	_	
109-16	19838-19849	subcortical	_	
109-17	19850-19857	volumes	_	
109-18	19857-19858	,	_	
109-19	19859-19862	and	_	
109-20	19863-19869	higher	_	
109-21	19870-19875	white	_	
109-22	19876-19882	matter	_	
109-23	19883-19885	FA	_	
109-24	19885-19886	.	_	

#Text=Despite also testing task-based fMRI using well-established social brain tasks (imitate/observe and empathic accuracy), we found that resting state connectivity was best able to distinguish biotypes with different SC/NC ability and real-world functional outcomes, while the task-based fMRI did less well and did not replicate in the independent sample.
110-1	19887-19894	Despite	_	
110-2	19895-19899	also	_	
110-3	19900-19907	testing	_	
110-4	19908-19918	task-based	_	
110-5	19919-19923	fMRI	_	
110-6	19924-19929	using	_	
110-7	19930-19946	well-established	_	
110-8	19947-19953	social	_	
110-9	19954-19959	brain	_	
110-10	19960-19965	tasks	_	
110-11	19966-19967	(	_	
110-12	19967-19974	imitate	_	
110-13	19974-19975	/	_	
110-14	19975-19982	observe	_	
110-15	19983-19986	and	_	
110-16	19987-19995	empathic	_	
110-17	19996-20004	accuracy	_	
110-18	20004-20005	)	_	
110-19	20005-20006	,	_	
110-20	20007-20009	we	_	
110-21	20010-20015	found	_	
110-22	20016-20020	that	_	
110-23	20021-20028	resting	_	
110-24	20029-20034	state	_	
110-25	20035-20047	connectivity	_	
110-26	20048-20051	was	_	
110-27	20052-20056	best	_	
110-28	20057-20061	able	_	
110-29	20062-20064	to	_	
110-30	20065-20076	distinguish	_	
110-31	20077-20085	biotypes	_	
110-32	20086-20090	with	_	
110-33	20091-20100	different	_	
110-34	20101-20103	SC	_	
110-35	20103-20104	/	_	
110-36	20104-20106	NC	_	
110-37	20107-20114	ability	_	
110-38	20115-20118	and	_	
110-39	20119-20129	real-world	_	
110-40	20130-20140	functional	_	
110-41	20141-20149	outcomes	_	
110-42	20149-20150	,	_	
110-43	20151-20156	while	_	
110-44	20157-20160	the	_	
110-45	20161-20171	task-based	_	
110-46	20172-20176	fMRI	_	
110-47	20177-20180	did	_	
110-48	20181-20185	less	_	
110-49	20186-20190	well	_	
110-50	20191-20194	and	_	
110-51	20195-20198	did	_	
110-52	20199-20202	not	_	
110-53	20203-20212	replicate	_	
110-54	20213-20215	in	_	
110-55	20216-20219	the	_	
110-56	20220-20231	independent	_	
110-57	20232-20238	sample	_	
110-58	20238-20239	.	_	

#Text=Only the resting state connectivity-based biotypes found a separation of the sample with SC/NC score differences greater than diagnosis (figure s1).
111-1	20240-20244	Only	_	
111-2	20245-20248	the	_	
111-3	20249-20256	resting	_	
111-4	20257-20262	state	_	
111-5	20263-20281	connectivity-based	_	
111-6	20282-20290	biotypes	_	
111-7	20291-20296	found	_	
111-8	20297-20298	a	_	
111-9	20299-20309	separation	_	
111-10	20310-20312	of	_	
111-11	20313-20316	the	_	
111-12	20317-20323	sample	_	
111-13	20324-20328	with	_	
111-14	20329-20331	SC	_	
111-15	20331-20332	/	_	
111-16	20332-20334	NC	_	
111-17	20335-20340	score	_	
111-18	20341-20352	differences	_	
111-19	20353-20360	greater	_	
111-20	20361-20365	than	_	
111-21	20366-20375	diagnosis	_	
111-22	20376-20377	(	_	
111-23	20377-20383	figure	_	
111-24	20384-20386	s1	_	
111-25	20386-20387	)	_	
111-26	20387-20388	.	_	

#Text=Those in the poorly-performing biotype demonstrated stronger functional connectivity between the occipital and parietal region with the rest of the brain.
112-1	20389-20394	Those	_	
112-2	20395-20397	in	_	
112-3	20398-20401	the	_	
112-4	20402-20419	poorly-performing	_	
112-5	20420-20427	biotype	_	
112-6	20428-20440	demonstrated	_	
112-7	20441-20449	stronger	_	
112-8	20450-20460	functional	_	
112-9	20461-20473	connectivity	_	
112-10	20474-20481	between	_	
112-11	20482-20485	the	_	
112-12	20486-20495	occipital	_	
112-13	20496-20499	and	_	
112-14	20500-20508	parietal	_	
112-15	20509-20515	region	_	
112-16	20516-20520	with	_	
112-17	20521-20524	the	_	
112-18	20525-20529	rest	_	
112-19	20530-20532	of	_	
112-20	20533-20536	the	_	
112-21	20537-20542	brain	_	
112-22	20542-20543	.	_	

#Text=These over-connected ROIs included the mirror network, a set of brain regions including the posterior superior temporal sulcus, anterior intraparietal sulcus, and the premotor cortex, which are engaged in both the perception of an execution of biological motion.
113-1	20544-20549	These	_	
113-2	20550-20564	over-connected	_	
113-3	20565-20569	ROIs	_	
113-4	20570-20578	included	_	
113-5	20579-20582	the	_	
113-6	20583-20589	mirror	_	
113-7	20590-20597	network	_	
113-8	20597-20598	,	_	
113-9	20599-20600	a	_	
113-10	20601-20604	set	_	
113-11	20605-20607	of	_	
113-12	20608-20613	brain	_	
113-13	20614-20621	regions	_	
113-14	20622-20631	including	_	
113-15	20632-20635	the	_	
113-16	20636-20645	posterior	_	
113-17	20646-20654	superior	_	
113-18	20655-20663	temporal	_	
113-19	20664-20670	sulcus	_	
113-20	20670-20671	,	_	
113-21	20672-20680	anterior	_	
113-22	20681-20694	intraparietal	_	
113-23	20695-20701	sulcus	_	
113-24	20701-20702	,	_	
113-25	20703-20706	and	_	
113-26	20707-20710	the	_	
113-27	20711-20719	premotor	_	
113-28	20720-20726	cortex	_	
113-29	20726-20727	,	_	
113-30	20728-20733	which	_	
113-31	20734-20737	are	_	
113-32	20738-20745	engaged	_	
113-33	20746-20748	in	_	
113-34	20749-20753	both	_	
113-35	20754-20757	the	_	
113-36	20758-20768	perception	_	
113-37	20769-20771	of	_	
113-38	20772-20774	an	_	
113-39	20775-20784	execution	_	
113-40	20785-20787	of	_	
113-41	20788-20798	biological	_	
113-42	20799-20805	motion	_	
113-43	20805-20806	.	_	

#Text=These regions replicated in an independent sample collected at one site (figure 2).
114-1	20807-20812	These	_	
114-2	20813-20820	regions	_	
114-3	20821-20831	replicated	_	
114-4	20832-20834	in	_	
114-5	20835-20837	an	_	
114-6	20838-20849	independent	_	
114-7	20850-20856	sample	_	
114-8	20857-20866	collected	_	
114-9	20867-20869	at	_	
114-10	20870-20873	one	_	
114-11	20874-20878	site	_	
114-12	20879-20880	(	_	
114-13	20880-20886	figure	_	
114-14	20887-20888	2	_	
114-15	20888-20889	)	_	
114-16	20889-20890	.	_	

#Text=These mirror network regions are also believed to be important for both social cognition and empathy, and here we show that differences in mirror network brain organization are associated with poor functional outcomes and greater negative symptom burden.
115-1	20891-20896	These	_	
115-2	20897-20903	mirror	_	
115-3	20904-20911	network	_	
115-4	20912-20919	regions	_	
115-5	20920-20923	are	_	
115-6	20924-20928	also	_	
115-7	20929-20937	believed	_	
115-8	20938-20940	to	_	
115-9	20941-20943	be	_	
115-10	20944-20953	important	_	
115-11	20954-20957	for	_	
115-12	20958-20962	both	_	
115-13	20963-20969	social	_	
115-14	20970-20979	cognition	_	
115-15	20980-20983	and	_	
115-16	20984-20991	empathy	_	
115-17	20991-20992	,	_	
115-18	20993-20996	and	_	
115-19	20997-21001	here	_	
115-20	21002-21004	we	_	
115-21	21005-21009	show	_	
115-22	21010-21014	that	_	
115-23	21015-21026	differences	_	
115-24	21027-21029	in	_	
115-25	21030-21036	mirror	_	
115-26	21037-21044	network	_	
115-27	21045-21050	brain	_	
115-28	21051-21063	organization	_	
115-29	21064-21067	are	_	
115-30	21068-21078	associated	_	
115-31	21079-21083	with	_	
115-32	21084-21088	poor	_	
115-33	21089-21099	functional	_	
115-34	21100-21108	outcomes	_	
115-35	21109-21112	and	_	
115-36	21113-21120	greater	_	
115-37	21121-21129	negative	_	
115-38	21130-21137	symptom	_	
115-39	21138-21144	burden	_	
115-40	21144-21145	.	_	

#Text=Furthermore, these groups showed significant differences in functional outcomes scores using the BSFS, which were not used to define the biotype groups.
116-1	21146-21157	Furthermore	_	
116-2	21157-21158	,	_	
116-3	21159-21164	these	_	
116-4	21165-21171	groups	_	
116-5	21172-21178	showed	_	
116-6	21179-21190	significant	_	
116-7	21191-21202	differences	_	
116-8	21203-21205	in	_	
116-9	21206-21216	functional	_	
116-10	21217-21225	outcomes	_	
116-11	21226-21232	scores	_	
116-12	21233-21238	using	_	
116-13	21239-21242	the	_	
116-14	21243-21247	BSFS	_	
116-15	21247-21248	,	_	
116-16	21249-21254	which	_	
116-17	21255-21259	were	_	
116-18	21260-21263	not	_	
116-19	21264-21268	used	_	
116-20	21269-21271	to	_	
116-21	21272-21278	define	_	
116-22	21279-21282	the	_	
116-23	21283-21290	biotype	_	
116-24	21291-21297	groups	_	
116-25	21297-21298	.	_	

#Text=This suggests that the brain connectivity differences found in the poorly-performing biotype derived from the resting state data have real-world implications.
117-1	21299-21303	This	_	
117-2	21304-21312	suggests	_	
117-3	21313-21317	that	_	
117-4	21318-21321	the	_	
117-5	21322-21327	brain	_	
117-6	21328-21340	connectivity	_	
117-7	21341-21352	differences	_	
117-8	21353-21358	found	_	
117-9	21359-21361	in	_	
117-10	21362-21365	the	_	
117-11	21366-21383	poorly-performing	_	
117-12	21384-21391	biotype	_	
117-13	21392-21399	derived	_	
117-14	21400-21404	from	_	
117-15	21405-21408	the	_	
117-16	21409-21416	resting	_	
117-17	21417-21422	state	_	
117-18	21423-21427	data	_	
117-19	21428-21432	have	_	
117-20	21433-21443	real-world	_	
117-21	21444-21456	implications	_	
117-22	21456-21457	.	_	

#Text=We performed a set of classification analyses to ensure that the fMRI features driving our biotype membership generalize to held-out participants.
118-1	21458-21460	We	_	
118-2	21461-21470	performed	_	
118-3	21471-21472	a	_	
118-4	21473-21476	set	_	
118-5	21477-21479	of	_	
118-6	21480-21494	classification	_	
118-7	21495-21503	analyses	_	
118-8	21504-21506	to	_	
118-9	21507-21513	ensure	_	
118-10	21514-21518	that	_	
118-11	21519-21522	the	_	
118-12	21523-21527	fMRI	_	
118-13	21528-21536	features	_	
118-14	21537-21544	driving	_	
118-15	21545-21548	our	_	
118-16	21549-21556	biotype	_	
118-17	21557-21567	membership	_	
118-18	21568-21578	generalize	_	
118-19	21579-21581	to	_	
118-20	21582-21590	held-out	_	
118-21	21591-21603	participants	_	
118-22	21603-21604	.	_	

#Text=The resting state biotype models outperformed all others considered in both the discovery and replication sample, and all biotype model-trained classifiers outperformed both cognitive-score based group-trained classifiers and diagnosis-based classifiers.
119-1	21605-21608	The	_	
119-2	21609-21616	resting	_	
119-3	21617-21622	state	_	
119-4	21623-21630	biotype	_	
119-5	21631-21637	models	_	
119-6	21638-21650	outperformed	_	
119-7	21651-21654	all	_	
119-8	21655-21661	others	_	
119-9	21662-21672	considered	_	
119-10	21673-21675	in	_	
119-11	21676-21680	both	_	
119-12	21681-21684	the	_	
119-13	21685-21694	discovery	_	
119-14	21695-21698	and	_	
119-15	21699-21710	replication	_	
119-16	21711-21717	sample	_	
119-17	21717-21718	,	_	
119-18	21719-21722	and	_	
119-19	21723-21726	all	_	
119-20	21727-21734	biotype	_	
119-21	21735-21748	model-trained	_	
119-22	21749-21760	classifiers	_	
119-23	21761-21773	outperformed	_	
119-24	21774-21778	both	_	
119-25	21779-21794	cognitive-score	_	
119-26	21795-21800	based	_	
119-27	21801-21814	group-trained	_	
119-28	21815-21826	classifiers	_	
119-29	21827-21830	and	_	
119-30	21831-21846	diagnosis-based	_	
119-31	21847-21858	classifiers	_	
119-32	21858-21859	.	_	

#Text=Therefore, we believe that our approach uncovered a distinct resting state-based biomarker that identifies a biologically-distinct subset of participants.
120-1	21860-21869	Therefore	_	
120-2	21869-21870	,	_	
120-3	21871-21873	we	_	
120-4	21874-21881	believe	_	
120-5	21882-21886	that	_	
120-6	21887-21890	our	_	
120-7	21891-21899	approach	_	
120-8	21900-21909	uncovered	_	
120-9	21910-21911	a	_	
120-10	21912-21920	distinct	_	
120-11	21921-21928	resting	_	
120-12	21929-21940	state-based	_	
120-13	21941-21950	biomarker	_	
120-14	21951-21955	that	_	
120-15	21956-21966	identifies	_	
120-16	21967-21968	a	_	
120-17	21969-21990	biologically-distinct	_	
120-18	21991-21997	subset	_	
120-19	21998-22000	of	_	
120-20	22001-22013	participants	_	
120-21	22013-22014	.	_	

#Text=Our results also suggest that neurophysiological heterogeneity renders diagnostic group-based contrasts insufficient to detect the true disease-related brain organization variability.
121-1	22015-22018	Our	_	
121-2	22019-22026	results	_	
121-3	22027-22031	also	_	
121-4	22032-22039	suggest	_	
121-5	22040-22044	that	_	
121-6	22045-22063	neurophysiological	_	
121-7	22064-22077	heterogeneity	_	
121-8	22078-22085	renders	_	
121-9	22086-22096	diagnostic	_	
121-10	22097-22108	group-based	_	
121-11	22109-22118	contrasts	_	
121-12	22119-22131	insufficient	_	
121-13	22132-22134	to	_	
121-14	22135-22141	detect	_	
121-15	22142-22145	the	_	
121-16	22146-22150	true	_	
121-17	22151-22166	disease-related	_	
121-18	22167-22172	brain	_	
121-19	22173-22185	organization	_	
121-20	22186-22197	variability	_	
121-21	22197-22198	.	_	

#Text=If a common functional brain organization gives rise to better and/or poorer cognitive performance, classifiers trained with cognitive score-based groups and biotypes would perform similarly: the classifier would simply learn to accurately associate the appropriate brain connectivity pattern with the appropriate cognitive group.
122-1	22199-22201	If	_	
122-2	22202-22203	a	_	
122-3	22204-22210	common	_	
122-4	22211-22221	functional	_	
122-5	22222-22227	brain	_	
122-6	22228-22240	organization	_	
122-7	22241-22246	gives	_	
122-8	22247-22251	rise	_	
122-9	22252-22254	to	_	
122-10	22255-22261	better	_	
122-11	22262-22265	and	_	
122-12	22265-22266	/	_	
122-13	22266-22268	or	_	
122-14	22269-22275	poorer	_	
122-15	22276-22285	cognitive	_	
122-16	22286-22297	performance	_	
122-17	22297-22298	,	_	
122-18	22299-22310	classifiers	_	
122-19	22311-22318	trained	_	
122-20	22319-22323	with	_	
122-21	22324-22333	cognitive	_	
122-22	22334-22345	score-based	_	
122-23	22346-22352	groups	_	
122-24	22353-22356	and	_	
122-25	22357-22365	biotypes	_	
122-26	22366-22371	would	_	
122-27	22372-22379	perform	_	
122-28	22380-22389	similarly	_	
122-29	22389-22390	:	_	
122-30	22391-22394	the	_	
122-31	22395-22405	classifier	_	
122-32	22406-22411	would	_	
122-33	22412-22418	simply	_	
122-34	22419-22424	learn	_	
122-35	22425-22427	to	_	
122-36	22428-22438	accurately	_	
122-37	22439-22448	associate	_	
122-38	22449-22452	the	_	
122-39	22453-22464	appropriate	_	
122-40	22465-22470	brain	_	
122-41	22471-22483	connectivity	_	
122-42	22484-22491	pattern	_	
122-43	22492-22496	with	_	
122-44	22497-22500	the	_	
122-45	22501-22512	appropriate	_	
122-46	22513-22522	cognitive	_	
122-47	22523-22528	group	_	
122-48	22528-22529	.	_	

#Text=This could not occur in our sample owing to the clear overlap in the SC/NC score distributions between the poorest performers of the normal biotype and the strongest performers of the poorly-performing biotype (figure 1; table s1).
123-1	22530-22534	This	_	
123-2	22535-22540	could	_	
123-3	22541-22544	not	_	
123-4	22545-22550	occur	_	
123-5	22551-22553	in	_	
123-6	22554-22557	our	_	
123-7	22558-22564	sample	_	
123-8	22565-22570	owing	_	
123-9	22571-22573	to	_	
123-10	22574-22577	the	_	
123-11	22578-22583	clear	_	
123-12	22584-22591	overlap	_	
123-13	22592-22594	in	_	
123-14	22595-22598	the	_	
123-15	22599-22601	SC	_	
123-16	22601-22602	/	_	
123-17	22602-22604	NC	_	
123-18	22605-22610	score	_	
123-19	22611-22624	distributions	_	
123-20	22625-22632	between	_	
123-21	22633-22636	the	_	
123-22	22637-22644	poorest	_	
123-23	22645-22655	performers	_	
123-24	22656-22658	of	_	
123-25	22659-22662	the	_	
123-26	22663-22669	normal	_	
123-27	22670-22677	biotype	_	
123-28	22678-22681	and	_	
123-29	22682-22685	the	_	
123-30	22686-22695	strongest	_	
123-31	22696-22706	performers	_	
123-32	22707-22709	of	_	
123-33	22710-22713	the	_	
123-34	22714-22731	poorly-performing	_	
123-35	22732-22739	biotype	_	
123-36	22740-22741	(	_	
123-37	22741-22747	figure	_	
123-38	22748-22749	1	_	
123-39	22749-22750	;	_	
123-40	22751-22756	table	_	
123-41	22757-22759	s1	_	
123-42	22759-22760	)	_	
123-43	22760-22761	.	_	

#Text=Therefore, participants with similar scores can show different brain organizations (figure 2).
124-1	22762-22771	Therefore	_	
124-2	22771-22772	,	_	
124-3	22773-22785	participants	_	
124-4	22786-22790	with	_	
124-5	22791-22798	similar	_	
124-6	22799-22805	scores	_	
124-7	22806-22809	can	_	
124-8	22810-22814	show	_	
124-9	22815-22824	different	_	
124-10	22825-22830	brain	_	
124-11	22831-22844	organizations	_	
124-12	22845-22846	(	_	
124-13	22846-22852	figure	_	
124-14	22853-22854	2	_	
124-15	22854-22855	)	_	
124-16	22855-22856	.	_	

#Text=The defining feature of the poorly-performing biotype was over-connectivity between ROIs in the posterior with the rest of the brain.
125-1	22857-22860	The	_	
125-2	22861-22869	defining	_	
125-3	22870-22877	feature	_	
125-4	22878-22880	of	_	
125-5	22881-22884	the	_	
125-6	22885-22902	poorly-performing	_	
125-7	22903-22910	biotype	_	
125-8	22911-22914	was	_	
125-9	22915-22932	over-connectivity	_	
125-10	22933-22940	between	_	
125-11	22941-22945	ROIs	_	
125-12	22946-22948	in	_	
125-13	22949-22952	the	_	
125-14	22953-22962	posterior	_	
125-15	22963-22967	with	_	
125-16	22968-22971	the	_	
125-17	22972-22976	rest	_	
125-18	22977-22979	of	_	
125-19	22980-22983	the	_	
125-20	22984-22989	brain	_	
125-21	22989-22990	.	_	

#Text=These results align a recent study showing that the occipital and motor regions are over-connected in healthy controls with poorer cognitive scores and outcome measures, suggesting this relationship is not SSD-specific.
126-1	22991-22996	These	_	
126-2	22997-23004	results	_	
126-3	23005-23010	align	_	
126-4	23011-23012	a	_	
126-5	23013-23019	recent	_	
126-6	23020-23025	study	_	
126-7	23026-23033	showing	_	
126-8	23034-23038	that	_	
126-9	23039-23042	the	_	
126-10	23043-23052	occipital	_	
126-11	23053-23056	and	_	
126-12	23057-23062	motor	_	
126-13	23063-23070	regions	_	
126-14	23071-23074	are	_	
126-15	23075-23089	over-connected	_	
126-16	23090-23092	in	_	
126-17	23093-23100	healthy	_	
126-18	23101-23109	controls	_	
126-19	23110-23114	with	_	
126-20	23115-23121	poorer	_	
126-21	23122-23131	cognitive	_	
126-22	23132-23138	scores	_	
126-23	23139-23142	and	_	
126-24	23143-23150	outcome	_	
126-25	23151-23159	measures	_	
126-26	23159-23160	,	_	
126-27	23161-23171	suggesting	_	
126-28	23172-23176	this	_	
126-29	23177-23189	relationship	_	
126-30	23190-23192	is	_	
126-31	23193-23196	not	_	
126-32	23197-23209	SSD-specific	_	
126-33	23209-23210	.	_	

#Text=Occipital lobe abnormalities have been reported in schizophrenia, and abnormal connectivity of the occipital regions is associated with general mental illness risk.
127-1	23211-23220	Occipital	_	
127-2	23221-23225	lobe	_	
127-3	23226-23239	abnormalities	_	
127-4	23240-23244	have	_	
127-5	23245-23249	been	_	
127-6	23250-23258	reported	_	
127-7	23259-23261	in	_	
127-8	23262-23275	schizophrenia	_	
127-9	23275-23276	,	_	
127-10	23277-23280	and	_	
127-11	23281-23289	abnormal	_	
127-12	23290-23302	connectivity	_	
127-13	23303-23305	of	_	
127-14	23306-23309	the	_	
127-15	23310-23319	occipital	_	
127-16	23320-23327	regions	_	
127-17	23328-23330	is	_	
127-18	23331-23341	associated	_	
127-19	23342-23346	with	_	
127-20	23347-23354	general	_	
127-21	23355-23361	mental	_	
127-22	23362-23369	illness	_	
127-23	23370-23374	risk	_	
127-24	23374-23375	.	_	

#Text=As cortical development generally progresses from the posterior to the anterior, this may be due to abnormal synaptic pruning associated with schizophrenia.
128-1	23376-23378	As	_	
128-2	23379-23387	cortical	_	
128-3	23388-23399	development	_	
128-4	23400-23409	generally	_	
128-5	23410-23420	progresses	_	
128-6	23421-23425	from	_	
128-7	23426-23429	the	_	
128-8	23430-23439	posterior	_	
128-9	23440-23442	to	_	
128-10	23443-23446	the	_	
128-11	23447-23455	anterior	_	
128-12	23455-23456	,	_	
128-13	23457-23461	this	_	
128-14	23462-23465	may	_	
128-15	23466-23468	be	_	
128-16	23469-23472	due	_	
128-17	23473-23475	to	_	
128-18	23476-23484	abnormal	_	
128-19	23485-23493	synaptic	_	
128-20	23494-23501	pruning	_	
128-21	23502-23512	associated	_	
128-22	23513-23517	with	_	
128-23	23518-23531	schizophrenia	_	
128-24	23531-23532	.	_	

#Text=The development of organized frontal activity in children and adolescents is dependent on the successful pruning of the parietal regions, including the mirror neuron network.
129-1	23533-23536	The	_	
129-2	23537-23548	development	_	
129-3	23549-23551	of	_	
129-4	23552-23561	organized	_	
129-5	23562-23569	frontal	_	
129-6	23570-23578	activity	_	
129-7	23579-23581	in	_	
129-8	23582-23590	children	_	
129-9	23591-23594	and	_	
129-10	23595-23606	adolescents	_	
129-11	23607-23609	is	_	
129-12	23610-23619	dependent	_	
129-13	23620-23622	on	_	
129-14	23623-23626	the	_	
129-15	23627-23637	successful	_	
129-16	23638-23645	pruning	_	
129-17	23646-23648	of	_	
129-18	23649-23652	the	_	
129-19	23653-23661	parietal	_	
129-20	23662-23669	regions	_	
129-21	23669-23670	,	_	
129-22	23671-23680	including	_	
129-23	23681-23684	the	_	
129-24	23685-23691	mirror	_	
129-25	23692-23698	neuron	_	
129-26	23699-23706	network	_	
129-27	23706-23707	.	_	

#Text=Therefore, the poorly-performing biotype might reflect those with halted or perturbed brain development at an earlier developmental stage.
130-1	23708-23717	Therefore	_	
130-2	23717-23718	,	_	
130-3	23719-23722	the	_	
130-4	23723-23740	poorly-performing	_	
130-5	23741-23748	biotype	_	
130-6	23749-23754	might	_	
130-7	23755-23762	reflect	_	
130-8	23763-23768	those	_	
130-9	23769-23773	with	_	
130-10	23774-23780	halted	_	
130-11	23781-23783	or	_	
130-12	23784-23793	perturbed	_	
130-13	23794-23799	brain	_	
130-14	23800-23811	development	_	
130-15	23812-23814	at	_	
130-16	23815-23817	an	_	
130-17	23818-23825	earlier	_	
130-18	23826-23839	developmental	_	
130-19	23840-23845	stage	_	
130-20	23845-23846	.	_	

#Text=Alternatively, over-connectivity of the parietal and occipital regions may be viewed as compensatory organization, potentially in relation to aberrant development of frontal regions, which is a well-supported finding in schizophrenia.
131-1	23847-23860	Alternatively	_	
131-2	23860-23861	,	_	
131-3	23862-23879	over-connectivity	_	
131-4	23880-23882	of	_	
131-5	23883-23886	the	_	
131-6	23887-23895	parietal	_	
131-7	23896-23899	and	_	
131-8	23900-23909	occipital	_	
131-9	23910-23917	regions	_	
131-10	23918-23921	may	_	
131-11	23922-23924	be	_	
131-12	23925-23931	viewed	_	
131-13	23932-23934	as	_	
131-14	23935-23947	compensatory	_	
131-15	23948-23960	organization	_	
131-16	23960-23961	,	_	
131-17	23962-23973	potentially	_	
131-18	23974-23976	in	_	
131-19	23977-23985	relation	_	
131-20	23986-23988	to	_	
131-21	23989-23997	aberrant	_	
131-22	23998-24009	development	_	
131-23	24010-24012	of	_	
131-24	24013-24020	frontal	_	
131-25	24021-24028	regions	_	
131-26	24028-24029	,	_	
131-27	24030-24035	which	_	
131-28	24036-24038	is	_	
131-29	24039-24040	a	_	
131-30	24041-24055	well-supported	_	
131-31	24056-24063	finding	_	
131-32	24064-24066	in	_	
131-33	24067-24080	schizophrenia	_	
131-34	24080-24081	.	_	

#Text=Differences between the two biotypes using structural neuroimaging data in cortical thickness, subcortical volumes, and white matter FA, also not included in the original biotype model, lend validity to the replicated data-driven results, similar to a previously described approach.
132-1	24082-24093	Differences	_	
132-2	24094-24101	between	_	
132-3	24102-24105	the	_	
132-4	24106-24109	two	_	
132-5	24110-24118	biotypes	_	
132-6	24119-24124	using	_	
132-7	24125-24135	structural	_	
132-8	24136-24148	neuroimaging	_	
132-9	24149-24153	data	_	
132-10	24154-24156	in	_	
132-11	24157-24165	cortical	_	
132-12	24166-24175	thickness	_	
132-13	24175-24176	,	_	
132-14	24177-24188	subcortical	_	
132-15	24189-24196	volumes	_	
132-16	24196-24197	,	_	
132-17	24198-24201	and	_	
132-18	24202-24207	white	_	
132-19	24208-24214	matter	_	
132-20	24215-24217	FA	_	
132-21	24217-24218	,	_	
132-22	24219-24223	also	_	
132-23	24224-24227	not	_	
132-24	24228-24236	included	_	
132-25	24237-24239	in	_	
132-26	24240-24243	the	_	
132-27	24244-24252	original	_	
132-28	24253-24260	biotype	_	
132-29	24261-24266	model	_	
132-30	24266-24267	,	_	
132-31	24268-24272	lend	_	
132-32	24273-24281	validity	_	
132-33	24282-24284	to	_	
132-34	24285-24288	the	_	
132-35	24289-24299	replicated	_	
132-36	24300-24311	data-driven	_	
132-37	24312-24319	results	_	
132-38	24319-24320	,	_	
132-39	24321-24328	similar	_	
132-40	24329-24331	to	_	
132-41	24332-24333	a	_	
132-42	24334-24344	previously	_	
132-43	24345-24354	described	_	
132-44	24355-24363	approach	_	
132-45	24363-24364	.	_	

#Text=A number of studies have attempted (using almost exclusively structural neuroimaging approaches) to compare people with Type 1 vs.
133-1	24365-24366	A	_	
133-2	24367-24373	number	_	
133-3	24374-24376	of	_	
133-4	24377-24384	studies	_	
133-5	24385-24389	have	_	
133-6	24390-24399	attempted	_	
133-7	24400-24401	(	_	
133-8	24401-24406	using	_	
133-9	24407-24413	almost	_	
133-10	24414-24425	exclusively	_	
133-11	24426-24436	structural	_	
133-12	24437-24449	neuroimaging	_	
133-13	24450-24460	approaches	_	
133-14	24460-24461	)	_	
133-15	24462-24464	to	_	
133-16	24465-24472	compare	_	
133-17	24473-24479	people	_	
133-18	24480-24484	with	_	
133-19	24485-24489	Type	_	
133-20	24490-24491	1	_	
133-21	24492-24494	vs	_	
133-22	24494-24495	.	_	

#Text=Type 2 schizophrenia, poor vs. good outcomes, deficit vs. nondeficit syndrome.
134-1	24496-24500	Type	_	
134-2	24501-24502	2	_	
134-3	24503-24516	schizophrenia	_	
134-4	24516-24517	,	_	
134-5	24518-24522	poor	_	
134-6	24523-24525	vs	_	
134-7	24525-24526	.	_	
134-8	24527-24531	good	_	
134-9	24532-24540	outcomes	_	
134-10	24540-24541	,	_	
134-11	24542-24549	deficit	_	
134-12	24550-24552	vs	_	
134-13	24552-24553	.	_	
134-14	24554-24564	nondeficit	_	
134-15	24565-24573	syndrome	_	
134-16	24573-24574	.	_	

#Text=These studies identified larger ventricles, gray matter differences, and more recently white matter diffusion metric differences as potentially having the greatest effect size between groups.
135-1	24575-24580	These	_	
135-2	24581-24588	studies	_	
135-3	24589-24599	identified	_	
135-4	24600-24606	larger	_	
135-5	24607-24617	ventricles	_	
135-6	24617-24618	,	_	
135-7	24619-24623	gray	_	
135-8	24624-24630	matter	_	
135-9	24631-24642	differences	_	
135-10	24642-24643	,	_	
135-11	24644-24647	and	_	
135-12	24648-24652	more	_	
135-13	24653-24661	recently	_	
135-14	24662-24667	white	_	
135-15	24668-24674	matter	_	
135-16	24675-24684	diffusion	_	
135-17	24685-24691	metric	_	
135-18	24692-24703	differences	_	
135-19	24704-24706	as	_	
135-20	24707-24718	potentially	_	
135-21	24719-24725	having	_	
135-22	24726-24729	the	_	
135-23	24730-24738	greatest	_	
135-24	24739-24745	effect	_	
135-25	24746-24750	size	_	
135-26	24751-24758	between	_	
135-27	24759-24765	groups	_	
135-28	24765-24766	.	_	

#Text=However, these approaches all require detailed and extensive clinical characterization, multiple assessments, and other time-intensive approaches.
136-1	24767-24774	However	_	
136-2	24774-24775	,	_	
136-3	24776-24781	these	_	
136-4	24782-24792	approaches	_	
136-5	24793-24796	all	_	
136-6	24797-24804	require	_	
136-7	24805-24813	detailed	_	
136-8	24814-24817	and	_	
136-9	24818-24827	extensive	_	
136-10	24828-24836	clinical	_	
136-11	24837-24853	characterization	_	
136-12	24853-24854	,	_	
136-13	24855-24863	multiple	_	
136-14	24864-24875	assessments	_	
136-15	24875-24876	,	_	
136-16	24877-24880	and	_	
136-17	24881-24886	other	_	
136-18	24887-24901	time-intensive	_	
136-19	24902-24912	approaches	_	
136-20	24912-24913	.	_	

#Text=Our data-driven approach required only a short resting state fMRI scan to reliably separate people with an SSD into two groups, one with poorer cognitive performance, greater negative symptom burden, and poorer functional outcome, and the other with performance more similar to the healthy control group.
137-1	24914-24917	Our	_	
137-2	24918-24929	data-driven	_	
137-3	24930-24938	approach	_	
137-4	24939-24947	required	_	
137-5	24948-24952	only	_	
137-6	24953-24954	a	_	
137-7	24955-24960	short	_	
137-8	24961-24968	resting	_	
137-9	24969-24974	state	_	
137-10	24975-24979	fMRI	_	
137-11	24980-24984	scan	_	
137-12	24985-24987	to	_	
137-13	24988-24996	reliably	_	
137-14	24997-25005	separate	_	
137-15	25006-25012	people	_	
137-16	25013-25017	with	_	
137-17	25018-25020	an	_	
137-18	25021-25024	SSD	_	
137-19	25025-25029	into	_	
137-20	25030-25033	two	_	
137-21	25034-25040	groups	_	
137-22	25040-25041	,	_	
137-23	25042-25045	one	_	
137-24	25046-25050	with	_	
137-25	25051-25057	poorer	_	
137-26	25058-25067	cognitive	_	
137-27	25068-25079	performance	_	
137-28	25079-25080	,	_	
137-29	25081-25088	greater	_	
137-30	25089-25097	negative	_	
137-31	25098-25105	symptom	_	
137-32	25106-25112	burden	_	
137-33	25112-25113	,	_	
137-34	25114-25117	and	_	
137-35	25118-25124	poorer	_	
137-36	25125-25135	functional	_	
137-37	25136-25143	outcome	_	
137-38	25143-25144	,	_	
137-39	25145-25148	and	_	
137-40	25149-25152	the	_	
137-41	25153-25158	other	_	
137-42	25159-25163	with	_	
137-43	25164-25175	performance	_	
137-44	25176-25180	more	_	
137-45	25181-25188	similar	_	
137-46	25189-25191	to	_	
137-47	25192-25195	the	_	
137-48	25196-25203	healthy	_	
137-49	25204-25211	control	_	
137-50	25212-25217	group	_	
137-51	25217-25218	.	_	

#Text=Our finding that resting state connectivity, and not task data, are best at isolating cognitively impaired participants with poor outcomes is in line with recent literature showing subject-specific brain connectivity patterns at rest, but not during tasks, allow for the reliable identification of individuals across scanning days and across scanners.
138-1	25219-25222	Our	_	
138-2	25223-25230	finding	_	
138-3	25231-25235	that	_	
138-4	25236-25243	resting	_	
138-5	25244-25249	state	_	
138-6	25250-25262	connectivity	_	
138-7	25262-25263	,	_	
138-8	25264-25267	and	_	
138-9	25268-25271	not	_	
138-10	25272-25276	task	_	
138-11	25277-25281	data	_	
138-12	25281-25282	,	_	
138-13	25283-25286	are	_	
138-14	25287-25291	best	_	
138-15	25292-25294	at	_	
138-16	25295-25304	isolating	_	
138-17	25305-25316	cognitively	_	
138-18	25317-25325	impaired	_	
138-19	25326-25338	participants	_	
138-20	25339-25343	with	_	
138-21	25344-25348	poor	_	
138-22	25349-25357	outcomes	_	
138-23	25358-25360	is	_	
138-24	25361-25363	in	_	
138-25	25364-25368	line	_	
138-26	25369-25373	with	_	
138-27	25374-25380	recent	_	
138-28	25381-25391	literature	_	
138-29	25392-25399	showing	_	
138-30	25400-25416	subject-specific	_	
138-31	25417-25422	brain	_	
138-32	25423-25435	connectivity	_	
138-33	25436-25444	patterns	_	
138-34	25445-25447	at	_	
138-35	25448-25452	rest	_	
138-36	25452-25453	,	_	
138-37	25454-25457	but	_	
138-38	25458-25461	not	_	
138-39	25462-25468	during	_	
138-40	25469-25474	tasks	_	
138-41	25474-25475	,	_	
138-42	25476-25481	allow	_	
138-43	25482-25485	for	_	
138-44	25486-25489	the	_	
138-45	25490-25498	reliable	_	
138-46	25499-25513	identification	_	
138-47	25514-25516	of	_	
138-48	25517-25528	individuals	_	
138-49	25529-25535	across	_	
138-50	25536-25544	scanning	_	
138-51	25545-25549	days	_	
138-52	25550-25553	and	_	
138-53	25554-25560	across	_	
138-54	25561-25569	scanners	_	
138-55	25569-25570	.	_	

#Text=The two tasks considered (imitate/observe and empathic accuracy) grouped participants differently into the two biotypes (figure s6), and results were inconsistent between the discovery and replication set.
139-1	25571-25574	The	_	
139-2	25575-25578	two	_	
139-3	25579-25584	tasks	_	
139-4	25585-25595	considered	_	
139-5	25596-25597	(	_	
139-6	25597-25604	imitate	_	
139-7	25604-25605	/	_	
139-8	25605-25612	observe	_	
139-9	25613-25616	and	_	
139-10	25617-25625	empathic	_	
139-11	25626-25634	accuracy	_	
139-12	25634-25635	)	_	
139-13	25636-25643	grouped	_	
139-14	25644-25656	participants	_	
139-15	25657-25668	differently	_	
139-16	25669-25673	into	_	
139-17	25674-25677	the	_	
139-18	25678-25681	two	_	
139-19	25682-25690	biotypes	_	
139-20	25691-25692	(	_	
139-21	25692-25698	figure	_	
139-22	25699-25701	s6	_	
139-23	25701-25702	)	_	
139-24	25702-25703	,	_	
139-25	25704-25707	and	_	
139-26	25708-25715	results	_	
139-27	25716-25720	were	_	
139-28	25721-25733	inconsistent	_	
139-29	25734-25741	between	_	
139-30	25742-25745	the	_	
139-31	25746-25755	discovery	_	
139-32	25756-25759	and	_	
139-33	25760-25771	replication	_	
139-34	25772-25775	set	_	
139-35	25775-25776	.	_	

#Text=It is worth highlighting that the connectivity differences between biotypes for empathic accuracy were large when compared with both imitate/observe and the resting state data, suggesting that this task elicited robust brain connectivity related to task engagement.
140-1	25777-25779	It	_	
140-2	25780-25782	is	_	
140-3	25783-25788	worth	_	
140-4	25789-25801	highlighting	_	
140-5	25802-25806	that	_	
140-6	25807-25810	the	_	
140-7	25811-25823	connectivity	_	
140-8	25824-25835	differences	_	
140-9	25836-25843	between	_	
140-10	25844-25852	biotypes	_	
140-11	25853-25856	for	_	
140-12	25857-25865	empathic	_	
140-13	25866-25874	accuracy	_	
140-14	25875-25879	were	_	
140-15	25880-25885	large	_	
140-16	25886-25890	when	_	
140-17	25891-25899	compared	_	
140-18	25900-25904	with	_	
140-19	25905-25909	both	_	
140-20	25910-25917	imitate	_	
140-21	25917-25918	/	_	
140-22	25918-25925	observe	_	
140-23	25926-25929	and	_	
140-24	25930-25933	the	_	
140-25	25934-25941	resting	_	
140-26	25942-25947	state	_	
140-27	25948-25952	data	_	
140-28	25952-25953	,	_	
140-29	25954-25964	suggesting	_	
140-30	25965-25969	that	_	
140-31	25970-25974	this	_	
140-32	25975-25979	task	_	
140-33	25980-25988	elicited	_	
140-34	25989-25995	robust	_	
140-35	25996-26001	brain	_	
140-36	26002-26014	connectivity	_	
140-37	26015-26022	related	_	
140-38	26023-26025	to	_	
140-39	26026-26030	task	_	
140-40	26031-26041	engagement	_	
140-41	26041-26042	.	_	

#Text=This measure of task engagement, however, does not seem to separate those with poor cognitive performance from the rest of the sample.
141-1	26043-26047	This	_	
141-2	26048-26055	measure	_	
141-3	26056-26058	of	_	
141-4	26059-26063	task	_	
141-5	26064-26074	engagement	_	
141-6	26074-26075	,	_	
141-7	26076-26083	however	_	
141-8	26083-26084	,	_	
141-9	26085-26089	does	_	
141-10	26090-26093	not	_	
141-11	26094-26098	seem	_	
141-12	26099-26101	to	_	
141-13	26102-26110	separate	_	
141-14	26111-26116	those	_	
141-15	26117-26121	with	_	
141-16	26122-26126	poor	_	
141-17	26127-26136	cognitive	_	
141-18	26137-26148	performance	_	
141-19	26149-26153	from	_	
141-20	26154-26157	the	_	
141-21	26158-26162	rest	_	
141-22	26163-26165	of	_	
141-23	26166-26169	the	_	
141-24	26170-26176	sample	_	
141-25	26176-26177	.	_	

#Text=We conclude that task fMRI activity better reflects task-specific brain activity than it does cognitive ability per se, and consequently is less useful for deriving biologically-different groups.
142-1	26178-26180	We	_	
142-2	26181-26189	conclude	_	
142-3	26190-26194	that	_	
142-4	26195-26199	task	_	
142-5	26200-26204	fMRI	_	
142-6	26205-26213	activity	_	
142-7	26214-26220	better	_	
142-8	26221-26229	reflects	_	
142-9	26230-26243	task-specific	_	
142-10	26244-26249	brain	_	
142-11	26250-26258	activity	_	
142-12	26259-26263	than	_	
142-13	26264-26266	it	_	
142-14	26267-26271	does	_	
142-15	26272-26281	cognitive	_	
142-16	26282-26289	ability	_	
142-17	26290-26293	per	_	
142-18	26294-26296	se	_	
142-19	26296-26297	,	_	
142-20	26298-26301	and	_	
142-21	26302-26314	consequently	_	
142-22	26315-26317	is	_	
142-23	26318-26322	less	_	
142-24	26323-26329	useful	_	
142-25	26330-26333	for	_	
142-26	26334-26342	deriving	_	
142-27	26343-26365	biologically-different	_	
142-28	26366-26372	groups	_	
142-29	26372-26373	.	_	

#Text=Our claim that resting state is more useful than the tasks considered is limited due to both tasks involving the execution of motor commands in the scanner.
143-1	26374-26377	Our	_	
143-2	26378-26383	claim	_	
143-3	26384-26388	that	_	
143-4	26389-26396	resting	_	
143-5	26397-26402	state	_	
143-6	26403-26405	is	_	
143-7	26406-26410	more	_	
143-8	26411-26417	useful	_	
143-9	26418-26422	than	_	
143-10	26423-26426	the	_	
143-11	26427-26432	tasks	_	
143-12	26433-26443	considered	_	
143-13	26444-26446	is	_	
143-14	26447-26454	limited	_	
143-15	26455-26458	due	_	
143-16	26459-26461	to	_	
143-17	26462-26466	both	_	
143-18	26467-26472	tasks	_	
143-19	26473-26482	involving	_	
143-20	26483-26486	the	_	
143-21	26487-26496	execution	_	
143-22	26497-26499	of	_	
143-23	26500-26505	motor	_	
143-24	26506-26514	commands	_	
143-25	26515-26517	in	_	
143-26	26518-26521	the	_	
143-27	26522-26529	scanner	_	
143-28	26529-26530	.	_	

#Text=Connectivity analysis is notoriously sensitive to motion.
144-1	26531-26543	Connectivity	_	
144-2	26544-26552	analysis	_	
144-3	26553-26555	is	_	
144-4	26556-26567	notoriously	_	
144-5	26568-26577	sensitive	_	
144-6	26578-26580	to	_	
144-7	26581-26587	motion	_	
144-8	26587-26588	.	_	

#Text=For both tasks, the removal of motion events may have had the unintended effect of removing task-related network activity or neurobiological information.
145-1	26589-26592	For	_	
145-2	26593-26597	both	_	
145-3	26598-26603	tasks	_	
145-4	26603-26604	,	_	
145-5	26605-26608	the	_	
145-6	26609-26616	removal	_	
145-7	26617-26619	of	_	
145-8	26620-26626	motion	_	
145-9	26627-26633	events	_	
145-10	26634-26637	may	_	
145-11	26638-26642	have	_	
145-12	26643-26646	had	_	
145-13	26647-26650	the	_	
145-14	26651-26661	unintended	_	
145-15	26662-26668	effect	_	
145-16	26669-26671	of	_	
145-17	26672-26680	removing	_	
145-18	26681-26693	task-related	_	
145-19	26694-26701	network	_	
145-20	26702-26710	activity	_	
145-21	26711-26713	or	_	
145-22	26714-26729	neurobiological	_	
145-23	26730-26741	information	_	
145-24	26741-26742	.	_	

#Text=Our ability to generalize these findings is limited by our use of closely-matched scanning parameters and hardware, in addition to our extensive inclusion/exclusion criteria.
146-1	26743-26746	Our	_	
146-2	26747-26754	ability	_	
146-3	26755-26757	to	_	
146-4	26758-26768	generalize	_	
146-5	26769-26774	these	_	
146-6	26775-26783	findings	_	
146-7	26784-26786	is	_	
146-8	26787-26794	limited	_	
146-9	26795-26797	by	_	
146-10	26798-26801	our	_	
146-11	26802-26805	use	_	
146-12	26806-26808	of	_	
146-13	26809-26824	closely-matched	_	
146-14	26825-26833	scanning	_	
146-15	26834-26844	parameters	_	
146-16	26845-26848	and	_	
146-17	26849-26857	hardware	_	
146-18	26857-26858	,	_	
146-19	26859-26861	in	_	
146-20	26862-26870	addition	_	
146-21	26871-26873	to	_	
146-22	26874-26877	our	_	
146-23	26878-26887	extensive	_	
146-24	26888-26897	inclusion	_	
146-25	26897-26898	/	_	
146-26	26898-26907	exclusion	_	
146-27	26908-26916	criteria	_	
146-28	26916-26917	.	_	

#Text=Future work will require a larger sample of participants with varying clinical phenomenologies collected on heterogeneous MRI configurations to train a classifier robust to these sources of variance.
147-1	26918-26924	Future	_	
147-2	26925-26929	work	_	
147-3	26930-26934	will	_	
147-4	26935-26942	require	_	
147-5	26943-26944	a	_	
147-6	26945-26951	larger	_	
147-7	26952-26958	sample	_	
147-8	26959-26961	of	_	
147-9	26962-26974	participants	_	
147-10	26975-26979	with	_	
147-11	26980-26987	varying	_	
147-12	26988-26996	clinical	_	
147-13	26997-27012	phenomenologies	_	
147-14	27013-27022	collected	_	
147-15	27023-27025	on	_	
147-16	27026-27039	heterogeneous	_	
147-17	27040-27043	MRI	_	
147-18	27044-27058	configurations	_	
147-19	27059-27061	to	_	
147-20	27062-27067	train	_	
147-21	27068-27069	a	_	
147-22	27070-27080	classifier	_	
147-23	27081-27087	robust	_	
147-24	27088-27090	to	_	
147-25	27091-27096	these	_	
147-26	27097-27104	sources	_	
147-27	27105-27107	of	_	
147-28	27108-27116	variance	_	
147-29	27116-27117	.	_	

#Text=Our use of a cross-sectional sample leaves us unable to verify the stability of the biotypes over time; therefore, these results require longitudinal confirmation.
148-1	27118-27121	Our	_	
148-2	27122-27125	use	_	
148-3	27126-27128	of	_	
148-4	27129-27130	a	_	
148-5	27131-27146	cross-sectional	_	
148-6	27147-27153	sample	_	
148-7	27154-27160	leaves	_	
148-8	27161-27163	us	_	
148-9	27164-27170	unable	_	
148-10	27171-27173	to	_	
148-11	27174-27180	verify	_	
148-12	27181-27184	the	_	
148-13	27185-27194	stability	_	
148-14	27195-27197	of	_	
148-15	27198-27201	the	_	
148-16	27202-27210	biotypes	_	
148-17	27211-27215	over	_	
148-18	27216-27220	time	_	
148-19	27220-27221	;	_	
148-20	27222-27231	therefore	_	
148-21	27231-27232	,	_	
148-22	27233-27238	these	_	
148-23	27239-27246	results	_	
148-24	27247-27254	require	_	
148-25	27255-27267	longitudinal	_	
148-26	27268-27280	confirmation	_	
148-27	27280-27281	.	_	

#Text=Site or scanner effects are typically sources of unwanted variance in connectivity studies, and can drive spurious results.
149-1	27282-27286	Site	_	
149-2	27287-27289	or	_	
149-3	27290-27297	scanner	_	
149-4	27298-27305	effects	_	
149-5	27306-27309	are	_	
149-6	27310-27319	typically	_	
149-7	27320-27327	sources	_	
149-8	27328-27330	of	_	
149-9	27331-27339	unwanted	_	
149-10	27340-27348	variance	_	
149-11	27349-27351	in	_	
149-12	27352-27364	connectivity	_	
149-13	27365-27372	studies	_	
149-14	27372-27373	,	_	
149-15	27374-27377	and	_	
149-16	27378-27381	can	_	
149-17	27382-27387	drive	_	
149-18	27388-27396	spurious	_	
149-19	27397-27404	results	_	
149-20	27404-27405	.	_	

#Text=However, there was no significant difference in the number of participants in each biotype found (table 2), and we replicated our findings in a second sample collected on a single scanner.
150-1	27406-27413	However	_	
150-2	27413-27414	,	_	
150-3	27415-27420	there	_	
150-4	27421-27424	was	_	
150-5	27425-27427	no	_	
150-6	27428-27439	significant	_	
150-7	27440-27450	difference	_	
150-8	27451-27453	in	_	
150-9	27454-27457	the	_	
150-10	27458-27464	number	_	
150-11	27465-27467	of	_	
150-12	27468-27480	participants	_	
150-13	27481-27483	in	_	
150-14	27484-27488	each	_	
150-15	27489-27496	biotype	_	
150-16	27497-27502	found	_	
150-17	27503-27504	(	_	
150-18	27504-27509	table	_	
150-19	27510-27511	2	_	
150-20	27511-27512	)	_	
150-21	27512-27513	,	_	
150-22	27514-27517	and	_	
150-23	27518-27520	we	_	
150-24	27521-27531	replicated	_	
150-25	27532-27535	our	_	
150-26	27536-27544	findings	_	
150-27	27545-27547	in	_	
150-28	27548-27549	a	_	
150-29	27550-27556	second	_	
150-30	27557-27563	sample	_	
150-31	27564-27573	collected	_	
150-32	27574-27576	on	_	
150-33	27577-27578	a	_	
150-34	27579-27585	single	_	
150-35	27586-27593	scanner	_	
150-36	27593-27594	.	_	

#Text=While our resting state poorly-performing biotype did show significantly worse general health as assessed by the CIRSG, they did not show significantly higher medication load as measured by CPZE (figure 1; table s1).
151-1	27595-27600	While	_	
151-2	27601-27604	our	_	
151-3	27605-27612	resting	_	
151-4	27613-27618	state	_	
151-5	27619-27636	poorly-performing	_	
151-6	27637-27644	biotype	_	
151-7	27645-27648	did	_	
151-8	27649-27653	show	_	
151-9	27654-27667	significantly	_	
151-10	27668-27673	worse	_	
151-11	27674-27681	general	_	
151-12	27682-27688	health	_	
151-13	27689-27691	as	_	
151-14	27692-27700	assessed	_	
151-15	27701-27703	by	_	
151-16	27704-27707	the	_	
151-17	27708-27713	CIRSG	_	
151-18	27713-27714	,	_	
151-19	27715-27719	they	_	
151-20	27720-27723	did	_	
151-21	27724-27727	not	_	
151-22	27728-27732	show	_	
151-23	27733-27746	significantly	_	
151-24	27747-27753	higher	_	
151-25	27754-27764	medication	_	
151-26	27765-27769	load	_	
151-27	27770-27772	as	_	
151-28	27773-27781	measured	_	
151-29	27782-27784	by	_	
151-30	27785-27789	CPZE	_	
151-31	27790-27791	(	_	
151-32	27791-27797	figure	_	
151-33	27798-27799	1	_	
151-34	27799-27800	;	_	
151-35	27801-27806	table	_	
151-36	27807-27809	s1	_	
151-37	27809-27810	)	_	
151-38	27810-27811	.	_	

#Text=A fully trained model that distinguishes poor performers with specific alterations within their functional brain organization, like the one shown here, is a first step toward a biologically-informed prognostic test that can be applied in the clinic to assess differences among patients that may be noted over a longer course of time in symptom burden, cognitive performance, and function.
152-1	27812-27813	A	_	
152-2	27814-27819	fully	_	
152-3	27820-27827	trained	_	
152-4	27828-27833	model	_	
152-5	27834-27838	that	_	
152-6	27839-27852	distinguishes	_	
152-7	27853-27857	poor	_	
152-8	27858-27868	performers	_	
152-9	27869-27873	with	_	
152-10	27874-27882	specific	_	
152-11	27883-27894	alterations	_	
152-12	27895-27901	within	_	
152-13	27902-27907	their	_	
152-14	27908-27918	functional	_	
152-15	27919-27924	brain	_	
152-16	27925-27937	organization	_	
152-17	27937-27938	,	_	
152-18	27939-27943	like	_	
152-19	27944-27947	the	_	
152-20	27948-27951	one	_	
152-21	27952-27957	shown	_	
152-22	27958-27962	here	_	
152-23	27962-27963	,	_	
152-24	27964-27966	is	_	
152-25	27967-27968	a	_	
152-26	27969-27974	first	_	
152-27	27975-27979	step	_	
152-28	27980-27986	toward	_	
152-29	27987-27988	a	_	
152-30	27989-28010	biologically-informed	_	
152-31	28011-28021	prognostic	_	
152-32	28022-28026	test	_	
152-33	28027-28031	that	_	
152-34	28032-28035	can	_	
152-35	28036-28038	be	_	
152-36	28039-28046	applied	_	
152-37	28047-28049	in	_	
152-38	28050-28053	the	_	
152-39	28054-28060	clinic	_	
152-40	28061-28063	to	_	
152-41	28064-28070	assess	_	
152-42	28071-28082	differences	_	
152-43	28083-28088	among	_	
152-44	28089-28097	patients	_	
152-45	28098-28102	that	_	
152-46	28103-28106	may	_	
152-47	28107-28109	be	_	
152-48	28110-28115	noted	_	
152-49	28116-28120	over	_	
152-50	28121-28122	a	_	
152-51	28123-28129	longer	_	
152-52	28130-28136	course	_	
152-53	28137-28139	of	_	
152-54	28140-28144	time	_	
152-55	28145-28147	in	_	
152-56	28148-28155	symptom	_	
152-57	28156-28162	burden	_	
152-58	28162-28163	,	_	
152-59	28164-28173	cognitive	_	
152-60	28174-28185	performance	_	
152-61	28185-28186	,	_	
152-62	28187-28190	and	_	
152-63	28191-28199	function	_	
152-64	28199-28200	.	_	

#Text=It may also have implications for treatment response.
153-1	28201-28203	It	_	
153-2	28204-28207	may	_	
153-3	28208-28212	also	_	
153-4	28213-28217	have	_	
153-5	28218-28230	implications	_	
153-6	28231-28234	for	_	
153-7	28235-28244	treatment	_	
153-8	28245-28253	response	_	
153-9	28253-28254	.	_	

#Text=The model presented here generalizes to held-out participants, and is demonstrated to work in an independent sample, suggesting strong external validity.
154-1	28255-28258	The	_	
154-2	28259-28264	model	_	
154-3	28265-28274	presented	_	
154-4	28275-28279	here	_	
154-5	28280-28291	generalizes	_	
154-6	28292-28294	to	_	
154-7	28295-28303	held-out	_	
154-8	28304-28316	participants	_	
154-9	28316-28317	,	_	
154-10	28318-28321	and	_	
154-11	28322-28324	is	_	
154-12	28325-28337	demonstrated	_	
154-13	28338-28340	to	_	
154-14	28341-28345	work	_	
154-15	28346-28348	in	_	
154-16	28349-28351	an	_	
154-17	28352-28363	independent	_	
154-18	28364-28370	sample	_	
154-19	28370-28371	,	_	
154-20	28372-28382	suggesting	_	
154-21	28383-28389	strong	_	
154-22	28390-28398	external	_	
154-23	28399-28407	validity	_	
154-24	28407-28408	.	_	

#Text=This general approach may be useful for development of biologically-driven tests for cognitive subtypes with divergent outcomes across psychiatric populations.
155-1	28409-28413	This	_	
155-2	28414-28421	general	_	
155-3	28422-28430	approach	_	
155-4	28431-28434	may	_	
155-5	28435-28437	be	_	
155-6	28438-28444	useful	_	
155-7	28445-28448	for	_	
155-8	28449-28460	development	_	
155-9	28461-28463	of	_	
155-10	28464-28483	biologically-driven	_	
155-11	28484-28489	tests	_	
155-12	28490-28493	for	_	
155-13	28494-28503	cognitive	_	
155-14	28504-28512	subtypes	_	
155-15	28513-28517	with	_	
155-16	28518-28527	divergent	_	
155-17	28528-28536	outcomes	_	
155-18	28537-28543	across	_	
155-19	28544-28555	psychiatric	_	
155-20	28556-28567	populations	_	
155-21	28567-28568	.	_	

#Text=Supplementary Material
#Text=           Conflict of Interest         
#Text=Anil K Malhotra has served as a Consultant to Genomind, Inc, Concert Pharmaceuticals, and Forum Pharmaceuticals.
156-1	28569-28582	Supplementary	_	
156-2	28583-28591	Material	_	
156-3	28603-28611	Conflict	_	
156-4	28612-28614	of	_	
156-5	28615-28623	Interest	_	
156-6	28633-28637	Anil	_	
156-7	28638-28639	K	_	
156-8	28640-28648	Malhotra	_	
156-9	28649-28652	has	_	
156-10	28653-28659	served	_	
156-11	28660-28662	as	_	
156-12	28663-28664	a	_	
156-13	28665-28675	Consultant	_	
156-14	28676-28678	to	_	
156-15	28679-28687	Genomind	_	
156-16	28687-28688	,	_	
156-17	28689-28692	Inc	_	
156-18	28692-28693	,	_	
156-19	28694-28701	Concert	_	
156-20	28702-28717	Pharmaceuticals	_	
156-21	28717-28718	,	_	
156-22	28719-28722	and	_	
156-23	28723-28728	Forum	_	
156-24	28729-28744	Pharmaceuticals	_	
156-25	28744-28745	.	_	

#Text=James Gold has consulted for Takeda, Lundback and Hoffman La Roche and receives royalty payments from the Banker’s Automated Clearing Services.
157-1	28746-28751	James	_	
157-2	28752-28756	Gold	_	
157-3	28757-28760	has	_	
157-4	28761-28770	consulted	_	
157-5	28771-28774	for	_	
157-6	28775-28781	Takeda	_	
157-7	28781-28782	,	_	
157-8	28783-28791	Lundback	_	
157-9	28792-28795	and	_	
157-10	28796-28803	Hoffman	_	
157-11	28804-28806	La	_	
157-12	28807-28812	Roche	_	
157-13	28813-28816	and	_	
157-14	28817-28825	receives	_	
157-15	28826-28833	royalty	_	
157-16	28834-28842	payments	_	
157-17	28843-28847	from	_	
157-18	28848-28851	the	_	
157-19	28852-28858	Banker	_	
157-20	28858-28859	’	_	
157-21	28859-28860	s	_	
157-22	28861-28870	Automated	_	
157-23	28871-28879	Clearing	_	
157-24	28880-28888	Services	_	
157-25	28888-28889	.	_	

#Text=Robert W.
158-1	28890-28896	Robert	_	
158-2	28897-28898	W	_	
158-3	28898-28899	.	_	

#Text=Buchanan served on the advisory board of Astellas Pharma; Avanir; Boehringer Ingelheim-RCV; ITI, Inc.; Lundbeck; Roche; and Takeda.
159-1	28900-28908	Buchanan	_	
159-2	28909-28915	served	_	
159-3	28916-28918	on	_	
159-4	28919-28922	the	_	
159-5	28923-28931	advisory	_	
159-6	28932-28937	board	_	
159-7	28938-28940	of	_	
159-8	28941-28949	Astellas	_	
159-9	28950-28956	Pharma	_	
159-10	28956-28957	;	_	
159-11	28958-28964	Avanir	_	
159-12	28964-28965	;	_	
159-13	28966-28976	Boehringer	_	
159-14	28977-28990	Ingelheim-RCV	_	
159-15	28990-28991	;	_	
159-16	28992-28995	ITI	_	
159-17	28995-28996	,	_	
159-18	28997-29000	Inc	_	
159-19	29000-29001	.	_	
159-20	29001-29002	;	_	
159-21	29003-29011	Lundbeck	_	
159-22	29011-29012	;	_	
159-23	29013-29018	Roche	_	
159-24	29018-29019	;	_	
159-25	29020-29023	and	_	
159-26	29024-29030	Takeda	_	
159-27	29030-29031	.	_	

#Text=He has consulted for Takeda; Upsher-Smith Laboratories, Inc., and served on the Data Safety Monitoring Board of Pfizer.
160-1	29032-29034	He	_	
160-2	29035-29038	has	_	
160-3	29039-29048	consulted	_	
160-4	29049-29052	for	_	
160-5	29053-29059	Takeda	_	
160-6	29059-29060	;	_	
160-7	29061-29073	Upsher-Smith	_	
160-8	29074-29086	Laboratories	_	
160-9	29086-29087	,	_	
160-10	29088-29091	Inc	_	
160-11	29091-29092	.	_	
160-12	29092-29093	,	_	
160-13	29094-29097	and	_	
160-14	29098-29104	served	_	
160-15	29105-29107	on	_	
160-16	29108-29111	the	_	
160-17	29112-29116	Data	_	
160-18	29117-29123	Safety	_	
160-19	29124-29134	Monitoring	_	
160-20	29135-29140	Board	_	
160-21	29141-29143	of	_	
160-22	29144-29150	Pfizer	_	
160-23	29150-29151	.	_	

#Text=George Foussias has served on advisory boards for Hoffman-La Roche and Takeda, and received speaker’s fees from Hoffman-La Roche, Lundbeck, and Novartis.
161-1	29152-29158	George	_	
161-2	29159-29167	Foussias	_	
161-3	29168-29171	has	_	
161-4	29172-29178	served	_	
161-5	29179-29181	on	_	
161-6	29182-29190	advisory	_	
161-7	29191-29197	boards	_	
161-8	29198-29201	for	_	
161-9	29202-29212	Hoffman-La	_	
161-10	29213-29218	Roche	_	
161-11	29219-29222	and	_	
161-12	29223-29229	Takeda	_	
161-13	29229-29230	,	_	
161-14	29231-29234	and	_	
161-15	29235-29243	received	_	
161-16	29244-29251	speaker	_	
161-17	29251-29252	’	_	
161-18	29252-29253	s	_	
161-19	29254-29258	fees	_	
161-20	29259-29263	from	_	
161-21	29264-29274	Hoffman-La	_	
161-22	29275-29280	Roche	_	
161-23	29280-29281	,	_	
161-24	29282-29290	Lundbeck	_	
161-25	29290-29291	,	_	
161-26	29292-29295	and	_	
161-27	29296-29304	Novartis	_	
161-28	29304-29305	.	_	

#Text=All other authors report no biomedical financial interests or potential conflicts of interest.
162-1	29306-29309	All	_	
162-2	29310-29315	other	_	
162-3	29316-29323	authors	_	
162-4	29324-29330	report	_	
162-5	29331-29333	no	_	
162-6	29334-29344	biomedical	_	
162-7	29345-29354	financial	_	
162-8	29355-29364	interests	_	
162-9	29365-29367	or	_	
162-10	29368-29377	potential	_	
162-11	29378-29387	conflicts	_	
162-12	29388-29390	of	_	
162-13	29391-29399	interest	_	
162-14	29399-29400	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
163-1	29401-29405	This	_	
163-2	29406-29408	is	_	
163-3	29409-29410	a	_	
163-4	29411-29414	PDF	_	
163-5	29415-29419	file	_	
163-6	29420-29422	of	_	
163-7	29423-29425	an	_	
163-8	29426-29434	unedited	_	
163-9	29435-29445	manuscript	_	
163-10	29446-29450	that	_	
163-11	29451-29454	has	_	
163-12	29455-29459	been	_	
163-13	29460-29468	accepted	_	
163-14	29469-29472	for	_	
163-15	29473-29484	publication	_	
163-16	29484-29485	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
164-1	29486-29488	As	_	
164-2	29489-29490	a	_	
164-3	29491-29498	service	_	
164-4	29499-29501	to	_	
164-5	29502-29505	our	_	
164-6	29506-29515	customers	_	
164-7	29516-29518	we	_	
164-8	29519-29522	are	_	
164-9	29523-29532	providing	_	
164-10	29533-29537	this	_	
164-11	29538-29543	early	_	
164-12	29544-29551	version	_	
164-13	29552-29554	of	_	
164-14	29555-29558	the	_	
164-15	29559-29569	manuscript	_	
164-16	29569-29570	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
165-1	29571-29574	The	_	
165-2	29575-29585	manuscript	_	
165-3	29586-29590	will	_	
165-4	29591-29598	undergo	_	
165-5	29599-29610	copyediting	_	
165-6	29610-29611	,	_	
165-7	29612-29623	typesetting	_	
165-8	29623-29624	,	_	
165-9	29625-29628	and	_	
165-10	29629-29635	review	_	
165-11	29636-29638	of	_	
165-12	29639-29642	the	_	
165-13	29643-29652	resulting	_	
165-14	29653-29658	proof	_	
165-15	29659-29665	before	_	
165-16	29666-29668	it	_	
165-17	29669-29671	is	_	
165-18	29672-29681	published	_	
165-19	29682-29684	in	_	
165-20	29685-29688	its	_	
165-21	29689-29694	final	_	
165-22	29695-29702	citable	_	
165-23	29703-29707	form	_	
165-24	29707-29708	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
166-1	29709-29715	Please	_	
166-2	29716-29720	note	_	
166-3	29721-29725	that	_	
166-4	29726-29732	during	_	
166-5	29733-29736	the	_	
166-6	29737-29747	production	_	
166-7	29748-29755	process	_	
166-8	29756-29762	errors	_	
166-9	29763-29766	may	_	
166-10	29767-29769	be	_	
166-11	29770-29780	discovered	_	
166-12	29781-29786	which	_	
166-13	29787-29792	could	_	
166-14	29793-29799	affect	_	
166-15	29800-29803	the	_	
166-16	29804-29811	content	_	
166-17	29811-29812	,	_	
166-18	29813-29816	and	_	
166-19	29817-29820	all	_	
166-20	29821-29826	legal	_	
166-21	29827-29838	disclaimers	_	
166-22	29839-29843	that	_	
166-23	29844-29849	apply	_	
166-24	29850-29852	to	_	
166-25	29853-29856	the	_	
166-26	29857-29864	journal	_	
166-27	29865-29872	pertain	_	
166-28	29872-29873	.	_	

#Text=Cognitive, clinical, and functional characteristics of verbally superior schizophrenia patients
#Text=Community outcome in cognitively normal schizophrenia patients
#Text=Regular review: molecular pathology of schizophrenia: more than one disease process?
167-1	29874-29883	Cognitive	_	
167-2	29883-29884	,	_	
167-3	29885-29893	clinical	_	
167-4	29893-29894	,	_	
167-5	29895-29898	and	_	
167-6	29899-29909	functional	_	
167-7	29910-29925	characteristics	_	
167-8	29926-29928	of	_	
167-9	29929-29937	verbally	_	
167-10	29938-29946	superior	_	
167-11	29947-29960	schizophrenia	_	
167-12	29961-29969	patients	_	
167-13	29970-29979	Community	_	
167-14	29980-29987	outcome	_	
167-15	29988-29990	in	_	
167-16	29991-30002	cognitively	_	
167-17	30003-30009	normal	_	
167-18	30010-30023	schizophrenia	_	
167-19	30024-30032	patients	_	
167-20	30033-30040	Regular	_	
167-21	30041-30047	review	_	
167-22	30047-30048	:	_	
167-23	30049-30058	molecular	_	
167-24	30059-30068	pathology	_	
167-25	30069-30071	of	_	
167-26	30072-30085	schizophrenia	_	
167-27	30085-30086	:	_	
167-28	30087-30091	more	_	
167-29	30092-30096	than	_	
167-30	30097-30100	one	_	
167-31	30101-30108	disease	_	
167-32	30109-30116	process	_	
167-33	30116-30117	?	_	

#Text=Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: A diffusion tensor imaging survey
#Text=Structural abnormalities in deficit and nondeficit schizophrenia
#Text=White Matter Alterations in Deficit Schizophrenia
#Text=Neuroimaging evidence for the deficit subtype of schizophrenia
#Text=Cortical structural abnormalities in deficit versus nondeficit schizophrenia
#Text=Further neuroimaging evidence for the deficit subtype of schizophrenia: A cortical connectomics analysis
#Text=Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia
#Text=Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms
#Text=Empirical validation of primary negative symptoms: independence from effects of medication and psychosis
#Text=Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models
#Text=Factor structure and construct validity of the scale for the assessment of negative symptoms
#Text=The prediction of outcome in schizophrenia: II.
168-1	30118-30126	Internal	_	
168-2	30127-30134	capsule	_	
168-3	30134-30135	,	_	
168-4	30136-30142	corpus	_	
168-5	30143-30151	callosum	_	
168-6	30152-30155	and	_	
168-7	30156-30160	long	_	
168-8	30161-30172	associative	_	
168-9	30173-30179	fibers	_	
168-10	30180-30182	in	_	
168-11	30183-30187	good	_	
168-12	30188-30191	and	_	
168-13	30192-30196	poor	_	
168-14	30197-30204	outcome	_	
168-15	30205-30218	schizophrenia	_	
168-16	30218-30219	:	_	
168-17	30220-30221	A	_	
168-18	30222-30231	diffusion	_	
168-19	30232-30238	tensor	_	
168-20	30239-30246	imaging	_	
168-21	30247-30253	survey	_	
168-22	30254-30264	Structural	_	
168-23	30265-30278	abnormalities	_	
168-24	30279-30281	in	_	
168-25	30282-30289	deficit	_	
168-26	30290-30293	and	_	
168-27	30294-30304	nondeficit	_	
168-28	30305-30318	schizophrenia	_	
168-29	30319-30324	White	_	
168-30	30325-30331	Matter	_	
168-31	30332-30343	Alterations	_	
168-32	30344-30346	in	_	
168-33	30347-30354	Deficit	_	
168-34	30355-30368	Schizophrenia	_	
168-35	30369-30381	Neuroimaging	_	
168-36	30382-30390	evidence	_	
168-37	30391-30394	for	_	
168-38	30395-30398	the	_	
168-39	30399-30406	deficit	_	
168-40	30407-30414	subtype	_	
168-41	30415-30417	of	_	
168-42	30418-30431	schizophrenia	_	
168-43	30432-30440	Cortical	_	
168-44	30441-30451	structural	_	
168-45	30452-30465	abnormalities	_	
168-46	30466-30468	in	_	
168-47	30469-30476	deficit	_	
168-48	30477-30483	versus	_	
168-49	30484-30494	nondeficit	_	
168-50	30495-30508	schizophrenia	_	
168-51	30509-30516	Further	_	
168-52	30517-30529	neuroimaging	_	
168-53	30530-30538	evidence	_	
168-54	30539-30542	for	_	
168-55	30543-30546	the	_	
168-56	30547-30554	deficit	_	
168-57	30555-30562	subtype	_	
168-58	30563-30565	of	_	
168-59	30566-30579	schizophrenia	_	
168-60	30579-30580	:	_	
168-61	30581-30582	A	_	
168-62	30583-30591	cortical	_	
168-63	30592-30604	connectomics	_	
168-64	30605-30613	analysis	_	
168-65	30614-30632	Neuropsychological	_	
168-66	30633-30644	impairments	_	
168-67	30645-30647	in	_	
168-68	30648-30655	deficit	_	
168-69	30656-30658	vs	_	
168-70	30659-30669	nondeficit	_	
168-71	30670-30675	forms	_	
168-72	30676-30678	of	_	
168-73	30679-30692	schizophrenia	_	
168-74	30693-30702	Empirical	_	
168-75	30703-30713	assessment	_	
168-76	30714-30716	of	_	
168-77	30717-30720	the	_	
168-78	30721-30730	factorial	_	
168-79	30731-30740	structure	_	
168-80	30741-30743	of	_	
168-81	30744-30752	clinical	_	
168-82	30753-30761	symptoms	_	
168-83	30762-30764	in	_	
168-84	30765-30778	schizophrenia	_	
168-85	30778-30779	:	_	
168-86	30780-30788	Negative	_	
168-87	30789-30797	symptoms	_	
168-88	30798-30807	Empirical	_	
168-89	30808-30818	validation	_	
168-90	30819-30821	of	_	
168-91	30822-30829	primary	_	
168-92	30830-30838	negative	_	
168-93	30839-30847	symptoms	_	
168-94	30847-30848	:	_	
168-95	30849-30861	independence	_	
168-96	30862-30866	from	_	
168-97	30867-30874	effects	_	
168-98	30875-30877	of	_	
168-99	30878-30888	medication	_	
168-100	30889-30892	and	_	
168-101	30893-30902	psychosis	_	
168-102	30903-30911	Negative	_	
168-103	30912-30920	symptoms	_	
168-104	30921-30923	in	_	
168-105	30924-30937	schizophrenia	_	
168-106	30937-30938	:	_	
168-107	30939-30940	a	_	
168-108	30941-30953	confirmatory	_	
168-109	30954-30960	factor	_	
168-110	30961-30969	analysis	_	
168-111	30970-30972	of	_	
168-112	30973-30982	competing	_	
168-113	30983-30989	models	_	
168-114	30990-30996	Factor	_	
168-115	30997-31006	structure	_	
168-116	31007-31010	and	_	
168-117	31011-31020	construct	_	
168-118	31021-31029	validity	_	
168-119	31030-31032	of	_	
168-120	31033-31036	the	_	
168-121	31037-31042	scale	_	
168-122	31043-31046	for	_	
168-123	31047-31050	the	_	
168-124	31051-31061	assessment	_	
168-125	31062-31064	of	_	
168-126	31065-31073	negative	_	
168-127	31074-31082	symptoms	_	
168-128	31083-31086	The	_	
168-129	31087-31097	prediction	_	
168-130	31098-31100	of	_	
168-131	31101-31108	outcome	_	
168-132	31109-31111	in	_	
168-133	31112-31125	schizophrenia	_	
168-134	31125-31126	:	_	
168-135	31127-31129	II	_	
168-136	31129-31130	.	_	

#Text=Relationships between predictor and outcome variables: A report from the WHO International Pilot Study of Schizophrenia
#Text=Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome
#Text=The RDoC controversy: alternate paradigm or dominant paradigm?
169-1	31131-31144	Relationships	_	
169-2	31145-31152	between	_	
169-3	31153-31162	predictor	_	
169-4	31163-31166	and	_	
169-5	31167-31174	outcome	_	
169-6	31175-31184	variables	_	
169-7	31184-31185	:	_	
169-8	31186-31187	A	_	
169-9	31188-31194	report	_	
169-10	31195-31199	from	_	
169-11	31200-31203	the	_	
169-12	31204-31207	WHO	_	
169-13	31208-31221	International	_	
169-14	31222-31227	Pilot	_	
169-15	31228-31233	Study	_	
169-16	31234-31236	of	_	
169-17	31237-31250	Schizophrenia	_	
169-18	31251-31265	Deconstructing	_	
169-19	31266-31274	negative	_	
169-20	31275-31283	symptoms	_	
169-21	31284-31286	of	_	
169-22	31287-31300	schizophrenia	_	
169-23	31300-31301	:	_	
169-24	31302-31318	Avolition–apathy	_	
169-25	31319-31322	and	_	
169-26	31323-31333	diminished	_	
169-27	31334-31344	expression	_	
169-28	31345-31353	clusters	_	
169-29	31354-31361	predict	_	
169-30	31362-31370	clinical	_	
169-31	31371-31383	presentation	_	
169-32	31384-31387	and	_	
169-33	31388-31398	functional	_	
169-34	31399-31406	outcome	_	
169-35	31407-31410	The	_	
169-36	31411-31415	RDoC	_	
169-37	31416-31427	controversy	_	
169-38	31427-31428	:	_	
169-39	31429-31438	alternate	_	
169-40	31439-31447	paradigm	_	
169-41	31448-31450	or	_	
169-42	31451-31459	dominant	_	
169-43	31460-31468	paradigm	_	
169-44	31468-31469	?	_	

#Text=Identification of distinct psychosis biotypes using brain-based biomarkers
#Text=Resting-state connectivity biomarkers define neurophysiological subtypes of depression
#Text=Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study
#Text=Biosocial pathways to functional outcome in schizophrenia
#Text=The heterogeneity of the long-term course of schizophrenia
#Text=An examination of social cognition, neurocognition, and symptoms as predictors of social functioning in schizophrenia
#Text=The functional significance of social cognition in schizophrenia: a review
#Text=Social cognitive impairments and psychotic symptoms: what is the nature of their association?
170-1	31470-31484	Identification	_	
170-2	31485-31487	of	_	
170-3	31488-31496	distinct	_	
170-4	31497-31506	psychosis	_	
170-5	31507-31515	biotypes	_	
170-6	31516-31521	using	_	
170-7	31522-31533	brain-based	_	
170-8	31534-31544	biomarkers	_	
170-9	31545-31558	Resting-state	_	
170-10	31559-31571	connectivity	_	
170-11	31572-31582	biomarkers	_	
170-12	31583-31589	define	_	
170-13	31590-31608	neurophysiological	_	
170-14	31609-31617	subtypes	_	
170-15	31618-31620	of	_	
170-16	31621-31631	depression	_	
170-17	31632-31650	Neuropsychological	_	
170-18	31651-31662	impairments	_	
170-19	31663-31665	in	_	
170-20	31666-31679	schizophrenia	_	
170-21	31680-31683	and	_	
170-22	31684-31693	psychotic	_	
170-23	31694-31701	bipolar	_	
170-24	31702-31710	disorder	_	
170-25	31710-31711	:	_	
170-26	31712-31720	findings	_	
170-27	31721-31725	from	_	
170-28	31726-31729	the	_	
170-29	31730-31751	Bipolar-Schizophrenia	_	
170-30	31752-31759	Network	_	
170-31	31760-31762	on	_	
170-32	31763-31775	Intermediate	_	
170-33	31776-31786	Phenotypes	_	
170-34	31787-31788	(	_	
170-35	31788-31794	B-SNIP	_	
170-36	31794-31795	)	_	
170-37	31796-31801	study	_	
170-38	31802-31811	Biosocial	_	
170-39	31812-31820	pathways	_	
170-40	31821-31823	to	_	
170-41	31824-31834	functional	_	
170-42	31835-31842	outcome	_	
170-43	31843-31845	in	_	
170-44	31846-31859	schizophrenia	_	
170-45	31860-31863	The	_	
170-46	31864-31877	heterogeneity	_	
170-47	31878-31880	of	_	
170-48	31881-31884	the	_	
170-49	31885-31894	long-term	_	
170-50	31895-31901	course	_	
170-51	31902-31904	of	_	
170-52	31905-31918	schizophrenia	_	
170-53	31919-31921	An	_	
170-54	31922-31933	examination	_	
170-55	31934-31936	of	_	
170-56	31937-31943	social	_	
170-57	31944-31953	cognition	_	
170-58	31953-31954	,	_	
170-59	31955-31969	neurocognition	_	
170-60	31969-31970	,	_	
170-61	31971-31974	and	_	
170-62	31975-31983	symptoms	_	
170-63	31984-31986	as	_	
170-64	31987-31997	predictors	_	
170-65	31998-32000	of	_	
170-66	32001-32007	social	_	
170-67	32008-32019	functioning	_	
170-68	32020-32022	in	_	
170-69	32023-32036	schizophrenia	_	
170-70	32037-32040	The	_	
170-71	32041-32051	functional	_	
170-72	32052-32064	significance	_	
170-73	32065-32067	of	_	
170-74	32068-32074	social	_	
170-75	32075-32084	cognition	_	
170-76	32085-32087	in	_	
170-77	32088-32101	schizophrenia	_	
170-78	32101-32102	:	_	
170-79	32103-32104	a	_	
170-80	32105-32111	review	_	
170-81	32112-32118	Social	_	
170-82	32119-32128	cognitive	_	
170-83	32129-32140	impairments	_	
170-84	32141-32144	and	_	
170-85	32145-32154	psychotic	_	
170-86	32155-32163	symptoms	_	
170-87	32163-32164	:	_	
170-88	32165-32169	what	_	
170-89	32170-32172	is	_	
170-90	32173-32176	the	_	
170-91	32177-32183	nature	_	
170-92	32184-32186	of	_	
170-93	32187-32192	their	_	
170-94	32193-32204	association	_	
170-95	32204-32205	?	_	

#Text=Social functioning in first-and multiepisode schizophrenia
#Text=Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference
#Text=Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities
#Text=Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients
#Text=Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence
#Text=The mirror neuron system and the consequences of its dysfunction
#Text=Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders
#Text=Functional resting-state networks are differentially affected in schizophrenia
#Text=Theory of mind in schizophrenia: Exploring neural mechanisms of belief attribution
#Text=An anterior-to-posterior shift in midline cortical activity in schizophrenia during self-reflection
#Text=Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach
#Text=Aberrant “default mode” functional connectivity in schizophrenia
#Text=Altered functional and anatomical connectivity in schizophrenia
#Text=Lateral differences in the default mode network in healthy controls and patients with schizophrenia
#Text=Facial emotion recognition in schizophrenia: intensity effects and error pattern
#Text=The “Reading the Mind in the Eyes” test revised version: A study with normal adults, and adults with Asperger syndrome or high-functioning autism
#Text=Development of a measure of relationship perception in schizophrenia
#Text=TASIT: A new clinical tool for assessing social perception after traumatic brain injury
#Text=The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity
#Text=The social functioning scale.
171-1	32206-32212	Social	_	
171-2	32213-32224	functioning	_	
171-3	32225-32227	in	_	
171-4	32228-32237	first-and	_	
171-5	32238-32250	multiepisode	_	
171-6	32251-32264	schizophrenia	_	
171-7	32265-32271	Social	_	
171-8	32272-32281	cognition	_	
171-9	32282-32284	in	_	
171-10	32285-32298	schizophrenia	_	
171-11	32298-32299	:	_	
171-12	32300-32315	recommendations	_	
171-13	32316-32320	from	_	
171-14	32321-32324	the	_	
171-15	32325-32336	measurement	_	
171-16	32337-32340	and	_	
171-17	32341-32350	treatment	_	
171-18	32351-32359	research	_	
171-19	32360-32362	to	_	
171-20	32363-32370	improve	_	
171-21	32371-32380	cognition	_	
171-22	32381-32383	in	_	
171-23	32384-32397	schizophrenia	_	
171-24	32398-32401	new	_	
171-25	32402-32412	approaches	_	
171-26	32413-32423	conference	_	
171-27	32424-32430	Social	_	
171-28	32431-32440	cognition	_	
171-29	32441-32443	in	_	
171-30	32444-32457	schizophrenia	_	
171-31	32457-32458	:	_	
171-32	32459-32461	an	_	
171-33	32462-32466	NIMH	_	
171-34	32467-32475	workshop	_	
171-35	32476-32478	on	_	
171-36	32479-32490	definitions	_	
171-37	32490-32491	,	_	
171-38	32492-32502	assessment	_	
171-39	32502-32503	,	_	
171-40	32504-32507	and	_	
171-41	32508-32516	research	_	
171-42	32517-32530	opportunities	_	
171-43	32531-32537	Social	_	
171-44	32538-32547	cognition	_	
171-45	32548-32550	in	_	
171-46	32551-32564	schizophrenia	_	
171-47	32564-32565	,	_	
171-48	32566-32570	Part	_	
171-49	32571-32572	2	_	
171-50	32572-32573	:	_	
171-51	32574-32576	12	_	
171-52	32576-32577	-	_	
171-53	32577-32582	month	_	
171-54	32583-32592	stability	_	
171-55	32593-32596	and	_	
171-56	32597-32607	prediction	_	
171-57	32608-32610	of	_	
171-58	32611-32621	functional	_	
171-59	32622-32629	outcome	_	
171-60	32630-32632	in	_	
171-61	32633-32646	first-episode	_	
171-62	32647-32655	patients	_	
171-63	32656-32664	Deficits	_	
171-64	32665-32667	in	_	
171-65	32668-32675	domains	_	
171-66	32676-32678	of	_	
171-67	32679-32685	social	_	
171-68	32686-32695	cognition	_	
171-69	32696-32698	in	_	
171-70	32699-32712	schizophrenia	_	
171-71	32712-32713	:	_	
171-72	32714-32715	a	_	
171-73	32716-32729	meta-analysis	_	
171-74	32730-32732	of	_	
171-75	32733-32736	the	_	
171-76	32737-32746	empirical	_	
171-77	32747-32755	evidence	_	
171-78	32756-32759	The	_	
171-79	32760-32766	mirror	_	
171-80	32767-32773	neuron	_	
171-81	32774-32780	system	_	
171-82	32781-32784	and	_	
171-83	32785-32788	the	_	
171-84	32789-32801	consequences	_	
171-85	32802-32804	of	_	
171-86	32805-32808	its	_	
171-87	32809-32820	dysfunction	_	
171-88	32821-32827	Neural	_	
171-89	32828-32833	bases	_	
171-90	32834-32837	for	_	
171-91	32838-32846	impaired	_	
171-92	32847-32853	social	_	
171-93	32854-32863	cognition	_	
171-94	32864-32866	in	_	
171-95	32867-32880	schizophrenia	_	
171-96	32881-32884	and	_	
171-97	32885-32891	autism	_	
171-98	32892-32900	spectrum	_	
171-99	32901-32910	disorders	_	
171-100	32911-32921	Functional	_	
171-101	32922-32935	resting-state	_	
171-102	32936-32944	networks	_	
171-103	32945-32948	are	_	
171-104	32949-32963	differentially	_	
171-105	32964-32972	affected	_	
171-106	32973-32975	in	_	
171-107	32976-32989	schizophrenia	_	
171-108	32990-32996	Theory	_	
171-109	32997-32999	of	_	
171-110	33000-33004	mind	_	
171-111	33005-33007	in	_	
171-112	33008-33021	schizophrenia	_	
171-113	33021-33022	:	_	
171-114	33023-33032	Exploring	_	
171-115	33033-33039	neural	_	
171-116	33040-33050	mechanisms	_	
171-117	33051-33053	of	_	
171-118	33054-33060	belief	_	
171-119	33061-33072	attribution	_	
171-120	33073-33075	An	_	
171-121	33076-33097	anterior-to-posterior	_	
171-122	33098-33103	shift	_	
171-123	33104-33106	in	_	
171-124	33107-33114	midline	_	
171-125	33115-33123	cortical	_	
171-126	33124-33132	activity	_	
171-127	33133-33135	in	_	
171-128	33136-33149	schizophrenia	_	
171-129	33150-33156	during	_	
171-130	33157-33172	self-reflection	_	
171-131	33173-33178	Brain	_	
171-132	33179-33191	connectivity	_	
171-133	33192-33194	is	_	
171-134	33195-33198	not	_	
171-135	33199-33203	only	_	
171-136	33204-33209	lower	_	
171-137	33210-33213	but	_	
171-138	33214-33223	different	_	
171-139	33224-33226	in	_	
171-140	33227-33240	schizophrenia	_	
171-141	33240-33241	:	_	
171-142	33242-33243	a	_	
171-143	33244-33252	combined	_	
171-144	33253-33263	anatomical	_	
171-145	33264-33267	and	_	
171-146	33268-33278	functional	_	
171-147	33279-33287	approach	_	
171-148	33288-33296	Aberrant	_	
171-149	33297-33298	“	_	
171-150	33298-33305	default	_	
171-151	33306-33310	mode	_	
171-152	33310-33311	”	_	
171-153	33312-33322	functional	_	
171-154	33323-33335	connectivity	_	
171-155	33336-33338	in	_	
171-156	33339-33352	schizophrenia	_	
171-157	33353-33360	Altered	_	
171-158	33361-33371	functional	_	
171-159	33372-33375	and	_	
171-160	33376-33386	anatomical	_	
171-161	33387-33399	connectivity	_	
171-162	33400-33402	in	_	
171-163	33403-33416	schizophrenia	_	
171-164	33417-33424	Lateral	_	
171-165	33425-33436	differences	_	
171-166	33437-33439	in	_	
171-167	33440-33443	the	_	
171-168	33444-33451	default	_	
171-169	33452-33456	mode	_	
171-170	33457-33464	network	_	
171-171	33465-33467	in	_	
171-172	33468-33475	healthy	_	
171-173	33476-33484	controls	_	
171-174	33485-33488	and	_	
171-175	33489-33497	patients	_	
171-176	33498-33502	with	_	
171-177	33503-33516	schizophrenia	_	
171-178	33517-33523	Facial	_	
171-179	33524-33531	emotion	_	
171-180	33532-33543	recognition	_	
171-181	33544-33546	in	_	
171-182	33547-33560	schizophrenia	_	
171-183	33560-33561	:	_	
171-184	33562-33571	intensity	_	
171-185	33572-33579	effects	_	
171-186	33580-33583	and	_	
171-187	33584-33589	error	_	
171-188	33590-33597	pattern	_	
171-189	33598-33601	The	_	
171-190	33602-33603	“	_	
171-191	33603-33610	Reading	_	
171-192	33611-33614	the	_	
171-193	33615-33619	Mind	_	
171-194	33620-33622	in	_	
171-195	33623-33626	the	_	
171-196	33627-33631	Eyes	_	
171-197	33631-33632	”	_	
171-198	33633-33637	test	_	
171-199	33638-33645	revised	_	
171-200	33646-33653	version	_	
171-201	33653-33654	:	_	
171-202	33655-33656	A	_	
171-203	33657-33662	study	_	
171-204	33663-33667	with	_	
171-205	33668-33674	normal	_	
171-206	33675-33681	adults	_	
171-207	33681-33682	,	_	
171-208	33683-33686	and	_	
171-209	33687-33693	adults	_	
171-210	33694-33698	with	_	
171-211	33699-33707	Asperger	_	
171-212	33708-33716	syndrome	_	
171-213	33717-33719	or	_	
171-214	33720-33736	high-functioning	_	
171-215	33737-33743	autism	_	
171-216	33744-33755	Development	_	
171-217	33756-33758	of	_	
171-218	33759-33760	a	_	
171-219	33761-33768	measure	_	
171-220	33769-33771	of	_	
171-221	33772-33784	relationship	_	
171-222	33785-33795	perception	_	
171-223	33796-33798	in	_	
171-224	33799-33812	schizophrenia	_	
171-225	33813-33818	TASIT	_	
171-226	33818-33819	:	_	
171-227	33820-33821	A	_	
171-228	33822-33825	new	_	
171-229	33826-33834	clinical	_	
171-230	33835-33839	tool	_	
171-231	33840-33843	for	_	
171-232	33844-33853	assessing	_	
171-233	33854-33860	social	_	
171-234	33861-33871	perception	_	
171-235	33872-33877	after	_	
171-236	33878-33887	traumatic	_	
171-237	33888-33893	brain	_	
171-238	33894-33900	injury	_	
171-239	33901-33904	The	_	
171-240	33905-33912	MATRICS	_	
171-241	33913-33922	consensus	_	
171-242	33923-33932	cognitive	_	
171-243	33933-33940	battery	_	
171-244	33940-33941	,	_	
171-245	33942-33946	part	_	
171-246	33947-33948	1	_	
171-247	33948-33949	:	_	
171-248	33950-33954	test	_	
171-249	33955-33964	selection	_	
171-250	33964-33965	,	_	
171-251	33966-33977	reliability	_	
171-252	33977-33978	,	_	
171-253	33979-33982	and	_	
171-254	33983-33991	validity	_	
171-255	33992-33995	The	_	
171-256	33996-34002	social	_	
171-257	34003-34014	functioning	_	
171-258	34015-34020	scale	_	
171-259	34020-34021	.	_	

#Text=The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients
#Text=The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome
#Text=The brief psychiatric rating scale
#Text=Scale for the assessment of negative symptoms (SANS)
#Text=The structure of negative symptoms within schizophrenia: implications for assessment
#Text=A rating scale for extrapyramidal side effects
#Text=Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale
#Text=Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
#Text=Guidelines for the dosage of neuroleptics.
172-1	34022-34025	The	_	
172-2	34026-34037	development	_	
172-3	34038-34041	and	_	
172-4	34042-34052	validation	_	
172-5	34053-34055	of	_	
172-6	34056-34057	a	_	
172-7	34058-34061	new	_	
172-8	34062-34067	scale	_	
172-9	34068-34070	of	_	
172-10	34071-34077	social	_	
172-11	34078-34088	adjustment	_	
172-12	34089-34092	for	_	
172-13	34093-34096	use	_	
172-14	34097-34099	in	_	
172-15	34100-34106	family	_	
172-16	34107-34119	intervention	_	
172-17	34120-34130	programmes	_	
172-18	34131-34135	with	_	
172-19	34136-34149	schizophrenic	_	
172-20	34150-34158	patients	_	
172-21	34159-34162	The	_	
172-22	34163-34170	Quality	_	
172-23	34171-34173	of	_	
172-24	34174-34178	Life	_	
172-25	34179-34184	Scale	_	
172-26	34184-34185	:	_	
172-27	34186-34188	an	_	
172-28	34189-34199	instrument	_	
172-29	34200-34203	for	_	
172-30	34204-34210	rating	_	
172-31	34211-34214	the	_	
172-32	34215-34228	schizophrenic	_	
172-33	34229-34236	deficit	_	
172-34	34237-34245	syndrome	_	
172-35	34246-34249	The	_	
172-36	34250-34255	brief	_	
172-37	34256-34267	psychiatric	_	
172-38	34268-34274	rating	_	
172-39	34275-34280	scale	_	
172-40	34281-34286	Scale	_	
172-41	34287-34290	for	_	
172-42	34291-34294	the	_	
172-43	34295-34305	assessment	_	
172-44	34306-34308	of	_	
172-45	34309-34317	negative	_	
172-46	34318-34326	symptoms	_	
172-47	34327-34328	(	_	
172-48	34328-34332	SANS	_	
172-49	34332-34333	)	_	
172-50	34334-34337	The	_	
172-51	34338-34347	structure	_	
172-52	34348-34350	of	_	
172-53	34351-34359	negative	_	
172-54	34360-34368	symptoms	_	
172-55	34369-34375	within	_	
172-56	34376-34389	schizophrenia	_	
172-57	34389-34390	:	_	
172-58	34391-34403	implications	_	
172-59	34404-34407	for	_	
172-60	34408-34418	assessment	_	
172-61	34419-34420	A	_	
172-62	34421-34427	rating	_	
172-63	34428-34433	scale	_	
172-64	34434-34437	for	_	
172-65	34438-34452	extrapyramidal	_	
172-66	34453-34457	side	_	
172-67	34458-34465	effects	_	
172-68	34466-34472	Rating	_	
172-69	34473-34480	chronic	_	
172-70	34481-34488	medical	_	
172-71	34489-34496	illness	_	
172-72	34497-34503	burden	_	
172-73	34504-34506	in	_	
172-74	34507-34522	geropsychiatric	_	
172-75	34523-34531	practice	_	
172-76	34532-34535	and	_	
172-77	34536-34544	research	_	
172-78	34544-34545	:	_	
172-79	34546-34557	application	_	
172-80	34558-34560	of	_	
172-81	34561-34564	the	_	
172-82	34565-34575	Cumulative	_	
172-83	34576-34583	Illness	_	
172-84	34584-34590	Rating	_	
172-85	34591-34596	Scale	_	
172-86	34597-34608	Translating	_	
172-87	34609-34617	research	_	
172-88	34618-34622	into	_	
172-89	34623-34631	practice	_	
172-90	34631-34632	:	_	
172-91	34633-34636	the	_	
172-92	34637-34650	Schizophrenia	_	
172-93	34651-34658	Patient	_	
172-94	34659-34667	Outcomes	_	
172-95	34668-34676	Research	_	
172-96	34677-34681	Team	_	
172-97	34682-34683	(	_	
172-98	34683-34687	PORT	_	
172-99	34687-34688	)	_	
172-100	34689-34698	treatment	_	
172-101	34699-34714	recommendations	_	
172-102	34715-34725	Guidelines	_	
172-103	34726-34729	for	_	
172-104	34730-34733	the	_	
172-105	34734-34740	dosage	_	
172-106	34741-34743	of	_	
172-107	34744-34756	neuroleptics	_	
172-108	34756-34757	.	_	

#Text=I: Chlorpromazine equivalents of orally administered neuroleptics
#Text=Integration of routine QA data into mega-analysis may improve quality and sensitivity of multisite diffusion tensor imaging studies
#Text=A novel DTI-QA tool: Automated metric extraction exploiting the sphericity of an agar filled phantom
#Text=Mirroring others’ emotions relates to empathy and interpersonal competence in children
#Text=The neural bases of empathic accuracy
#Text=FreeSurfer
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=FSL
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data
#Text=Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization
#Text=Controlling the false discovery rate: a practical and powerful approach to multiple testing
#Text=Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data
#Text=Understanding others’ actions and goals by mirror and mentalizing systems: a meta-analysis
#Text=A positive-negative mode of population covariation links brain connectivity, demographics and behavior
#Text=MRI study of white matter diffusion anisotropy in schizophrenia
#Text=Magnocellular Pathway Impairment in Schizophrenia: Evidence from Functional Magnetic Resonance Imaging
#Text=A Connectome Wide Functional Signature of Broad Risk for Mental Illness
#Text=Dynamic mapping of human cortical development during childhood through early adulthood
#Text=Schizophrenia risk from complex variation of complement component 4
#Text=Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex?
173-1	34758-34759	I	_	
173-2	34759-34760	:	_	
173-3	34761-34775	Chlorpromazine	_	
173-4	34776-34787	equivalents	_	
173-5	34788-34790	of	_	
173-6	34791-34797	orally	_	
173-7	34798-34810	administered	_	
173-8	34811-34823	neuroleptics	_	
173-9	34824-34835	Integration	_	
173-10	34836-34838	of	_	
173-11	34839-34846	routine	_	
173-12	34847-34849	QA	_	
173-13	34850-34854	data	_	
173-14	34855-34859	into	_	
173-15	34860-34873	mega-analysis	_	
173-16	34874-34877	may	_	
173-17	34878-34885	improve	_	
173-18	34886-34893	quality	_	
173-19	34894-34897	and	_	
173-20	34898-34909	sensitivity	_	
173-21	34910-34912	of	_	
173-22	34913-34922	multisite	_	
173-23	34923-34932	diffusion	_	
173-24	34933-34939	tensor	_	
173-25	34940-34947	imaging	_	
173-26	34948-34955	studies	_	
173-27	34956-34957	A	_	
173-28	34958-34963	novel	_	
173-29	34964-34970	DTI-QA	_	
173-30	34971-34975	tool	_	
173-31	34975-34976	:	_	
173-32	34977-34986	Automated	_	
173-33	34987-34993	metric	_	
173-34	34994-35004	extraction	_	
173-35	35005-35015	exploiting	_	
173-36	35016-35019	the	_	
173-37	35020-35030	sphericity	_	
173-38	35031-35033	of	_	
173-39	35034-35036	an	_	
173-40	35037-35041	agar	_	
173-41	35042-35048	filled	_	
173-42	35049-35056	phantom	_	
173-43	35057-35066	Mirroring	_	
173-44	35067-35073	others	_	
173-45	35073-35074	’	_	
173-46	35075-35083	emotions	_	
173-47	35084-35091	relates	_	
173-48	35092-35094	to	_	
173-49	35095-35102	empathy	_	
173-50	35103-35106	and	_	
173-51	35107-35120	interpersonal	_	
173-52	35121-35131	competence	_	
173-53	35132-35134	in	_	
173-54	35135-35143	children	_	
173-55	35144-35147	The	_	
173-56	35148-35154	neural	_	
173-57	35155-35160	bases	_	
173-58	35161-35163	of	_	
173-59	35164-35172	empathic	_	
173-60	35173-35181	accuracy	_	
173-61	35182-35192	FreeSurfer	_	
173-62	35193-35197	AFNI	_	
173-63	35197-35198	:	_	
173-64	35199-35207	software	_	
173-65	35208-35211	for	_	
173-66	35212-35220	analysis	_	
173-67	35221-35224	and	_	
173-68	35225-35238	visualization	_	
173-69	35239-35241	of	_	
173-70	35242-35252	functional	_	
173-71	35253-35261	magnetic	_	
173-72	35262-35271	resonance	_	
173-73	35272-35283	neuroimages	_	
173-74	35284-35287	FSL	_	
173-75	35288-35296	Spurious	_	
173-76	35297-35300	but	_	
173-77	35301-35311	systematic	_	
173-78	35312-35324	correlations	_	
173-79	35325-35327	in	_	
173-80	35328-35338	functional	_	
173-81	35339-35351	connectivity	_	
173-82	35352-35355	MRI	_	
173-83	35356-35364	networks	_	
173-84	35365-35370	arise	_	
173-85	35371-35375	from	_	
173-86	35376-35383	subject	_	
173-87	35384-35390	motion	_	
173-88	35391-35393	An	_	
173-89	35394-35402	improved	_	
173-90	35403-35412	framework	_	
173-91	35413-35416	for	_	
173-92	35417-35425	confound	_	
173-93	35426-35436	regression	_	
173-94	35437-35440	and	_	
173-95	35441-35450	filtering	_	
173-96	35451-35454	for	_	
173-97	35455-35462	control	_	
173-98	35463-35465	of	_	
173-99	35466-35472	motion	_	
173-100	35473-35481	artifact	_	
173-101	35482-35484	in	_	
173-102	35485-35488	the	_	
173-103	35489-35502	preprocessing	_	
173-104	35503-35505	of	_	
173-105	35506-35519	resting-state	_	
173-106	35520-35530	functional	_	
173-107	35531-35543	connectivity	_	
173-108	35544-35548	data	_	
173-109	35549-35558	Intrinsic	_	
173-110	35559-35569	functional	_	
173-111	35570-35582	connectivity	_	
173-112	35583-35585	as	_	
173-113	35586-35587	a	_	
173-114	35588-35592	tool	_	
173-115	35593-35596	for	_	
173-116	35597-35602	human	_	
173-117	35603-35615	connectomics	_	
173-118	35615-35616	:	_	
173-119	35617-35623	theory	_	
173-120	35623-35624	,	_	
173-121	35625-35635	properties	_	
173-122	35635-35636	,	_	
173-123	35637-35640	and	_	
173-124	35641-35653	optimization	_	
173-125	35654-35665	Controlling	_	
173-126	35666-35669	the	_	
173-127	35670-35675	false	_	
173-128	35676-35685	discovery	_	
173-129	35686-35690	rate	_	
173-130	35690-35691	:	_	
173-131	35692-35693	a	_	
173-132	35694-35703	practical	_	
173-133	35704-35707	and	_	
173-134	35708-35716	powerful	_	
173-135	35717-35725	approach	_	
173-136	35726-35728	to	_	
173-137	35729-35737	multiple	_	
173-138	35738-35745	testing	_	
173-139	35746-35757	Tract-based	_	
173-140	35758-35765	spatial	_	
173-141	35766-35776	statistics	_	
173-142	35776-35777	:	_	
173-143	35778-35787	Voxelwise	_	
173-144	35788-35796	analysis	_	
173-145	35797-35799	of	_	
173-146	35800-35813	multi-subject	_	
173-147	35814-35823	diffusion	_	
173-148	35824-35828	data	_	
173-149	35829-35842	Understanding	_	
173-150	35843-35849	others	_	
173-151	35849-35850	’	_	
173-152	35851-35858	actions	_	
173-153	35859-35862	and	_	
173-154	35863-35868	goals	_	
173-155	35869-35871	by	_	
173-156	35872-35878	mirror	_	
173-157	35879-35882	and	_	
173-158	35883-35894	mentalizing	_	
173-159	35895-35902	systems	_	
173-160	35902-35903	:	_	
173-161	35904-35905	a	_	
173-162	35906-35919	meta-analysis	_	
173-163	35920-35921	A	_	
173-164	35922-35939	positive-negative	_	
173-165	35940-35944	mode	_	
173-166	35945-35947	of	_	
173-167	35948-35958	population	_	
173-168	35959-35970	covariation	_	
173-169	35971-35976	links	_	
173-170	35977-35982	brain	_	
173-171	35983-35995	connectivity	_	
173-172	35995-35996	,	_	
173-173	35997-36009	demographics	_	
173-174	36010-36013	and	_	
173-175	36014-36022	behavior	_	
173-176	36023-36026	MRI	_	
173-177	36027-36032	study	_	
173-178	36033-36035	of	_	
173-179	36036-36041	white	_	
173-180	36042-36048	matter	_	
173-181	36049-36058	diffusion	_	
173-182	36059-36069	anisotropy	_	
173-183	36070-36072	in	_	
173-184	36073-36086	schizophrenia	_	
173-185	36087-36100	Magnocellular	_	
173-186	36101-36108	Pathway	_	
173-187	36109-36119	Impairment	_	
173-188	36120-36122	in	_	
173-189	36123-36136	Schizophrenia	_	
173-190	36136-36137	:	_	
173-191	36138-36146	Evidence	_	
173-192	36147-36151	from	_	
173-193	36152-36162	Functional	_	
173-194	36163-36171	Magnetic	_	
173-195	36172-36181	Resonance	_	
173-196	36182-36189	Imaging	_	
173-197	36190-36191	A	_	
173-198	36192-36202	Connectome	_	
173-199	36203-36207	Wide	_	
173-200	36208-36218	Functional	_	
173-201	36219-36228	Signature	_	
173-202	36229-36231	of	_	
173-203	36232-36237	Broad	_	
173-204	36238-36242	Risk	_	
173-205	36243-36246	for	_	
173-206	36247-36253	Mental	_	
173-207	36254-36261	Illness	_	
173-208	36262-36269	Dynamic	_	
173-209	36270-36277	mapping	_	
173-210	36278-36280	of	_	
173-211	36281-36286	human	_	
173-212	36287-36295	cortical	_	
173-213	36296-36307	development	_	
173-214	36308-36314	during	_	
173-215	36315-36324	childhood	_	
173-216	36325-36332	through	_	
173-217	36333-36338	early	_	
173-218	36339-36348	adulthood	_	
173-219	36349-36362	Schizophrenia	_	
173-220	36363-36367	risk	_	
173-221	36368-36372	from	_	
173-222	36373-36380	complex	_	
173-223	36381-36390	variation	_	
173-224	36391-36393	of	_	
173-225	36394-36404	complement	_	
173-226	36405-36414	component	_	
173-227	36415-36416	4	_	
173-228	36417-36419	Is	_	
173-229	36420-36433	schizophrenia	_	
173-230	36434-36437	due	_	
173-231	36438-36440	to	_	
173-232	36441-36450	excessive	_	
173-233	36451-36459	synaptic	_	
173-234	36460-36467	pruning	_	
173-235	36468-36470	in	_	
173-236	36471-36474	the	_	
173-237	36475-36485	prefrontal	_	
173-238	36486-36492	cortex	_	
173-239	36492-36493	?	_	

#Text=The Feinberg hypothesis revisited
#Text=Development of the adolescent brain: implications for executive function and social cognition
#Text=Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments
#Text=Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity
#Text=A longitudinal human phantom study of multi-center T1-weighted, DTI, and resting state fMRI data
#Text=Neurobiological basis of head motion in brain imaging
#Text=Cognitive scores/domains and outcome measures of biotypes based on resting state functional connectivity
#Text=All cognitive scores were Z-scored against the mean of the healthy controls.
174-1	36494-36497	The	_	
174-2	36498-36506	Feinberg	_	
174-3	36507-36517	hypothesis	_	
174-4	36518-36527	revisited	_	
174-5	36528-36539	Development	_	
174-6	36540-36542	of	_	
174-7	36543-36546	the	_	
174-8	36547-36557	adolescent	_	
174-9	36558-36563	brain	_	
174-10	36563-36564	:	_	
174-11	36565-36577	implications	_	
174-12	36578-36581	for	_	
174-13	36582-36591	executive	_	
174-14	36592-36600	function	_	
174-15	36601-36604	and	_	
174-16	36605-36611	social	_	
174-17	36612-36621	cognition	_	
174-18	36622-36632	Converging	_	
174-19	36633-36639	models	_	
174-20	36640-36642	of	_	
174-21	36643-36656	schizophrenia	_	
174-22	36657-36658	–	_	
174-23	36659-36666	Network	_	
174-24	36667-36678	alterations	_	
174-25	36679-36681	of	_	
174-26	36682-36692	prefrontal	_	
174-27	36693-36699	cortex	_	
174-28	36700-36710	underlying	_	
174-29	36711-36720	cognitive	_	
174-30	36721-36732	impairments	_	
174-31	36733-36743	Functional	_	
174-32	36744-36754	connectome	_	
174-33	36755-36769	fingerprinting	_	
174-34	36769-36770	:	_	
174-35	36771-36782	identifying	_	
174-36	36783-36794	individuals	_	
174-37	36795-36800	using	_	
174-38	36801-36809	patterns	_	
174-39	36810-36812	of	_	
174-40	36813-36818	brain	_	
174-41	36819-36831	connectivity	_	
174-42	36832-36833	A	_	
174-43	36834-36846	longitudinal	_	
174-44	36847-36852	human	_	
174-45	36853-36860	phantom	_	
174-46	36861-36866	study	_	
174-47	36867-36869	of	_	
174-48	36870-36882	multi-center	_	
174-49	36883-36885	T1	_	
174-50	36885-36886	-	_	
174-51	36886-36894	weighted	_	
174-52	36894-36895	,	_	
174-53	36896-36899	DTI	_	
174-54	36899-36900	,	_	
174-55	36901-36904	and	_	
174-56	36905-36912	resting	_	
174-57	36913-36918	state	_	
174-58	36919-36923	fMRI	_	
174-59	36924-36928	data	_	
174-60	36929-36944	Neurobiological	_	
174-61	36945-36950	basis	_	
174-62	36951-36953	of	_	
174-63	36954-36958	head	_	
174-64	36959-36965	motion	_	
174-65	36966-36968	in	_	
174-66	36969-36974	brain	_	
174-67	36975-36982	imaging	_	
174-68	36983-36992	Cognitive	_	
174-69	36993-36999	scores	_	
174-70	36999-37000	/	_	
174-71	37000-37007	domains	_	
174-72	37008-37011	and	_	
174-73	37012-37019	outcome	_	
174-74	37020-37028	measures	_	
174-75	37029-37031	of	_	
174-76	37032-37040	biotypes	_	
174-77	37041-37046	based	_	
174-78	37047-37049	on	_	
174-79	37050-37057	resting	_	
174-80	37058-37063	state	_	
174-81	37064-37074	functional	_	
174-82	37075-37087	connectivity	_	
174-83	37088-37091	All	_	
174-84	37092-37101	cognitive	_	
174-85	37102-37108	scores	_	
174-86	37109-37113	were	_	
174-87	37114-37122	Z-scored	_	
174-88	37123-37130	against	_	
174-89	37131-37134	the	_	
174-90	37135-37139	mean	_	
174-91	37140-37142	of	_	
174-92	37143-37146	the	_	
174-93	37147-37154	healthy	_	
174-94	37155-37163	controls	_	
174-95	37163-37164	.	_	

#Text=All outcome scores were only compared within the cases, and therefore Z-scored within the group. * denote significant differences after correcting for multiple comparisons with FDR (q=0.05).
175-1	37165-37168	All	_	
175-2	37169-37176	outcome	_	
175-3	37177-37183	scores	_	
175-4	37184-37188	were	_	
175-5	37189-37193	only	_	
175-6	37194-37202	compared	_	
175-7	37203-37209	within	_	
175-8	37210-37213	the	_	
175-9	37214-37219	cases	_	
175-10	37219-37220	,	_	
175-11	37221-37224	and	_	
175-12	37225-37234	therefore	_	
175-13	37235-37243	Z-scored	_	
175-14	37244-37250	within	_	
175-15	37251-37254	the	_	
175-16	37255-37260	group	_	
175-17	37260-37261	.	_	
175-18	37262-37263	*	_	
175-19	37264-37270	denote	_	
175-20	37271-37282	significant	_	
175-21	37283-37294	differences	_	
175-22	37295-37300	after	_	
175-23	37301-37311	correcting	_	
175-24	37312-37315	for	_	
175-25	37316-37324	multiple	_	
175-26	37325-37336	comparisons	_	
175-27	37337-37341	with	_	
175-28	37342-37345	FDR	_	
175-29	37346-37347	(	_	
175-30	37347-37348	q	_	
175-31	37348-37349	=	_	
175-32	37349-37353	0.05	_	
175-33	37353-37354	)	_	
175-34	37354-37355	.	_	

#Text=The poorly-performing biotype performs significantly worse on all cognitive scores and outcome measures tested.
176-1	37356-37359	The	_	
176-2	37360-37377	poorly-performing	_	
176-3	37378-37385	biotype	_	
176-4	37386-37394	performs	_	
176-5	37395-37408	significantly	_	
176-6	37409-37414	worse	_	
176-7	37415-37417	on	_	
176-8	37418-37421	all	_	
176-9	37422-37431	cognitive	_	
176-10	37432-37438	scores	_	
176-11	37439-37442	and	_	
176-12	37443-37450	outcome	_	
176-13	37451-37459	measures	_	
176-14	37460-37466	tested	_	
176-15	37466-37467	.	_	

#Text=They also have higher general health symptom burden (as assessed by the CIRS–G).
177-1	37468-37472	They	_	
177-2	37473-37477	also	_	
177-3	37478-37482	have	_	
177-4	37483-37489	higher	_	
177-5	37490-37497	general	_	
177-6	37498-37504	health	_	
177-7	37505-37512	symptom	_	
177-8	37513-37519	burden	_	
177-9	37520-37521	(	_	
177-10	37521-37523	as	_	
177-11	37524-37532	assessed	_	
177-12	37533-37535	by	_	
177-13	37536-37539	the	_	
177-14	37540-37546	CIRS–G	_	
177-15	37546-37547	)	_	
177-16	37547-37548	.	_	

#Text=Inlays for each show the probability density function of all Z- scored variables for each biotype to illustrate the overlap in cognitive scores and outcome variables between biotypes around Z=0 (vertical black line).
178-1	37549-37555	Inlays	_	
178-2	37556-37559	for	_	
178-3	37560-37564	each	_	
178-4	37565-37569	show	_	
178-5	37570-37573	the	_	
178-6	37574-37585	probability	_	
178-7	37586-37593	density	_	
178-8	37594-37602	function	_	
178-9	37603-37605	of	_	
178-10	37606-37609	all	_	
178-11	37610-37611	Z	_	
178-12	37611-37612	-	_	
178-13	37613-37619	scored	_	
178-14	37620-37629	variables	_	
178-15	37630-37633	for	_	
178-16	37634-37638	each	_	
178-17	37639-37646	biotype	_	
178-18	37647-37649	to	_	
178-19	37650-37660	illustrate	_	
178-20	37661-37664	the	_	
178-21	37665-37672	overlap	_	
178-22	37673-37675	in	_	
178-23	37676-37685	cognitive	_	
178-24	37686-37692	scores	_	
178-25	37693-37696	and	_	
178-26	37697-37704	outcome	_	
178-27	37705-37714	variables	_	
178-28	37715-37722	between	_	
178-29	37723-37731	biotypes	_	
178-30	37732-37738	around	_	
178-31	37739-37740	Z	_	
178-32	37740-37741	=	_	
178-33	37741-37742	0	_	
178-34	37743-37744	(	_	
178-35	37744-37752	vertical	_	
178-36	37753-37758	black	_	
178-37	37759-37763	line	_	
178-38	37763-37764	)	_	
178-39	37764-37765	.	_	

#Text=For this plot only, scores where higher scores indicate higher impairment were inverted for visualization purposes.
179-1	37766-37769	For	_	
179-2	37770-37774	this	_	
179-3	37775-37779	plot	_	
179-4	37780-37784	only	_	
179-5	37784-37785	,	_	
179-6	37786-37792	scores	_	
179-7	37793-37798	where	_	
179-8	37799-37805	higher	_	
179-9	37806-37812	scores	_	
179-10	37813-37821	indicate	_	
179-11	37822-37828	higher	_	
179-12	37829-37839	impairment	_	
179-13	37840-37844	were	_	
179-14	37845-37853	inverted	_	
179-15	37854-37857	for	_	
179-16	37858-37871	visualization	_	
179-17	37872-37880	purposes	_	
179-18	37880-37881	.	_	

#Text=ER40 RT (inv)=Inverted Eemotion Recognition reaction time; Tasit=Awareness of Social Inference Test; RMET=Reading the Mind in the Eyes; RAD=Relationships Across Domains; QLS=Quality of Life Scale; SANS=Scale for the Assessment of Negative Symptoms; BPRS=Brief Psychiatric Rating Scale; CIRSG=Cumulative Illness Rating Scale – Geriatrics; SAS=Simpson– Angus Scale; CPZ=Chlorpromazine.
180-1	37882-37886	ER40	_	
180-2	37887-37889	RT	_	
180-3	37890-37891	(	_	
180-4	37891-37894	inv	_	
180-5	37894-37895	)	_	
180-6	37895-37896	=	_	
180-7	37896-37904	Inverted	_	
180-8	37905-37913	Eemotion	_	
180-9	37914-37925	Recognition	_	
180-10	37926-37934	reaction	_	
180-11	37935-37939	time	_	
180-12	37939-37940	;	_	
180-13	37941-37946	Tasit	_	
180-14	37946-37947	=	_	
180-15	37947-37956	Awareness	_	
180-16	37957-37959	of	_	
180-17	37960-37966	Social	_	
180-18	37967-37976	Inference	_	
180-19	37977-37981	Test	_	
180-20	37981-37982	;	_	
180-21	37983-37987	RMET	_	
180-22	37987-37988	=	_	
180-23	37988-37995	Reading	_	
180-24	37996-37999	the	_	
180-25	38000-38004	Mind	_	
180-26	38005-38007	in	_	
180-27	38008-38011	the	_	
180-28	38012-38016	Eyes	_	
180-29	38016-38017	;	_	
180-30	38018-38021	RAD	_	
180-31	38021-38022	=	_	
180-32	38022-38035	Relationships	_	
180-33	38036-38042	Across	_	
180-34	38043-38050	Domains	_	
180-35	38050-38051	;	_	
180-36	38052-38055	QLS	_	
180-37	38055-38056	=	_	
180-38	38056-38063	Quality	_	
180-39	38064-38066	of	_	
180-40	38067-38071	Life	_	
180-41	38072-38077	Scale	_	
180-42	38077-38078	;	_	
180-43	38079-38083	SANS	_	
180-44	38083-38084	=	_	
180-45	38084-38089	Scale	_	
180-46	38090-38093	for	_	
180-47	38094-38097	the	_	
180-48	38098-38108	Assessment	_	
180-49	38109-38111	of	_	
180-50	38112-38120	Negative	_	
180-51	38121-38129	Symptoms	_	
180-52	38129-38130	;	_	
180-53	38131-38135	BPRS	_	
180-54	38135-38136	=	_	
180-55	38136-38141	Brief	_	
180-56	38142-38153	Psychiatric	_	
180-57	38154-38160	Rating	_	
180-58	38161-38166	Scale	_	
180-59	38166-38167	;	_	
180-60	38168-38173	CIRSG	_	
180-61	38173-38174	=	_	
180-62	38174-38184	Cumulative	_	
180-63	38185-38192	Illness	_	
180-64	38193-38199	Rating	_	
180-65	38200-38205	Scale	_	
180-66	38206-38207	–	_	
180-67	38208-38218	Geriatrics	_	
180-68	38218-38219	;	_	
180-69	38220-38223	SAS	_	
180-70	38223-38224	=	_	
180-71	38224-38231	Simpson	_	
180-72	38231-38232	–	_	
180-73	38233-38238	Angus	_	
180-74	38239-38244	Scale	_	
180-75	38244-38245	;	_	
180-76	38246-38249	CPZ	_	
180-77	38249-38250	=	_	
180-78	38250-38264	Chlorpromazine	_	
180-79	38264-38265	.	_	

#Text=Resting state connectivity differences between biotypes
#Text=In A, the value in each ROI represents the difference of the summed connectivity values (r-values) associated with that ROI between groups (normal vs. poorly-performing biotype).
181-1	38266-38273	Resting	_	
181-2	38274-38279	state	_	
181-3	38280-38292	connectivity	_	
181-4	38293-38304	differences	_	
181-5	38305-38312	between	_	
181-6	38313-38321	biotypes	_	
181-7	38322-38324	In	_	
181-8	38325-38326	A	_	
181-9	38326-38327	,	_	
181-10	38328-38331	the	_	
181-11	38332-38337	value	_	
181-12	38338-38340	in	_	
181-13	38341-38345	each	_	
181-14	38346-38349	ROI	_	
181-15	38350-38360	represents	_	
181-16	38361-38364	the	_	
181-17	38365-38375	difference	_	
181-18	38376-38378	of	_	
181-19	38379-38382	the	_	
181-20	38383-38389	summed	_	
181-21	38390-38402	connectivity	_	
181-22	38403-38409	values	_	
181-23	38410-38411	(	_	
181-24	38411-38419	r-values	_	
181-25	38419-38420	)	_	
181-26	38421-38431	associated	_	
181-27	38432-38436	with	_	
181-28	38437-38441	that	_	
181-29	38442-38445	ROI	_	
181-30	38446-38453	between	_	
181-31	38454-38460	groups	_	
181-32	38461-38462	(	_	
181-33	38462-38468	normal	_	
181-34	38469-38471	vs	_	
181-35	38471-38472	.	_	
181-36	38473-38490	poorly-performing	_	
181-37	38491-38498	biotype	_	
181-38	38498-38499	)	_	
181-39	38499-38500	.	_	

#Text=The top 25% of all differences calculated between groups are shown.
182-1	38501-38504	The	_	
182-2	38505-38508	top	_	
182-3	38509-38512	25%	_	
182-4	38513-38515	of	_	
182-5	38516-38519	all	_	
182-6	38520-38531	differences	_	
182-7	38532-38542	calculated	_	
182-8	38543-38550	between	_	
182-9	38551-38557	groups	_	
182-10	38558-38561	are	_	
182-11	38562-38567	shown	_	
182-12	38567-38568	.	_	

#Text=The contrast shows widespread differences along the frontal-posterior gradient.
183-1	38569-38572	The	_	
183-2	38573-38581	contrast	_	
183-3	38582-38587	shows	_	
183-4	38588-38598	widespread	_	
183-5	38599-38610	differences	_	
183-6	38611-38616	along	_	
183-7	38617-38620	the	_	
183-8	38621-38638	frontal-posterior	_	
183-9	38639-38647	gradient	_	
183-10	38647-38648	.	_	

#Text=The normal performing group shows stronger connectivity emanating from general cognition and reaction time ROIs (red-orange), while the poorly- performing biotype shows strong connectivity emanating from occipital /mirror ROIs (blues).
184-1	38649-38652	The	_	
184-2	38653-38659	normal	_	
184-3	38660-38670	performing	_	
184-4	38671-38676	group	_	
184-5	38677-38682	shows	_	
184-6	38683-38691	stronger	_	
184-7	38692-38704	connectivity	_	
184-8	38705-38714	emanating	_	
184-9	38715-38719	from	_	
184-10	38720-38727	general	_	
184-11	38728-38737	cognition	_	
184-12	38738-38741	and	_	
184-13	38742-38750	reaction	_	
184-14	38751-38755	time	_	
184-15	38756-38760	ROIs	_	
184-16	38761-38762	(	_	
184-17	38762-38772	red-orange	_	
184-18	38772-38773	)	_	
184-19	38773-38774	,	_	
184-20	38775-38780	while	_	
184-21	38781-38784	the	_	
184-22	38785-38791	poorly	_	
184-23	38791-38792	-	_	
184-24	38793-38803	performing	_	
184-25	38804-38811	biotype	_	
184-26	38812-38817	shows	_	
184-27	38818-38824	strong	_	
184-28	38825-38837	connectivity	_	
184-29	38838-38847	emanating	_	
184-30	38848-38852	from	_	
184-31	38853-38862	occipital	_	
184-32	38863-38864	/	_	
184-33	38864-38870	mirror	_	
184-34	38871-38875	ROIs	_	
184-35	38876-38877	(	_	
184-36	38877-38882	blues	_	
184-37	38882-38883	)	_	
184-38	38883-38884	.	_	

#Text=Brain connections that were significantly different between biotypes in both samples (discovery and replication) are highly correlated (r=0.42, p<1×10−5 after 10000 permutations), shown in B.
185-1	38885-38890	Brain	_	
185-2	38891-38902	connections	_	
185-3	38903-38907	that	_	
185-4	38908-38912	were	_	
185-5	38913-38926	significantly	_	
185-6	38927-38936	different	_	
185-7	38937-38944	between	_	
185-8	38945-38953	biotypes	_	
185-9	38954-38956	in	_	
185-10	38957-38961	both	_	
185-11	38962-38969	samples	_	
185-12	38970-38971	(	_	
185-13	38971-38980	discovery	_	
185-14	38981-38984	and	_	
185-15	38985-38996	replication	_	
185-16	38996-38997	)	_	
185-17	38998-39001	are	_	
185-18	39002-39008	highly	_	
185-19	39009-39019	correlated	_	
185-20	39020-39021	(	_	
185-21	39021-39022	r	_	
185-22	39022-39023	=	_	
185-23	39023-39027	0.42	_	
185-24	39027-39028	,	_	
185-25	39029-39030	p	_	
185-26	39030-39031	<	_	
185-27	39031-39032	1	_	
185-28	39032-39033	×	_	
185-29	39033-39035	10	_	
185-30	39035-39036	−	_	
185-31	39036-39037	5	_	
185-32	39038-39043	after	_	
185-33	39044-39049	10000	_	
185-34	39050-39062	permutations	_	
185-35	39062-39063	)	_	
185-36	39063-39064	,	_	
185-37	39065-39070	shown	_	
185-38	39071-39073	in	_	
185-39	39074-39075	B	_	
185-40	39075-39076	.	_	

#Text=Specifically, this demonstrates that the pattern of connectivity differences between biotypes is similar in the two independent samples.
186-1	39077-39089	Specifically	_	
186-2	39089-39090	,	_	
186-3	39091-39095	this	_	
186-4	39096-39108	demonstrates	_	
186-5	39109-39113	that	_	
186-6	39114-39117	the	_	
186-7	39118-39125	pattern	_	
186-8	39126-39128	of	_	
186-9	39129-39141	connectivity	_	
186-10	39142-39153	differences	_	
186-11	39154-39161	between	_	
186-12	39162-39170	biotypes	_	
186-13	39171-39173	is	_	
186-14	39174-39181	similar	_	
186-15	39182-39184	in	_	
186-16	39185-39188	the	_	
186-17	39189-39192	two	_	
186-18	39193-39204	independent	_	
186-19	39205-39212	samples	_	
186-20	39212-39213	.	_	

#Text=Demographics from the three sites of data collection
#Text=\tSite CAMH\tSite MPRC\tSite ZHH\t \tGroup (SSD:HC)\t44:29\t43:26\t27:19\t \tSex (F:M)\t27:46\t20:49\t23:23\t \tEthnicity (nh:h)\t65:7\t66:3\t34:11\t \tLanguage (efl:esl)\t62:11\t66:3\t44:2\t \tMarital status (m:d:s)\t11:2:60\t13:6:50\t6:5:33\t \tSpecial education (Y/N)\t6:67\t11:58\t12:34\t \tAge\t27.81±7.70\t36.20±10.67\t34.42±9.04\t \tEducation\t14.40±2.43\t14.33±2.37\t14.33±2.54\t \tMother education\t14.28±2.93\t14.36±2.80\t14.31±3.30\t \tFather education\t15.02±3.38\t14.56±2.67\t13.89±3.49\t \tHandedness (left=0, right=1)\t0.65±0.49\t0.63±0.41\t0.55±0.62\t \tIQ\t112.13±12.45\t107.04±15.95\t101.58±15.31\t \t
#Text=CAMH=Centre for Addiction and Mental Health, MPRC=Maryland Research Centre, ZHH=Zucker Hillside Hospital, SSD=cases, HC=controls, nh=not hispanic, h=hispanic, efl=English as a first language, esl=English as a second language, m=married, d=divorced, s=single.
187-1	39214-39226	Demographics	_	
187-2	39227-39231	from	_	
187-3	39232-39235	the	_	
187-4	39236-39241	three	_	
187-5	39242-39247	sites	_	
187-6	39248-39250	of	_	
187-7	39251-39255	data	_	
187-8	39256-39266	collection	_	
187-9	39268-39272	Site	_	
187-10	39273-39277	CAMH	_	
187-11	39278-39282	Site	_	
187-12	39283-39287	MPRC	_	
187-13	39288-39292	Site	_	
187-14	39293-39296	ZHH	_	
187-15	39299-39304	Group	_	
187-16	39305-39306	(	_	
187-17	39306-39309	SSD	_	
187-18	39309-39310	:	_	
187-19	39310-39312	HC	_	
187-20	39312-39313	)	_	
187-21	39314-39316	44	_	
187-22	39316-39317	:	_	
187-23	39317-39319	29	_	
187-24	39320-39322	43	_	
187-25	39322-39323	:	_	
187-26	39323-39325	26	_	
187-27	39326-39328	27	_	
187-28	39328-39329	:	_	
187-29	39329-39331	19	_	
187-30	39334-39337	Sex	_	
187-31	39338-39339	(	_	
187-32	39339-39340	F	_	
187-33	39340-39341	:	_	
187-34	39341-39342	M	_	
187-35	39342-39343	)	_	
187-36	39344-39346	27	_	
187-37	39346-39347	:	_	
187-38	39347-39349	46	_	
187-39	39350-39352	20	_	
187-40	39352-39353	:	_	
187-41	39353-39355	49	_	
187-42	39356-39358	23	_	
187-43	39358-39359	:	_	
187-44	39359-39361	23	_	
187-45	39364-39373	Ethnicity	_	
187-46	39374-39375	(	_	
187-47	39375-39377	nh	_	
187-48	39377-39378	:	_	
187-49	39378-39379	h	_	
187-50	39379-39380	)	_	
187-51	39381-39383	65	_	
187-52	39383-39384	:	_	
187-53	39384-39385	7	_	
187-54	39386-39388	66	_	
187-55	39388-39389	:	_	
187-56	39389-39390	3	_	
187-57	39391-39393	34	_	
187-58	39393-39394	:	_	
187-59	39394-39396	11	_	
187-60	39399-39407	Language	_	
187-61	39408-39409	(	_	
187-62	39409-39412	efl	_	
187-63	39412-39413	:	_	
187-64	39413-39416	esl	_	
187-65	39416-39417	)	_	
187-66	39418-39420	62	_	
187-67	39420-39421	:	_	
187-68	39421-39423	11	_	
187-69	39424-39426	66	_	
187-70	39426-39427	:	_	
187-71	39427-39428	3	_	
187-72	39429-39431	44	_	
187-73	39431-39432	:	_	
187-74	39432-39433	2	_	
187-75	39436-39443	Marital	_	
187-76	39444-39450	status	_	
187-77	39451-39452	(	_	
187-78	39452-39453	m	_	
187-79	39453-39454	:	_	
187-80	39454-39455	d	_	
187-81	39455-39456	:	_	
187-82	39456-39457	s	_	
187-83	39457-39458	)	_	
187-84	39459-39461	11	_	
187-85	39461-39462	:	_	
187-86	39462-39463	2	_	
187-87	39463-39464	:	_	
187-88	39464-39466	60	_	
187-89	39467-39469	13	_	
187-90	39469-39470	:	_	
187-91	39470-39471	6	_	
187-92	39471-39472	:	_	
187-93	39472-39474	50	_	
187-94	39475-39476	6	_	
187-95	39476-39477	:	_	
187-96	39477-39478	5	_	
187-97	39478-39479	:	_	
187-98	39479-39481	33	_	
187-99	39484-39491	Special	_	
187-100	39492-39501	education	_	
187-101	39502-39503	(	_	
187-102	39503-39504	Y	_	
187-103	39504-39505	/	_	
187-104	39505-39506	N	_	
187-105	39506-39507	)	_	
187-106	39508-39509	6	_	
187-107	39509-39510	:	_	
187-108	39510-39512	67	_	
187-109	39513-39515	11	_	
187-110	39515-39516	:	_	
187-111	39516-39518	58	_	
187-112	39519-39521	12	_	
187-113	39521-39522	:	_	
187-114	39522-39524	34	_	
187-115	39527-39530	Age	_	
187-116	39531-39536	27.81	_	
187-117	39536-39537	±	_	
187-118	39537-39541	7.70	_	
187-119	39542-39547	36.20	_	
187-120	39547-39548	±	_	
187-121	39548-39553	10.67	_	
187-122	39554-39559	34.42	_	
187-123	39559-39560	±	_	
187-124	39560-39564	9.04	_	
187-125	39567-39576	Education	_	
187-126	39577-39582	14.40	_	
187-127	39582-39583	±	_	
187-128	39583-39587	2.43	_	
187-129	39588-39593	14.33	_	
187-130	39593-39594	±	_	
187-131	39594-39598	2.37	_	
187-132	39599-39604	14.33	_	
187-133	39604-39605	±	_	
187-134	39605-39609	2.54	_	
187-135	39612-39618	Mother	_	
187-136	39619-39628	education	_	
187-137	39629-39634	14.28	_	
187-138	39634-39635	±	_	
187-139	39635-39639	2.93	_	
187-140	39640-39645	14.36	_	
187-141	39645-39646	±	_	
187-142	39646-39650	2.80	_	
187-143	39651-39656	14.31	_	
187-144	39656-39657	±	_	
187-145	39657-39661	3.30	_	
187-146	39664-39670	Father	_	
187-147	39671-39680	education	_	
187-148	39681-39686	15.02	_	
187-149	39686-39687	±	_	
187-150	39687-39691	3.38	_	
187-151	39692-39697	14.56	_	
187-152	39697-39698	±	_	
187-153	39698-39702	2.67	_	
187-154	39703-39708	13.89	_	
187-155	39708-39709	±	_	
187-156	39709-39713	3.49	_	
187-157	39716-39726	Handedness	_	
187-158	39727-39728	(	_	
187-159	39728-39732	left	_	
187-160	39732-39733	=	_	
187-161	39733-39734	0	_	
187-162	39734-39735	,	_	
187-163	39736-39741	right	_	
187-164	39741-39742	=	_	
187-165	39742-39743	1	_	
187-166	39743-39744	)	_	
187-167	39745-39749	0.65	_	
187-168	39749-39750	±	_	
187-169	39750-39754	0.49	_	
187-170	39755-39759	0.63	_	
187-171	39759-39760	±	_	
187-172	39760-39764	0.41	_	
187-173	39765-39769	0.55	_	
187-174	39769-39770	±	_	
187-175	39770-39774	0.62	_	
187-176	39777-39779	IQ	_	
187-177	39780-39786	112.13	_	
187-178	39786-39787	±	_	
187-179	39787-39792	12.45	_	
187-180	39793-39799	107.04	_	
187-181	39799-39800	±	_	
187-182	39800-39805	15.95	_	
187-183	39806-39812	101.58	_	
187-184	39812-39813	±	_	
187-185	39813-39818	15.31	_	
187-186	39822-39826	CAMH	_	
187-187	39826-39827	=	_	
187-188	39827-39833	Centre	_	
187-189	39834-39837	for	_	
187-190	39838-39847	Addiction	_	
187-191	39848-39851	and	_	
187-192	39852-39858	Mental	_	
187-193	39859-39865	Health	_	
187-194	39865-39866	,	_	
187-195	39867-39871	MPRC	_	
187-196	39871-39872	=	_	
187-197	39872-39880	Maryland	_	
187-198	39881-39889	Research	_	
187-199	39890-39896	Centre	_	
187-200	39896-39897	,	_	
187-201	39898-39901	ZHH	_	
187-202	39901-39902	=	_	
187-203	39902-39908	Zucker	_	
187-204	39909-39917	Hillside	_	
187-205	39918-39926	Hospital	_	
187-206	39926-39927	,	_	
187-207	39928-39931	SSD	_	
187-208	39931-39932	=	_	
187-209	39932-39937	cases	_	
187-210	39937-39938	,	_	
187-211	39939-39941	HC	_	
187-212	39941-39942	=	_	
187-213	39942-39950	controls	_	
187-214	39950-39951	,	_	
187-215	39952-39954	nh	_	
187-216	39954-39955	=	_	
187-217	39955-39958	not	_	
187-218	39959-39967	hispanic	_	
187-219	39967-39968	,	_	
187-220	39969-39970	h	_	
187-221	39970-39971	=	_	
187-222	39971-39979	hispanic	_	
187-223	39979-39980	,	_	
187-224	39981-39984	efl	_	
187-225	39984-39985	=	_	
187-226	39985-39992	English	_	
187-227	39993-39995	as	_	
187-228	39996-39997	a	_	
187-229	39998-40003	first	_	
187-230	40004-40012	language	_	
187-231	40012-40013	,	_	
187-232	40014-40017	esl	_	
187-233	40017-40018	=	_	
187-234	40018-40025	English	_	
187-235	40026-40028	as	_	
187-236	40029-40030	a	_	
187-237	40031-40037	second	_	
187-238	40038-40046	language	_	
187-239	40046-40047	,	_	
187-240	40048-40049	m	_	
187-241	40049-40050	=	_	
187-242	40050-40057	married	_	
187-243	40057-40058	,	_	
187-244	40059-40060	d	_	
187-245	40060-40061	=	_	
187-246	40061-40069	divorced	_	
187-247	40069-40070	,	_	
187-248	40071-40072	s	_	
187-249	40072-40073	=	_	
187-250	40073-40079	single	_	
187-251	40079-40080	.	_	

#Text=Demographics from the resting state connectivity biotypes
#Text=\tNormal Biotype\tPoorly-Performing Biotype\tTest Statistic\tp (* = sig.
188-1	40081-40093	Demographics	_	
188-2	40094-40098	from	_	
188-3	40099-40102	the	_	
188-4	40103-40110	resting	_	
188-5	40111-40116	state	_	
188-6	40117-40129	connectivity	_	
188-7	40130-40138	biotypes	_	
188-8	40140-40146	Normal	_	
188-9	40147-40154	Biotype	_	
188-10	40155-40172	Poorly-Performing	_	
188-11	40173-40180	Biotype	_	
188-12	40181-40185	Test	_	
188-13	40186-40195	Statistic	_	
188-14	40196-40197	p	_	
188-15	40198-40199	(	_	
188-16	40199-40200	*	_	
188-17	40201-40202	=	_	
188-18	40203-40206	sig	_	
188-19	40206-40207	.	_	

#Text=FDR q=0.05)\t \tSite (CAMH:MPRC:ZHH)\t48:32:23\t16:28:17\tX2(2)=6.86\t3.23×10−2\t \tGroup (SSD:HC)\t42:61\t53:8\tX2(1)=31.55\t1.93×10−8*\t \tSex (F:M)\t41:62\t17:44\tX2(1)=1.89\t1.69×10−8\t \tEthnicity (nh:h)\t94:8\t52:9\tX2(1)=1.28\t2.58×10−1\t \tLanguage (efl:esl)\t93:10\t58:3\tX2(1)=0.64\t4.25×10−1\t \tOffspring (Y/N)\t11:92\t12:48\tX2(1)=2.00\t1.57×10−1\t \tMarital status (m:d:s)\t20:1:81\t8:10:43\tX2(2)=14.77\t6.19×10−4*\t \tSpecial education (Y/N)\t10:93\t15:44\tX2(1)=5.95\t1.48×10−2*\t \tAge\t29.66 (8.90)\t36.43±10.01\tt(162)=−4.36\t2.90×10−5*\t \tIllness Duration (Years)\t7.61±6.3\t16.32±10.63\tt(93)=−4.6\t1.34×10−5*\t \tEducation\t15.11±2.12\t13.05±2.25\tt(162)=5.74\t7.35×10−8*\t \tMother education\t14.60±2.92\t13.86±2.94\tt(162)=1.46\t1.47×10−1\t \tFather education\t14.92±3.36\t13.88±2.94\tt(162)=1.94\t5.41×10−2\t \tHandedness (l=0:r=1)\t0.61±0.50\t0.67±0.47\tt(162)=−0.77\t4.40×10−1\t \tIQ\t111.68±12.67\t99.66±15.41\tt(162)=5.14\t1.19×10−6*\t \t
#Text=CAMH=Centre for Addiction and Mental Health, MPRC=Maryland Research Centre, ZHH=Zucker Hillside Hospital, SSD=cases, HC=controls, nh=not hispanic, h=hispanic, efl=English as a first language, esl=English as a second language, m=married, d=divorced, s=single.
189-1	40208-40211	FDR	_	
189-2	40212-40213	q	_	
189-3	40213-40214	=	_	
189-4	40214-40218	0.05	_	
189-5	40218-40219	)	_	
189-6	40222-40226	Site	_	
189-7	40227-40228	(	_	
189-8	40228-40232	CAMH	_	
189-9	40232-40233	:	_	
189-10	40233-40237	MPRC	_	
189-11	40237-40238	:	_	
189-12	40238-40241	ZHH	_	
189-13	40241-40242	)	_	
189-14	40243-40245	48	_	
189-15	40245-40246	:	_	
189-16	40246-40248	32	_	
189-17	40248-40249	:	_	
189-18	40249-40251	23	_	
189-19	40252-40254	16	_	
189-20	40254-40255	:	_	
189-21	40255-40257	28	_	
189-22	40257-40258	:	_	
189-23	40258-40260	17	_	
189-24	40261-40263	X2	_	
189-25	40263-40264	(	_	
189-26	40264-40265	2	_	
189-27	40265-40266	)	_	
189-28	40266-40267	=	_	
189-29	40267-40271	6.86	_	
189-30	40272-40276	3.23	_	
189-31	40276-40277	×	_	
189-32	40277-40279	10	_	
189-33	40279-40280	−	_	
189-34	40280-40281	2	_	
189-35	40284-40289	Group	_	
189-36	40290-40291	(	_	
189-37	40291-40294	SSD	_	
189-38	40294-40295	:	_	
189-39	40295-40297	HC	_	
189-40	40297-40298	)	_	
189-41	40299-40301	42	_	
189-42	40301-40302	:	_	
189-43	40302-40304	61	_	
189-44	40305-40307	53	_	
189-45	40307-40308	:	_	
189-46	40308-40309	8	_	
189-47	40310-40312	X2	_	
189-48	40312-40313	(	_	
189-49	40313-40314	1	_	
189-50	40314-40315	)	_	
189-51	40315-40316	=	_	
189-52	40316-40321	31.55	_	
189-53	40322-40326	1.93	_	
189-54	40326-40327	×	_	
189-55	40327-40329	10	_	
189-56	40329-40330	−	_	
189-57	40330-40331	8	_	
189-58	40331-40332	*	_	
189-59	40335-40338	Sex	_	
189-60	40339-40340	(	_	
189-61	40340-40341	F	_	
189-62	40341-40342	:	_	
189-63	40342-40343	M	_	
189-64	40343-40344	)	_	
189-65	40345-40347	41	_	
189-66	40347-40348	:	_	
189-67	40348-40350	62	_	
189-68	40351-40353	17	_	
189-69	40353-40354	:	_	
189-70	40354-40356	44	_	
189-71	40357-40359	X2	_	
189-72	40359-40360	(	_	
189-73	40360-40361	1	_	
189-74	40361-40362	)	_	
189-75	40362-40363	=	_	
189-76	40363-40367	1.89	_	
189-77	40368-40372	1.69	_	
189-78	40372-40373	×	_	
189-79	40373-40375	10	_	
189-80	40375-40376	−	_	
189-81	40376-40377	8	_	
189-82	40380-40389	Ethnicity	_	
189-83	40390-40391	(	_	
189-84	40391-40393	nh	_	
189-85	40393-40394	:	_	
189-86	40394-40395	h	_	
189-87	40395-40396	)	_	
189-88	40397-40399	94	_	
189-89	40399-40400	:	_	
189-90	40400-40401	8	_	
189-91	40402-40404	52	_	
189-92	40404-40405	:	_	
189-93	40405-40406	9	_	
189-94	40407-40409	X2	_	
189-95	40409-40410	(	_	
189-96	40410-40411	1	_	
189-97	40411-40412	)	_	
189-98	40412-40413	=	_	
189-99	40413-40417	1.28	_	
189-100	40418-40422	2.58	_	
189-101	40422-40423	×	_	
189-102	40423-40425	10	_	
189-103	40425-40426	−	_	
189-104	40426-40427	1	_	
189-105	40430-40438	Language	_	
189-106	40439-40440	(	_	
189-107	40440-40443	efl	_	
189-108	40443-40444	:	_	
189-109	40444-40447	esl	_	
189-110	40447-40448	)	_	
189-111	40449-40451	93	_	
189-112	40451-40452	:	_	
189-113	40452-40454	10	_	
189-114	40455-40457	58	_	
189-115	40457-40458	:	_	
189-116	40458-40459	3	_	
189-117	40460-40462	X2	_	
189-118	40462-40463	(	_	
189-119	40463-40464	1	_	
189-120	40464-40465	)	_	
189-121	40465-40466	=	_	
189-122	40466-40470	0.64	_	
189-123	40471-40475	4.25	_	
189-124	40475-40476	×	_	
189-125	40476-40478	10	_	
189-126	40478-40479	−	_	
189-127	40479-40480	1	_	
189-128	40483-40492	Offspring	_	
189-129	40493-40494	(	_	
189-130	40494-40495	Y	_	
189-131	40495-40496	/	_	
189-132	40496-40497	N	_	
189-133	40497-40498	)	_	
189-134	40499-40501	11	_	
189-135	40501-40502	:	_	
189-136	40502-40504	92	_	
189-137	40505-40507	12	_	
189-138	40507-40508	:	_	
189-139	40508-40510	48	_	
189-140	40511-40513	X2	_	
189-141	40513-40514	(	_	
189-142	40514-40515	1	_	
189-143	40515-40516	)	_	
189-144	40516-40517	=	_	
189-145	40517-40521	2.00	_	
189-146	40522-40526	1.57	_	
189-147	40526-40527	×	_	
189-148	40527-40529	10	_	
189-149	40529-40530	−	_	
189-150	40530-40531	1	_	
189-151	40534-40541	Marital	_	
189-152	40542-40548	status	_	
189-153	40549-40550	(	_	
189-154	40550-40551	m	_	
189-155	40551-40552	:	_	
189-156	40552-40553	d	_	
189-157	40553-40554	:	_	
189-158	40554-40555	s	_	
189-159	40555-40556	)	_	
189-160	40557-40559	20	_	
189-161	40559-40560	:	_	
189-162	40560-40561	1	_	
189-163	40561-40562	:	_	
189-164	40562-40564	81	_	
189-165	40565-40566	8	_	
189-166	40566-40567	:	_	
189-167	40567-40569	10	_	
189-168	40569-40570	:	_	
189-169	40570-40572	43	_	
189-170	40573-40575	X2	_	
189-171	40575-40576	(	_	
189-172	40576-40577	2	_	
189-173	40577-40578	)	_	
189-174	40578-40579	=	_	
189-175	40579-40584	14.77	_	
189-176	40585-40589	6.19	_	
189-177	40589-40590	×	_	
189-178	40590-40592	10	_	
189-179	40592-40593	−	_	
189-180	40593-40594	4	_	
189-181	40594-40595	*	_	
189-182	40598-40605	Special	_	
189-183	40606-40615	education	_	
189-184	40616-40617	(	_	
189-185	40617-40618	Y	_	
189-186	40618-40619	/	_	
189-187	40619-40620	N	_	
189-188	40620-40621	)	_	
189-189	40622-40624	10	_	
189-190	40624-40625	:	_	
189-191	40625-40627	93	_	
189-192	40628-40630	15	_	
189-193	40630-40631	:	_	
189-194	40631-40633	44	_	
189-195	40634-40636	X2	_	
189-196	40636-40637	(	_	
189-197	40637-40638	1	_	
189-198	40638-40639	)	_	
189-199	40639-40640	=	_	
189-200	40640-40644	5.95	_	
189-201	40645-40649	1.48	_	
189-202	40649-40650	×	_	
189-203	40650-40652	10	_	
189-204	40652-40653	−	_	
189-205	40653-40654	2	_	
189-206	40654-40655	*	_	
189-207	40658-40661	Age	_	
189-208	40662-40667	29.66	_	
189-209	40668-40669	(	_	
189-210	40669-40673	8.90	_	
189-211	40673-40674	)	_	
189-212	40675-40680	36.43	_	
189-213	40680-40681	±	_	
189-214	40681-40686	10.01	_	
189-215	40687-40688	t	_	
189-216	40688-40689	(	_	
189-217	40689-40692	162	_	
189-218	40692-40693	)	_	
189-219	40693-40694	=	_	
189-220	40694-40695	−	_	
189-221	40695-40699	4.36	_	
189-222	40700-40704	2.90	_	
189-223	40704-40705	×	_	
189-224	40705-40707	10	_	
189-225	40707-40708	−	_	
189-226	40708-40709	5	_	
189-227	40709-40710	*	_	
189-228	40713-40720	Illness	_	
189-229	40721-40729	Duration	_	
189-230	40730-40731	(	_	
189-231	40731-40736	Years	_	
189-232	40736-40737	)	_	
189-233	40738-40742	7.61	_	
189-234	40742-40743	±	_	
189-235	40743-40746	6.3	_	
189-236	40747-40752	16.32	_	
189-237	40752-40753	±	_	
189-238	40753-40758	10.63	_	
189-239	40759-40760	t	_	
189-240	40760-40761	(	_	
189-241	40761-40763	93	_	
189-242	40763-40764	)	_	
189-243	40764-40765	=	_	
189-244	40765-40766	−	_	
189-245	40766-40769	4.6	_	
189-246	40770-40774	1.34	_	
189-247	40774-40775	×	_	
189-248	40775-40777	10	_	
189-249	40777-40778	−	_	
189-250	40778-40779	5	_	
189-251	40779-40780	*	_	
189-252	40783-40792	Education	_	
189-253	40793-40798	15.11	_	
189-254	40798-40799	±	_	
189-255	40799-40803	2.12	_	
189-256	40804-40809	13.05	_	
189-257	40809-40810	±	_	
189-258	40810-40814	2.25	_	
189-259	40815-40816	t	_	
189-260	40816-40817	(	_	
189-261	40817-40820	162	_	
189-262	40820-40821	)	_	
189-263	40821-40822	=	_	
189-264	40822-40826	5.74	_	
189-265	40827-40831	7.35	_	
189-266	40831-40832	×	_	
189-267	40832-40834	10	_	
189-268	40834-40835	−	_	
189-269	40835-40836	8	_	
189-270	40836-40837	*	_	
189-271	40840-40846	Mother	_	
189-272	40847-40856	education	_	
189-273	40857-40862	14.60	_	
189-274	40862-40863	±	_	
189-275	40863-40867	2.92	_	
189-276	40868-40873	13.86	_	
189-277	40873-40874	±	_	
189-278	40874-40878	2.94	_	
189-279	40879-40880	t	_	
189-280	40880-40881	(	_	
189-281	40881-40884	162	_	
189-282	40884-40885	)	_	
189-283	40885-40886	=	_	
189-284	40886-40890	1.46	_	
189-285	40891-40895	1.47	_	
189-286	40895-40896	×	_	
189-287	40896-40898	10	_	
189-288	40898-40899	−	_	
189-289	40899-40900	1	_	
189-290	40903-40909	Father	_	
189-291	40910-40919	education	_	
189-292	40920-40925	14.92	_	
189-293	40925-40926	±	_	
189-294	40926-40930	3.36	_	
189-295	40931-40936	13.88	_	
189-296	40936-40937	±	_	
189-297	40937-40941	2.94	_	
189-298	40942-40943	t	_	
189-299	40943-40944	(	_	
189-300	40944-40947	162	_	
189-301	40947-40948	)	_	
189-302	40948-40949	=	_	
189-303	40949-40953	1.94	_	
189-304	40954-40958	5.41	_	
189-305	40958-40959	×	_	
189-306	40959-40961	10	_	
189-307	40961-40962	−	_	
189-308	40962-40963	2	_	
189-309	40966-40976	Handedness	_	
189-310	40977-40978	(	_	
189-311	40978-40979	l	_	
189-312	40979-40980	=	_	
189-313	40980-40981	0	_	
189-314	40981-40982	:	_	
189-315	40982-40983	r	_	
189-316	40983-40984	=	_	
189-317	40984-40985	1	_	
189-318	40985-40986	)	_	
189-319	40987-40991	0.61	_	
189-320	40991-40992	±	_	
189-321	40992-40996	0.50	_	
189-322	40997-41001	0.67	_	
189-323	41001-41002	±	_	
189-324	41002-41006	0.47	_	
189-325	41007-41008	t	_	
189-326	41008-41009	(	_	
189-327	41009-41012	162	_	
189-328	41012-41013	)	_	
189-329	41013-41014	=	_	
189-330	41014-41015	−	_	
189-331	41015-41019	0.77	_	
189-332	41020-41024	4.40	_	
189-333	41024-41025	×	_	
189-334	41025-41027	10	_	
189-335	41027-41028	−	_	
189-336	41028-41029	1	_	
189-337	41032-41034	IQ	_	
189-338	41035-41041	111.68	_	
189-339	41041-41042	±	_	
189-340	41042-41047	12.67	_	
189-341	41048-41053	99.66	_	
189-342	41053-41054	±	_	
189-343	41054-41059	15.41	_	
189-344	41060-41061	t	_	
189-345	41061-41062	(	_	
189-346	41062-41065	162	_	
189-347	41065-41066	)	_	
189-348	41066-41067	=	_	
189-349	41067-41071	5.14	_	
189-350	41072-41076	1.19	_	
189-351	41076-41077	×	_	
189-352	41077-41079	10	_	
189-353	41079-41080	−	_	
189-354	41080-41081	6	_	
189-355	41081-41082	*	_	
189-356	41086-41090	CAMH	_	
189-357	41090-41091	=	_	
189-358	41091-41097	Centre	_	
189-359	41098-41101	for	_	
189-360	41102-41111	Addiction	_	
189-361	41112-41115	and	_	
189-362	41116-41122	Mental	_	
189-363	41123-41129	Health	_	
189-364	41129-41130	,	_	
189-365	41131-41135	MPRC	_	
189-366	41135-41136	=	_	
189-367	41136-41144	Maryland	_	
189-368	41145-41153	Research	_	
189-369	41154-41160	Centre	_	
189-370	41160-41161	,	_	
189-371	41162-41165	ZHH	_	
189-372	41165-41166	=	_	
189-373	41166-41172	Zucker	_	
189-374	41173-41181	Hillside	_	
189-375	41182-41190	Hospital	_	
189-376	41190-41191	,	_	
189-377	41192-41195	SSD	_	
189-378	41195-41196	=	_	
189-379	41196-41201	cases	_	
189-380	41201-41202	,	_	
189-381	41203-41205	HC	_	
189-382	41205-41206	=	_	
189-383	41206-41214	controls	_	
189-384	41214-41215	,	_	
189-385	41216-41218	nh	_	
189-386	41218-41219	=	_	
189-387	41219-41222	not	_	
189-388	41223-41231	hispanic	_	
189-389	41231-41232	,	_	
189-390	41233-41234	h	_	
189-391	41234-41235	=	_	
189-392	41235-41243	hispanic	_	
189-393	41243-41244	,	_	
189-394	41245-41248	efl	_	
189-395	41248-41249	=	_	
189-396	41249-41256	English	_	
189-397	41257-41259	as	_	
189-398	41260-41261	a	_	
189-399	41262-41267	first	_	
189-400	41268-41276	language	_	
189-401	41276-41277	,	_	
189-402	41278-41281	esl	_	
189-403	41281-41282	=	_	
189-404	41282-41289	English	_	
189-405	41290-41292	as	_	
189-406	41293-41294	a	_	
189-407	41295-41301	second	_	
189-408	41302-41310	language	_	
189-409	41310-41311	,	_	
189-410	41312-41313	m	_	
189-411	41313-41314	=	_	
189-412	41314-41321	married	_	
189-413	41321-41322	,	_	
189-414	41323-41324	d	_	
189-415	41324-41325	=	_	
189-416	41325-41333	divorced	_	
189-417	41333-41334	,	_	
189-418	41335-41336	s	_	
189-419	41336-41337	=	_	
189-420	41337-41343	single	_	
189-421	41343-41344	.	_	

#Text==significant group differences after FDR correction (q=0.05).
190-1	41345-41346	=	_	
190-2	41346-41357	significant	_	
190-3	41358-41363	group	_	
190-4	41364-41375	differences	_	
190-5	41376-41381	after	_	
190-6	41382-41385	FDR	_	
190-7	41386-41396	correction	_	
190-8	41397-41398	(	_	
190-9	41398-41399	q	_	
190-10	41399-41400	=	_	
190-11	41400-41404	0.05	_	
190-12	41404-41405	)	_	
190-13	41405-41406	.	_	

#Text=Classification scores for biotype, cognitive score split, and diagnosis experiments
#Text=Each cell contains the mean and standard deviation test score over folds.
191-1	41407-41421	Classification	_	
191-2	41422-41428	scores	_	
191-3	41429-41432	for	_	
191-4	41433-41440	biotype	_	
191-5	41440-41441	,	_	
191-6	41442-41451	cognitive	_	
191-7	41452-41457	score	_	
191-8	41458-41463	split	_	
191-9	41463-41464	,	_	
191-10	41465-41468	and	_	
191-11	41469-41478	diagnosis	_	
191-12	41479-41490	experiments	_	
191-13	41491-41495	Each	_	
191-14	41496-41500	cell	_	
191-15	41501-41509	contains	_	
191-16	41510-41513	the	_	
191-17	41514-41518	mean	_	
191-18	41519-41522	and	_	
191-19	41523-41531	standard	_	
191-20	41532-41541	deviation	_	
191-21	41542-41546	test	_	
191-22	41547-41552	score	_	
191-23	41553-41557	over	_	
191-24	41558-41563	folds	_	
191-25	41563-41564	.	_	

#Text=The data column denotes which dataset was used to perform the experiment.
192-1	41565-41568	The	_	
192-2	41569-41573	data	_	
192-3	41574-41580	column	_	
192-4	41581-41588	denotes	_	
192-5	41589-41594	which	_	
192-6	41595-41602	dataset	_	
192-7	41603-41606	was	_	
192-8	41607-41611	used	_	
192-9	41612-41614	to	_	
192-10	41615-41622	perform	_	
192-11	41623-41626	the	_	
192-12	41627-41637	experiment	_	
192-13	41637-41638	.	_	

#Text=For all biotype experiments, the same data type was used to biotype the subjects and train the SVM for classification.
193-1	41639-41642	For	_	
193-2	41643-41646	all	_	
193-3	41647-41654	biotype	_	
193-4	41655-41666	experiments	_	
193-5	41666-41667	,	_	
193-6	41668-41671	the	_	
193-7	41672-41676	same	_	
193-8	41677-41681	data	_	
193-9	41682-41686	type	_	
193-10	41687-41690	was	_	
193-11	41691-41695	used	_	
193-12	41696-41698	to	_	
193-13	41699-41706	biotype	_	
193-14	41707-41710	the	_	
193-15	41711-41719	subjects	_	
193-16	41720-41723	and	_	
193-17	41724-41729	train	_	
193-18	41730-41733	the	_	
193-19	41734-41737	SVM	_	
193-20	41738-41741	for	_	
193-21	41742-41756	classification	_	
193-22	41756-41757	.	_	

#Text=For all cognitive score split (cog split) experiments, the percentile used to split the first principal component of the 12 scores/domains is shown.
194-1	41758-41761	For	_	
194-2	41762-41765	all	_	
194-3	41766-41775	cognitive	_	
194-4	41776-41781	score	_	
194-5	41782-41787	split	_	
194-6	41788-41789	(	_	
194-7	41789-41792	cog	_	
194-8	41793-41798	split	_	
194-9	41798-41799	)	_	
194-10	41800-41811	experiments	_	
194-11	41811-41812	,	_	
194-12	41813-41816	the	_	
194-13	41817-41827	percentile	_	
194-14	41828-41832	used	_	
194-15	41833-41835	to	_	
194-16	41836-41841	split	_	
194-17	41842-41845	the	_	
194-18	41846-41851	first	_	
194-19	41852-41861	principal	_	
194-20	41862-41871	component	_	
194-21	41872-41874	of	_	
194-22	41875-41878	the	_	
194-23	41879-41881	12	_	
194-24	41882-41888	scores	_	
194-25	41888-41889	/	_	
194-26	41889-41896	domains	_	
194-27	41897-41899	is	_	
194-28	41900-41905	shown	_	
194-29	41905-41906	.	_	

#Text=This threshold defined the high and low scoring group.
195-1	41907-41911	This	_	
195-2	41912-41921	threshold	_	
195-3	41922-41929	defined	_	
195-4	41930-41933	the	_	
195-5	41934-41938	high	_	
195-6	41939-41942	and	_	
195-7	41943-41946	low	_	
195-8	41947-41954	scoring	_	
195-9	41955-41960	group	_	
195-10	41960-41961	.	_	

#Text=For all diagnosis experiments, no social cognitive or neurocognitive variables were used.
196-1	41962-41965	For	_	
196-2	41966-41969	all	_	
196-3	41970-41979	diagnosis	_	
196-4	41980-41991	experiments	_	
196-5	41991-41992	,	_	
196-6	41993-41995	no	_	
196-7	41996-42002	social	_	
196-8	42003-42012	cognitive	_	
196-9	42013-42015	or	_	
196-10	42016-42030	neurocognitive	_	
196-11	42031-42040	variables	_	
196-12	42041-42045	were	_	
196-13	42046-42050	used	_	
196-14	42050-42051	.	_	

#Text=REST=resting state fMRI, IMOB=imitate/observe, EA=empathic accuracy, GLM=genealized linear model.
197-1	42052-42056	REST	_	
197-2	42056-42057	=	_	
197-3	42057-42064	resting	_	
197-4	42065-42070	state	_	
197-5	42071-42075	fMRI	_	
197-6	42075-42076	,	_	
197-7	42077-42081	IMOB	_	
197-8	42081-42082	=	_	
197-9	42082-42089	imitate	_	
197-10	42089-42090	/	_	
197-11	42090-42097	observe	_	
197-12	42097-42098	,	_	
197-13	42099-42101	EA	_	
197-14	42101-42102	=	_	
197-15	42102-42110	empathic	_	
197-16	42111-42119	accuracy	_	
197-17	42119-42120	,	_	
197-18	42121-42124	GLM	_	
197-19	42124-42125	=	_	
197-20	42125-42135	genealized	_	
197-21	42136-42142	linear	_	
197-22	42143-42148	model	_	
197-23	42148-42149	.	_	

#Text=Analyses\tData\t# of variables\tAUC\tAccuracy\tRecall\tPrecision\tf1\t \tBiotype\tREST Connectivity\t35,778\t0.88±0.03\t0.81±0.06\t0.88±0.03\t0.83±0.05\t0.79±0.07\t \tBiotype\tREST Connectivity Replication\t35,778\t0.83±0.03\t0.73±0.06\t0.83±0.03\t0.75±0.05\t0.71±0.07\t \tBiotype\tIMOB GLM\t268\t0.89±0.02\t0.87±0.03\t0.89±0.02\t0.84±0.04\t0.83±0.04\t \tBiotype\tIMOB Connectivity\t35,778\t0.39±0.16\t0.77±0.06\t0.58±0.11\t0.68±0.07\t0.61±0.09\t \tBiotype\tIMOB Connectivity Replication\t35,778\t0.62±0.20\t0.75±0.11\t0.67±0.17\t0.70±0.12\t0.67±0.14\t \tBiotype\tEA GLM\t268\t0.60±0.11\t0.82±0.05\t0.72±0.08\t0.72±0.06\t0.71±0.07\t \tBiotype\tEA Connectivity\t35,778\t0.86±0.02\t0.78±0.04\t0.86±0.02\t0.77±0.04\t0.76±0.05\t \tCog Split (50%)\tREST Connectivity\t35,778\t0.67±0.03\t0.67±0.03\t0.67±0.03\t0.68±0.03\t0.67±0.03\t \tCog Split (50%)\tIMOB GLM\t268\t0.56±0.03\t0.56±0.03\t0.56±0.03\t0.56±0.03\t0.55±0.03\t \tCog Split (50%)\tIMOB Connectivity\t35,778\t0.56±0.05\t0.56±0.05\t0.56±0.05\t0.57±0.06\t0.56±0.05\t \tCog Split (50%)\tEA GLM\t268\t0.57±0.04\t0.57±0.04\t0.57±0.04\t0.58±0.04\t0.57±0.04\t \tCog Split (50%)\tEA Connectivity\t35,778\t0.58±0.03\t0.58±0.03\t0.58±0.03\t0.58±0.03\t0.58±0.03\t \tCog Split (30%)\tREST Connectivity\t35,778\t0.64±0.04\t0.61±0.04\t0.64±0.04\t0.62±0.04\t0.59±0.04\t \tCog Split (30%)\tIMOB GLM\t268\t0.49±0.05\t0.53±0.04\t0.49±0.05\t0.50±0.04\t0.49±0.04\t \tCog Split (30%)\tIMOB Connectivity\t35,778\t0.60±0.07\t0.60±0.07\t0.60±0.07\t0.59±0.06\t0.57±0.07\t \tCog Split (30%)\tEA GLM\t268\t0.59±0.03\t0.59±0.03\t0.59±0.03\t0.58±0.02\t0.56±0.03\t \tCog Split (30%)\tEA Connectivity\t35,778\t0.57±0.04\t0.57±0.04\t0.57±0.04\t0.56±0.04\t0.54±0.04\t \tDiagnosis\tREST Connectivity\t35,778\t0.74±0.02\t0.72±0.02\t0.74±0.02\t0.72±0.02\t0.72±0.02\t \tDiagnosis\tIMOB GLM\t268\t0.49±0.02\t0.50±0.02\t0.49±0.02\t0.49±0.02\t0.49±0.02\t \tDiagnosis\tIMOB Connectivity\t35,778\t0.62±0.04\t0.61±0.04\t0.62±0.04\t0.62±0.04\t0.61±0.04\t \tDiagnosis\tEA GLM\t268\t0.57±0.03\t0.58±0.03\t0.57±0.03\t0.57±0.03\t0.57±0.03\t \tDiagnosis\tEA Connectivity\t35,778\t0.52±0.04\t0.52±0.04\t0.52±0.04\t0.52±0.04\t0.52±0.04
198-1	42150-42158	Analyses	_	
198-2	42159-42163	Data	_	
198-3	42164-42165	#	_	
198-4	42166-42168	of	_	
198-5	42169-42178	variables	_	
198-6	42179-42182	AUC	_	
198-7	42183-42191	Accuracy	_	
198-8	42192-42198	Recall	_	
198-9	42199-42208	Precision	_	
198-10	42209-42211	f1	_	
198-11	42214-42221	Biotype	_	
198-12	42222-42226	REST	_	
198-13	42227-42239	Connectivity	_	
198-14	42240-42246	35,778	_	
198-15	42247-42251	0.88	_	
198-16	42251-42252	±	_	
198-17	42252-42256	0.03	_	
198-18	42257-42261	0.81	_	
198-19	42261-42262	±	_	
198-20	42262-42266	0.06	_	
198-21	42267-42271	0.88	_	
198-22	42271-42272	±	_	
198-23	42272-42276	0.03	_	
198-24	42277-42281	0.83	_	
198-25	42281-42282	±	_	
198-26	42282-42286	0.05	_	
198-27	42287-42291	0.79	_	
198-28	42291-42292	±	_	
198-29	42292-42296	0.07	_	
198-30	42299-42306	Biotype	_	
198-31	42307-42311	REST	_	
198-32	42312-42324	Connectivity	_	
198-33	42325-42336	Replication	_	
198-34	42337-42343	35,778	_	
198-35	42344-42348	0.83	_	
198-36	42348-42349	±	_	
198-37	42349-42353	0.03	_	
198-38	42354-42358	0.73	_	
198-39	42358-42359	±	_	
198-40	42359-42363	0.06	_	
198-41	42364-42368	0.83	_	
198-42	42368-42369	±	_	
198-43	42369-42373	0.03	_	
198-44	42374-42378	0.75	_	
198-45	42378-42379	±	_	
198-46	42379-42383	0.05	_	
198-47	42384-42388	0.71	_	
198-48	42388-42389	±	_	
198-49	42389-42393	0.07	_	
198-50	42396-42403	Biotype	_	
198-51	42404-42408	IMOB	_	
198-52	42409-42412	GLM	_	
198-53	42413-42416	268	_	
198-54	42417-42421	0.89	_	
198-55	42421-42422	±	_	
198-56	42422-42426	0.02	_	
198-57	42427-42431	0.87	_	
198-58	42431-42432	±	_	
198-59	42432-42436	0.03	_	
198-60	42437-42441	0.89	_	
198-61	42441-42442	±	_	
198-62	42442-42446	0.02	_	
198-63	42447-42451	0.84	_	
198-64	42451-42452	±	_	
198-65	42452-42456	0.04	_	
198-66	42457-42461	0.83	_	
198-67	42461-42462	±	_	
198-68	42462-42466	0.04	_	
198-69	42469-42476	Biotype	_	
198-70	42477-42481	IMOB	_	
198-71	42482-42494	Connectivity	_	
198-72	42495-42501	35,778	_	
198-73	42502-42506	0.39	_	
198-74	42506-42507	±	_	
198-75	42507-42511	0.16	_	
198-76	42512-42516	0.77	_	
198-77	42516-42517	±	_	
198-78	42517-42521	0.06	_	
198-79	42522-42526	0.58	_	
198-80	42526-42527	±	_	
198-81	42527-42531	0.11	_	
198-82	42532-42536	0.68	_	
198-83	42536-42537	±	_	
198-84	42537-42541	0.07	_	
198-85	42542-42546	0.61	_	
198-86	42546-42547	±	_	
198-87	42547-42551	0.09	_	
198-88	42554-42561	Biotype	_	
198-89	42562-42566	IMOB	_	
198-90	42567-42579	Connectivity	_	
198-91	42580-42591	Replication	_	
198-92	42592-42598	35,778	_	
198-93	42599-42603	0.62	_	
198-94	42603-42604	±	_	
198-95	42604-42608	0.20	_	
198-96	42609-42613	0.75	_	
198-97	42613-42614	±	_	
198-98	42614-42618	0.11	_	
198-99	42619-42623	0.67	_	
198-100	42623-42624	±	_	
198-101	42624-42628	0.17	_	
198-102	42629-42633	0.70	_	
198-103	42633-42634	±	_	
198-104	42634-42638	0.12	_	
198-105	42639-42643	0.67	_	
198-106	42643-42644	±	_	
198-107	42644-42648	0.14	_	
198-108	42651-42658	Biotype	_	
198-109	42659-42661	EA	_	
198-110	42662-42665	GLM	_	
198-111	42666-42669	268	_	
198-112	42670-42674	0.60	_	
198-113	42674-42675	±	_	
198-114	42675-42679	0.11	_	
198-115	42680-42684	0.82	_	
198-116	42684-42685	±	_	
198-117	42685-42689	0.05	_	
198-118	42690-42694	0.72	_	
198-119	42694-42695	±	_	
198-120	42695-42699	0.08	_	
198-121	42700-42704	0.72	_	
198-122	42704-42705	±	_	
198-123	42705-42709	0.06	_	
198-124	42710-42714	0.71	_	
198-125	42714-42715	±	_	
198-126	42715-42719	0.07	_	
198-127	42722-42729	Biotype	_	
198-128	42730-42732	EA	_	
198-129	42733-42745	Connectivity	_	
198-130	42746-42752	35,778	_	
198-131	42753-42757	0.86	_	
198-132	42757-42758	±	_	
198-133	42758-42762	0.02	_	
198-134	42763-42767	0.78	_	
198-135	42767-42768	±	_	
198-136	42768-42772	0.04	_	
198-137	42773-42777	0.86	_	
198-138	42777-42778	±	_	
198-139	42778-42782	0.02	_	
198-140	42783-42787	0.77	_	
198-141	42787-42788	±	_	
198-142	42788-42792	0.04	_	
198-143	42793-42797	0.76	_	
198-144	42797-42798	±	_	
198-145	42798-42802	0.05	_	
198-146	42805-42808	Cog	_	
198-147	42809-42814	Split	_	
198-148	42815-42816	(	_	
198-149	42816-42819	50%	_	
198-150	42819-42820	)	_	
198-151	42821-42825	REST	_	
198-152	42826-42838	Connectivity	_	
198-153	42839-42845	35,778	_	
198-154	42846-42850	0.67	_	
198-155	42850-42851	±	_	
198-156	42851-42855	0.03	_	
198-157	42856-42860	0.67	_	
198-158	42860-42861	±	_	
198-159	42861-42865	0.03	_	
198-160	42866-42870	0.67	_	
198-161	42870-42871	±	_	
198-162	42871-42875	0.03	_	
198-163	42876-42880	0.68	_	
198-164	42880-42881	±	_	
198-165	42881-42885	0.03	_	
198-166	42886-42890	0.67	_	
198-167	42890-42891	±	_	
198-168	42891-42895	0.03	_	
198-169	42898-42901	Cog	_	
198-170	42902-42907	Split	_	
198-171	42908-42909	(	_	
198-172	42909-42912	50%	_	
198-173	42912-42913	)	_	
198-174	42914-42918	IMOB	_	
198-175	42919-42922	GLM	_	
198-176	42923-42926	268	_	
198-177	42927-42931	0.56	_	
198-178	42931-42932	±	_	
198-179	42932-42936	0.03	_	
198-180	42937-42941	0.56	_	
198-181	42941-42942	±	_	
198-182	42942-42946	0.03	_	
198-183	42947-42951	0.56	_	
198-184	42951-42952	±	_	
198-185	42952-42956	0.03	_	
198-186	42957-42961	0.56	_	
198-187	42961-42962	±	_	
198-188	42962-42966	0.03	_	
198-189	42967-42971	0.55	_	
198-190	42971-42972	±	_	
198-191	42972-42976	0.03	_	
198-192	42979-42982	Cog	_	
198-193	42983-42988	Split	_	
198-194	42989-42990	(	_	
198-195	42990-42993	50%	_	
198-196	42993-42994	)	_	
198-197	42995-42999	IMOB	_	
198-198	43000-43012	Connectivity	_	
198-199	43013-43019	35,778	_	
198-200	43020-43024	0.56	_	
198-201	43024-43025	±	_	
198-202	43025-43029	0.05	_	
198-203	43030-43034	0.56	_	
198-204	43034-43035	±	_	
198-205	43035-43039	0.05	_	
198-206	43040-43044	0.56	_	
198-207	43044-43045	±	_	
198-208	43045-43049	0.05	_	
198-209	43050-43054	0.57	_	
198-210	43054-43055	±	_	
198-211	43055-43059	0.06	_	
198-212	43060-43064	0.56	_	
198-213	43064-43065	±	_	
198-214	43065-43069	0.05	_	
198-215	43072-43075	Cog	_	
198-216	43076-43081	Split	_	
198-217	43082-43083	(	_	
198-218	43083-43086	50%	_	
198-219	43086-43087	)	_	
198-220	43088-43090	EA	_	
198-221	43091-43094	GLM	_	
198-222	43095-43098	268	_	
198-223	43099-43103	0.57	_	
198-224	43103-43104	±	_	
198-225	43104-43108	0.04	_	
198-226	43109-43113	0.57	_	
198-227	43113-43114	±	_	
198-228	43114-43118	0.04	_	
198-229	43119-43123	0.57	_	
198-230	43123-43124	±	_	
198-231	43124-43128	0.04	_	
198-232	43129-43133	0.58	_	
198-233	43133-43134	±	_	
198-234	43134-43138	0.04	_	
198-235	43139-43143	0.57	_	
198-236	43143-43144	±	_	
198-237	43144-43148	0.04	_	
198-238	43151-43154	Cog	_	
198-239	43155-43160	Split	_	
198-240	43161-43162	(	_	
198-241	43162-43165	50%	_	
198-242	43165-43166	)	_	
198-243	43167-43169	EA	_	
198-244	43170-43182	Connectivity	_	
198-245	43183-43189	35,778	_	
198-246	43190-43194	0.58	_	
198-247	43194-43195	±	_	
198-248	43195-43199	0.03	_	
198-249	43200-43204	0.58	_	
198-250	43204-43205	±	_	
198-251	43205-43209	0.03	_	
198-252	43210-43214	0.58	_	
198-253	43214-43215	±	_	
198-254	43215-43219	0.03	_	
198-255	43220-43224	0.58	_	
198-256	43224-43225	±	_	
198-257	43225-43229	0.03	_	
198-258	43230-43234	0.58	_	
198-259	43234-43235	±	_	
198-260	43235-43239	0.03	_	
198-261	43242-43245	Cog	_	
198-262	43246-43251	Split	_	
198-263	43252-43253	(	_	
198-264	43253-43256	30%	_	
198-265	43256-43257	)	_	
198-266	43258-43262	REST	_	
198-267	43263-43275	Connectivity	_	
198-268	43276-43282	35,778	_	
198-269	43283-43287	0.64	_	
198-270	43287-43288	±	_	
198-271	43288-43292	0.04	_	
198-272	43293-43297	0.61	_	
198-273	43297-43298	±	_	
198-274	43298-43302	0.04	_	
198-275	43303-43307	0.64	_	
198-276	43307-43308	±	_	
198-277	43308-43312	0.04	_	
198-278	43313-43317	0.62	_	
198-279	43317-43318	±	_	
198-280	43318-43322	0.04	_	
198-281	43323-43327	0.59	_	
198-282	43327-43328	±	_	
198-283	43328-43332	0.04	_	
198-284	43335-43338	Cog	_	
198-285	43339-43344	Split	_	
198-286	43345-43346	(	_	
198-287	43346-43349	30%	_	
198-288	43349-43350	)	_	
198-289	43351-43355	IMOB	_	
198-290	43356-43359	GLM	_	
198-291	43360-43363	268	_	
198-292	43364-43368	0.49	_	
198-293	43368-43369	±	_	
198-294	43369-43373	0.05	_	
198-295	43374-43378	0.53	_	
198-296	43378-43379	±	_	
198-297	43379-43383	0.04	_	
198-298	43384-43388	0.49	_	
198-299	43388-43389	±	_	
198-300	43389-43393	0.05	_	
198-301	43394-43398	0.50	_	
198-302	43398-43399	±	_	
198-303	43399-43403	0.04	_	
198-304	43404-43408	0.49	_	
198-305	43408-43409	±	_	
198-306	43409-43413	0.04	_	
198-307	43416-43419	Cog	_	
198-308	43420-43425	Split	_	
198-309	43426-43427	(	_	
198-310	43427-43430	30%	_	
198-311	43430-43431	)	_	
198-312	43432-43436	IMOB	_	
198-313	43437-43449	Connectivity	_	
198-314	43450-43456	35,778	_	
198-315	43457-43461	0.60	_	
198-316	43461-43462	±	_	
198-317	43462-43466	0.07	_	
198-318	43467-43471	0.60	_	
198-319	43471-43472	±	_	
198-320	43472-43476	0.07	_	
198-321	43477-43481	0.60	_	
198-322	43481-43482	±	_	
198-323	43482-43486	0.07	_	
198-324	43487-43491	0.59	_	
198-325	43491-43492	±	_	
198-326	43492-43496	0.06	_	
198-327	43497-43501	0.57	_	
198-328	43501-43502	±	_	
198-329	43502-43506	0.07	_	
198-330	43509-43512	Cog	_	
198-331	43513-43518	Split	_	
198-332	43519-43520	(	_	
198-333	43520-43523	30%	_	
198-334	43523-43524	)	_	
198-335	43525-43527	EA	_	
198-336	43528-43531	GLM	_	
198-337	43532-43535	268	_	
198-338	43536-43540	0.59	_	
198-339	43540-43541	±	_	
198-340	43541-43545	0.03	_	
198-341	43546-43550	0.59	_	
198-342	43550-43551	±	_	
198-343	43551-43555	0.03	_	
198-344	43556-43560	0.59	_	
198-345	43560-43561	±	_	
198-346	43561-43565	0.03	_	
198-347	43566-43570	0.58	_	
198-348	43570-43571	±	_	
198-349	43571-43575	0.02	_	
198-350	43576-43580	0.56	_	
198-351	43580-43581	±	_	
198-352	43581-43585	0.03	_	
198-353	43588-43591	Cog	_	
198-354	43592-43597	Split	_	
198-355	43598-43599	(	_	
198-356	43599-43602	30%	_	
198-357	43602-43603	)	_	
198-358	43604-43606	EA	_	
198-359	43607-43619	Connectivity	_	
198-360	43620-43626	35,778	_	
198-361	43627-43631	0.57	_	
198-362	43631-43632	±	_	
198-363	43632-43636	0.04	_	
198-364	43637-43641	0.57	_	
198-365	43641-43642	±	_	
198-366	43642-43646	0.04	_	
198-367	43647-43651	0.57	_	
198-368	43651-43652	±	_	
198-369	43652-43656	0.04	_	
198-370	43657-43661	0.56	_	
198-371	43661-43662	±	_	
198-372	43662-43666	0.04	_	
198-373	43667-43671	0.54	_	
198-374	43671-43672	±	_	
198-375	43672-43676	0.04	_	
198-376	43679-43688	Diagnosis	_	
198-377	43689-43693	REST	_	
198-378	43694-43706	Connectivity	_	
198-379	43707-43713	35,778	_	
198-380	43714-43718	0.74	_	
198-381	43718-43719	±	_	
198-382	43719-43723	0.02	_	
198-383	43724-43728	0.72	_	
198-384	43728-43729	±	_	
198-385	43729-43733	0.02	_	
198-386	43734-43738	0.74	_	
198-387	43738-43739	±	_	
198-388	43739-43743	0.02	_	
198-389	43744-43748	0.72	_	
198-390	43748-43749	±	_	
198-391	43749-43753	0.02	_	
198-392	43754-43758	0.72	_	
198-393	43758-43759	±	_	
198-394	43759-43763	0.02	_	
198-395	43766-43775	Diagnosis	_	
198-396	43776-43780	IMOB	_	
198-397	43781-43784	GLM	_	
198-398	43785-43788	268	_	
198-399	43789-43793	0.49	_	
198-400	43793-43794	±	_	
198-401	43794-43798	0.02	_	
198-402	43799-43803	0.50	_	
198-403	43803-43804	±	_	
198-404	43804-43808	0.02	_	
198-405	43809-43813	0.49	_	
198-406	43813-43814	±	_	
198-407	43814-43818	0.02	_	
198-408	43819-43823	0.49	_	
198-409	43823-43824	±	_	
198-410	43824-43828	0.02	_	
198-411	43829-43833	0.49	_	
198-412	43833-43834	±	_	
198-413	43834-43838	0.02	_	
198-414	43841-43850	Diagnosis	_	
198-415	43851-43855	IMOB	_	
198-416	43856-43868	Connectivity	_	
198-417	43869-43875	35,778	_	
198-418	43876-43880	0.62	_	
198-419	43880-43881	±	_	
198-420	43881-43885	0.04	_	
198-421	43886-43890	0.61	_	
198-422	43890-43891	±	_	
198-423	43891-43895	0.04	_	
198-424	43896-43900	0.62	_	
198-425	43900-43901	±	_	
198-426	43901-43905	0.04	_	
198-427	43906-43910	0.62	_	
198-428	43910-43911	±	_	
198-429	43911-43915	0.04	_	
198-430	43916-43920	0.61	_	
198-431	43920-43921	±	_	
198-432	43921-43925	0.04	_	
198-433	43928-43937	Diagnosis	_	
198-434	43938-43940	EA	_	
198-435	43941-43944	GLM	_	
198-436	43945-43948	268	_	
198-437	43949-43953	0.57	_	
198-438	43953-43954	±	_	
198-439	43954-43958	0.03	_	
198-440	43959-43963	0.58	_	
198-441	43963-43964	±	_	
198-442	43964-43968	0.03	_	
198-443	43969-43973	0.57	_	
198-444	43973-43974	±	_	
198-445	43974-43978	0.03	_	
198-446	43979-43983	0.57	_	
198-447	43983-43984	±	_	
198-448	43984-43988	0.03	_	
198-449	43989-43993	0.57	_	
198-450	43993-43994	±	_	
198-451	43994-43998	0.03	_	
198-452	44001-44010	Diagnosis	_	
198-453	44011-44013	EA	_	
198-454	44014-44026	Connectivity	_	
198-455	44027-44033	35,778	_	
198-456	44034-44038	0.52	_	
198-457	44038-44039	±	_	
198-458	44039-44043	0.04	_	
198-459	44044-44048	0.52	_	
198-460	44048-44049	±	_	
198-461	44049-44053	0.04	_	
198-462	44054-44058	0.52	_	
198-463	44058-44059	±	_	
198-464	44059-44063	0.04	_	
198-465	44064-44068	0.52	_	
198-466	44068-44069	±	_	
198-467	44069-44073	0.04	_	
198-468	44074-44078	0.52	_	
198-469	44078-44079	±	_	
198-470	44079-44083	0.04	_	
